Medical devices comprising poly (butylene succinate) and copolymers thereof

By developing biocompatible implants of poly(butylene succinate) and its copolymers, the problem of insufficient mechanical properties in the prior art was solved, and implantation with high tensile strength and extended strength retention rate was achieved , suitable for a variety of surgical applications and avoids the toxicity problems of traditional methods.

CN119020878APending Publication Date: 2024-11-26TEPHA INC
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411040035.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-08-29
Filing Date
2020-08-31
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The mechanical properties of existing resorbable polymers in vivo are unsatisfactory, especially when high tensile strength and extended strength retention are required, limiting their application in surgery, and traditional methods have toxicity problems.

Method used

Developed biocompatible implants containing poly(butylene succinate) and its copolymers, increased molecular weight through new polymer synthesis methods, replaced with isocyanate chemicals to avoid toxicity, 3D printing and orientation Fiber technology prepares implants with high initial tensile strength and extended strength retention.

Benefits of technology

Implants that maintain long-term high tensile strength and prolong strength retention rate in the body have good biocompatibility and degradability, and are suitable for a variety of surgical applications, including hernia repair, breast reconstruction and pelvic floor reconstruction. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020878A_ABST
    Figure CN119020878A_ABST
Patent Text Reader

Abstract

The present invention relates to medical devices comprising poly (butylene succinate) and copolymers thereof. Resorbable implants, covers, and containers having poly (butylene succinate) and copolymers thereof have been developed. The implants are preferably sterilized and comprise less than 20 endotoxin units per device and are particularly suited for operations requiring extended strength retention and may comprise one or more bioactive agents. Implants may be made from fibers and meshes of poly (butylene succinate) and copolymers thereof, or by 3d printing / pultrusion or other melt or solvent processing methods. The implant, or the pre-set fibers therein, may be oriented. These covers and containers may be used to accommodate or partially / fully cover devices such as pacemakers and neurostimulators. The coverings, containers, and implants may be made from a mesh, a mesh, a grid, a nonwoven, a film, a fiber, a foam, a molded / pultruded / machined form, and a 3D printed form.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of a Chinese patent application filed on August 31, 2020, with application number 202080076183.9 and invention name “Medical device comprising poly(butylene succinate) and copolymers thereof”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 893,565, filed on August 29, 2019, which is hereby incorporated by reference in its entirety. Technical Field

[0004] The present invention generally relates to resorbable polymer compositions that can be processed into implants or coverings and implant containers. The implants comprise poly(butylene succinate) and copolymers thereof. Background Art

[0005] Multifilament products made of copolymers of resorbable polymers such as glycolide and lactide and monofilament products made of resorbable polymers such as polydioxanone (PDO) are well known in the prior art and are widely used in wound closure and general surgery. However, these products experience rapid loss of strength retention in vivo, which limits their application mainly to rapid healing repair and repair of strength retention that does not require extension. For example, although surgeons can use resorbable multifilament sutures to approach soft tissues that are not under significant tension, when the load on the suture may be very high and remain high for a long time (such as in rotator cuff repair), surgeons usually do not use resorbable sutures. On the contrary, although it would be desirable to use a suture that is completely resorbed once healing is completed, surgeons usually use permanent sutures to repair rotator cuffs. Similarly, surgeons can use resorbable monofilament sutures or meshes to approach soft tissues that are not under significant tension, but when the load on the device may be very high and remain high for a long time (such as in hernia repair), resorbable monofilament sutures or meshes are usually not used. In contrast, surgeons typically use permanent (eg, polypropylene) mesh for hernia repair, although it would be desirable to use a device that completely resorbs after healing is complete.

[0006] Recently, aliphatic polyester poly(butylene succinate) (PBS) has been commercialized for industrial applications such as paper coatings, packaging and covering films (U.S. Patent No. 7,317,069 to Aoshima, U.S. Patent No. 8,680,229 to Maeda, U.S. Patent No. 8,747,974 to Nakano, WO2014173055A1 to Xu, and U.S. Patent Application No. 20100249332 to Ferguson). The industrial polymer is produced by polycondensation of the readily available starting materials succinic acid and 1,4-butanediol. Xu and Guo, Biotechnol. J. 5: 1149-1163 (2010) reviewed the industrialization of PBS polymers, Li et al. evaluated poly (butylene succinate) in vitro (Li et al. Macromol. Biosci. 5: 433-440 (2005)), Vandesteene et al. Chin. J. Polym. Sci., 34 (7): 873-888 (2016) studied the structure-property relationship of polymers. Kun et al. ASAIO Journal, 58: 262-267 (2012) studied the biocompatibility of blends of PBS and polylactic acid, and Gigli et al. Eur. Polym. J., 75: 431-460 (2016) reviewed the in vitro biocompatibility of polymers. Du et al. WO2016192632 discloses a bone plate with a three-dimensional structure. WO2014173055 to Xu et al. discloses yarns produced with orientation ratios of 1.2 to 1.85x, apparently in the context of making apparel fabrics. However, no FDA-approved implants comprising poly(butylene succinate) or copolymers thereof have been successfully developed.

[0007] One reason for preventing the development progress of the implant made of PBS and its copolymer is that the mechanical properties of polymer are not satisfactory, particularly when compared with alternative medical grade polymers. The low molecular weight of PBS and its copolymer is the main cause causing poor mechanical properties. In order to improve the molecular weight, a new polymer synthesis method has been successfully developed recently, and the industrial product made of PBS and its copolymer has been introduced now. These progresses that improve the molecular weight rely on using isocyanate chemicals to improve the molecular weight of PBS, and provide polymers with good mechanical properties (USP the 5th, 349, No. 028). Unfortunately, due to the toxicity relevant to isocyanate chemicals, this method is not a good choice for developing biocompatible degradable implants.

[0008] In surgical practice, there are currently resorbable fibers, films and other polymer products with high tensile strength and strength retention rate of extension. These fibers (comprising multifilament yarn and monofilament fiber) and films and other polymer products will allow surgeons to use resorbable devices instead of permanent devices when initially needing high strength or when needing strength retention rate of extension. For example, the monofilament resorbable fibers with high strength and strength retention rate of extension can be used to manufacture the monofilament surgical mesh applicable to hernia repair, breast reconstruction and mastopexy, stress urinary incontinence treatment and pelvic floor reconstruction and other applications for soft tissue support and strengthening. Pelvic floor reconstruction includes the treatment of pelvic organ prolapse, cystocele, urethrocele, uterine prolapse, vaginal misprolapse, enterocele and rectocele. In addition, the multifilament yarn with high tenacity and strength retention rate of extension can be used for example to repair rotator cuff and other ligaments and tendons, and for hernia repair or breast lifting operation. Resorbable membranes with high strength and extended strength retention, including porous membranes having these properties, can be used for similar medical indications, including hernia repair, breast reconstruction, mastopexy, stress urinary incontinence treatment, pelvic floor reconstruction, repair of rotator cuffs and other ligaments and tendons. Other processing techniques, such as 3D printing, including fused filament fabrication, can also be used to make implants with extended strength retention, including lattice structures and other porous constructs, suitable for use in, for example, hernia repair, breast reconstruction and mastopexy, stress urinary incontinence treatment, and pelvic floor reconstruction.

[0009] Therefore, there is a need to develop resorbable implants that have prolonged strength retention and preferably high initial tensile strength, that also have good biocompatibility, can be produced economically, and that degrade into non-toxic degradation products.

[0010] It is an object of the present invention to provide biocompatible implants of poly(butylene succinate) and copolymers thereof having prolonged strength retention.

[0011] It is another object of the present invention to provide implants of poly(butylene succinate) and copolymers thereof made from oriented fibers, including monofilament and multifilament fibers.

[0012] It is yet another object of the present invention to provide implants of poly(butylene succinate) and copolymers thereof made from films, including porous films, particularly films that have been oriented in one or more directions.

[0013] Yet another object of the present invention is to provide implants of poly(butylene succinate) and copolymers thereof manufactured by 3D printing.

[0014] Yet another object of the present invention is to provide methods for producing oriented implants and 3D printed implants of poly(butylene succinate) and its copolymers.

[0015] It is yet another object of the present invention to provide methods for implanting implants made of poly(butylene succinate) and copolymers thereof. Summary of the invention

[0016] Resorbable biocompatible implants comprising poly(butylene succinate) and copolymers thereof have been developed. These implants are manufactured using poly(butylene succinate), copolymers or blends thereof, and are produced such that the implants are biocompatible, contain less than 20 endotoxin units / device as determined by the limulus amebocyte lysate (LAL) assay, and are sterile.

[0017] The poly(butylene succinate) polymer comprises succinic acid and 1,4-butanediol, which are also hydrolytic degradation products of poly(butylene succinate), are enzymatically converted into natural metabolites in vivo, and are degraded to carbon dioxide and water through known metabolic / catabolic pathways without forming toxic metabolites.

[0018] Poly(butylene succinate) and copolymers thereof are also prepared without the use of cross-linking agents, which may result in the release of toxic metabolites from the implant as the polymer degrades.

[0019] The implants are particularly useful for procedures requiring prolonged strength retention, such as hernia repair, soft tissue reinforcement, breast reconstruction and augmentation, mastopexy, orthopedic repair, wound management, pelvic floor reconstruction, stress urinary incontinence treatment, stent implantation, heart valve surgery, dental procedures, and other plastic surgeries. Such implants of poly(butylene succinate) and copolymers thereof include, but are not limited to, the following implants:

[0020] (i) Made from oriented fibers, including monofilament and multifilament fibers:

[0021] (ii) made from films, including porous films, particularly films oriented in one or more directions; or

[0022] (iii) Made by 3D printing.

[0023] The preparation of the implant avoids the use of production techniques that generate endotoxins or require the use of antibiotics.

[0024] Preferably, the implant is made of a polymer composition of poly(butylene succinate) and copolymers thereof, wherein the composition has a melting temperature of 105°C to 120°C, so that the implant is stable during transportation in hot climates and in storage.

[0025] The polymer composition used to prepare the implant preferably excludes the use of poly(butylene succinate) and copolymers thereof prepared by using isocyanates.

[0026] In a preferred embodiment, the implant comprises a polymer composition comprising 1,4-butanediol and succinic acid units copolymerized with one or more hydroxycarboxylic acid units, even more preferably, wherein the hydroxycarboxylic acid units are malic acid, citric acid or tartaric acid. In a particularly preferred embodiment, the implant comprises succinic acid-1,4-butanediol-malic acid copolyester. In another embodiment, the implant comprises a polymer composition comprising 1,4-butanediol and succinic acid units copolymerized with maleic acid, fumaric acid or a combination thereof. These polymer compositions may also comprise other monomers, including malic acid, citric acid or tartaric acid.

[0027] In one embodiment, the implant is made of fibers and meshes comprising poly(butylene succinate) and copolymers thereof. In a preferred embodiment, the fibers are oriented.

[0028] It has been found that the oriented fibers do not curl when uneven forces are applied to the surface of the oriented fibers during implantation. For example, when these fibers are used as sutures and tension is unevenly applied to the surface of the suture, these fibers do not curl or form a pigtail structure. Pigtailing of suture fibers is undesirable because it makes handling or tying of surgical sutures during implantation very difficult.

[0029] It has also been found that oriented fibers of poly(butylene succinate) and copolymers thereof that do not produce dents during degradation after in vivo implantation can be prepared. This fiber property provides a predictable in vivo degradation spectrum, which is particularly important for the performance of small diameter fibers and multifilament fibers. The dents on the surface of small diameter fibers or the uneven erosion of the fiber surface may cause the premature loss of fiber strength retention, thereby causing the fiber to fail prematurely in vivo. The premature loss of strength retention causes the effective cross-section of the fiber to reduce due to the introduction of defects and the dents.

[0030] The absence of fiber dimples is particularly important in all fiber-based implants, and is particularly important in implants where extended strength retention is desired, such as resorbable wound closure materials, e.g., sutures and staples, surgical meshes, hernia meshes, breast reconstruction meshes, implants for soft tissue reinforcement, mastopexy meshes, and slings. Dimples can be visualized as indentations, micropores, or hollows in the fiber surface using SEM.

[0031] In one embodiment, oriented monofilaments and multifilaments of poly(butylene succinate) and copolymers with very high tensile strength but still degradable in vivo over time and other oriented products have been developed. As discussed in Manavitehrani et al., 2016, Polymers, 8:20-52 (see Table 1 thereof), the tensile strength of PBS is generally about 17.5 MPa, while Wang et al., 2009, Acta Biomaterialia, 5 (1):279-287 (see Table 1 thereof) report that the tensile strength of PBS is 58 MPa. However, as reported in the present application, oriented monofilaments and multifilaments of poly(butylene succinate) and copolymers with tensile strength much higher than previously reported tensile strengths have been developed, for example, greater than 400 MPa, 500 MPa, 600 MPa, 700 MPa, or 800 MPa, but less than 2,000 Pa, more preferably 400 MPa to 1,200 MPa. It has been found that these fibers can be prepared using multi-stage orientation in combination with a heated conductive liquid chamber. In addition, it has been found that orientation can be used to change the degradation characteristics of articles formed from poly(butylene succinate) and copolymers. For example, the present application shows that oriented PBS articles can retain 83.1% of the initial weight average molecular weight (Mw) after 12 weeks of incubation in phosphate buffered saline (see Example 13, Table 6), and can retain 72.5% after 12 weeks of implantation in vivo (Example 15, Table 12). In contrast, Li et al. evaluated poly(butylene succinate) articles formed by hot pressing (a method that does not provide orientation) by incubating them in phosphate buffered saline for several weeks in vitro, showing that the articles retained only about 40% of the initial Mw after 12 weeks of incubation, and only about 12.5% ​​of the initial Mw after 15 weeks of incubation (Li et al. Macromol. Biosci. 5:433-440 (2005); Figure 4 ). This suggests that orientation over time during use can provide important benefits of resilience to implants formed from poly(butylene succinate) and copolymers. The high tensile strength and improved resilience of these fibers make them suitable for resorbable implant applications requiring high tensile strength and extended strength retention.

[0032] Such applications include hernia repair, breast reconstruction, treatment of urinary incontinence with slings, resorbable wound closure materials (eg, sutures and staples), mesh sutures, and ligament and tendon repair.

[0033] In another embodiment, it has been found that this new fiber formation method can also be used to prepare relatively rigid oriented monofilament and multifilament fibers of poly (butylene succinate) and copolymers, with Young's modulus values ​​of 1 GPa to 5 GPa, such as 2 GPa to 3 GPa. In contrast, Manavitehrani et al., supra (see Table 1 thereof) reported that the modulus of PBS is generally 0.7 GPa, while Wang et al., 2009, supra (see Table 1 thereof) reported that the tensile strength of PBS is 0.67 GPa. The high stiffness of the fibers provided by this embodiment of the invention can be particularly advantageous in the preparation, processing and performance of resorbable implantable wound closure materials (e.g., sutures and staples) and surgical meshes.

[0034] In another embodiment, it has been discovered that this new fiber formation method can also be used to prepare absorbable devices and oriented monofilament and multifilament fibers of poly(butylene succinate) and copolymers having low acidity degradation products. For example, the two acid dissociation constants (pKa) of succinic acid, which is a hydrolysis degradation product of poly(butylene succinate) and its copolymers, are about 4.21 and 5.64. These pKa values ​​are higher (less acidic) than the pKa values ​​of monomers used in many other absorbable polymers (e.g., polyglycolic acid (PGA), polylactic acid (PLA), poly-L-lactic acid (PLLA), poly-lactic-co-glycolic acid (PLGA), etc.), because the pKa of glycolic acid and lactic acid are about 3.83 and 3.86, respectively. Therefore, the disclosed implants have major advantages over existing methods using absorbable polygalactin 910 (PLGA) or other similar meshes containing monomers with pKa values ​​lower than succinic acid. Upon hydrolysis, the latter mesh releases hydrolysis degradation products that are more acidic than succinic acid and 1,4-butanediol. Acidic degradation products may cause local tissue irritation, toxicity, sterile sinus formation, tissue damage or necrosis at the implant site, and degradation products with lower acidity such as succinic acid and 1,4-butanediol are preferred to avoid such adverse tissue reactions.

[0035] It has also been discovered that the poly(butylene succinate) and copolymer compositions can be used to prepare orthopedic implants having sufficient stiffness and torsional strength to allow their use in resorbable implants, such as interference screws, bone screws, and suture anchors.

[0036] It is also found that surgical mesh can be prepared by poly (butylene succinate) and copolymers thereof, which are dimensionally stable when implanted in vivo, and do not shrink in at least 4 weeks or at least 12 weeks after implantation, that is, the width and length of the mesh are not significantly or significantly reduced in size. Table 8 shows that the relative area of ​​the mesh is not shrunk. The width and length remain relatively constant. The data of the GalaFLEX mesh are given in Table 9, and the area and size of the mesh are reduced. Therefore, in this embodiment, the area of ​​the mesh is reduced by less than 6%, for example, less than 5%, less than 4%, less than 2% and less than 1% compared to its initial area by 12 weeks, and 4 weeks after implantation, the area of ​​the mesh is reduced by less than 4%, preferably less than 2%, even more preferably 0% to 1% compared to its initial area. In this context, the term "area of ​​the mesh" preferably refers to a single plane surface area, i.e., the product of the width and length of the mesh.

[0037] Surgical meshes prepared from oriented fibers of poly(butylene succinate) and copolymers thereof are described herein. The improved meshes prevent additional tension from being placed on tissue at the implantation site and maintain the original reinforcement or repair region. In addition, it is also found that the meshes do not curl along their edges after implantation and continue to conform to the patient's anatomical contour. Implantable mesh curling along its edges is undesirable because it may expose adjacent tissues to the mesh edges and cause tissue damage.

[0038] In another embodiment, the implant is made of a 3D printed composition comprising poly(butylene succinate) and copolymers thereof. In a particularly preferred embodiment, the implant made by 3D printing has a porous structure, and even more preferably a grid structure. It has been found that certain compositions of poly(butylene succinate) and copolymers thereof can be 3D printed to produce implants, wherein unexpectedly, the printed polymer has a higher weight average molecular weight than the composition from which it is derived. This increase in weight average molecular weight may be the result of a chain extension reaction above the melting point of the composition.

[0039] In another embodiment, the implant comprises one or more antimicrobial agents to prevent colonization of the implant and reduce or prevent infection following implantation in a patient.

[0040] Covers and containers made from forms of poly(butylene succinate) and its copolymers have also been developed for use with cardiac rhythm management devices and other implantable devices. These covers and containers can be used to contain or partially or completely cover devices such as pacemakers, breast implants, and neurostimulators. In a preferred embodiment, the covers and containers are made from meshes, nonwovens, films, fibers, foams, 3D printed objects, and contain antibiotics such as rifampicin and minocycline.

[0041] Implants comprising poly(butylene succinate) and copolymers thereof can be sterilized, for example, by irradiation, but more preferably by ethylene oxide gas or cold ethylene oxide gas. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 is an image showing a 3D printed mesh produced by melt extrusion deposition (MED) of succinic acid-1,4-butanediol-malic acid copolyester.

[0043] Figure 2 are images of paraffin-embedded tissue slides showing histology at 20× magnification using H&E staining of PBS mesh following subcutaneous implantation in rabbits for a period of 4 weeks.

[0044] Figure 3 are images of paraffin-embedded tissue slides showing histology at 200× magnification using H&E staining of PBS mesh following subcutaneous implantation in rabbits for a period of 4 weeks.

[0045] Figure 4 is a SEM image at 400× magnification of an oriented PBS monofilament suture fiber before implantation, showing a smooth surface.

[0046] Figure 5 is a SEM image of an oriented PBS monofilament suture fiber implanted in a rabbit subcutaneous site 4 weeks after implantation. The image at 400× magnification shows a smooth surface without surface pitting or localized surface erosion.

[0047] Figure 6 is a diagram of an asymmetric implant for breast reconstruction having a teardrop shape and additional protrusions (12, 14, 16, 18).

[0048] Figure 7 Illustration of an asymmetric two-dimensional implant (95) for reconstruction of a right breast having a width (W), height (H), medial curved support (90) and projections (94) that allow the implant to spread over the breast mound without bunching.

[0049] Figure 8 is a diagram of a split metal template (20) including an inwardly curved half (22) and a mating outwardly curved half (28) having a semicircular recess (26) in the peripheral boundary of the inwardly curved half (22), the split metal template being used to manufacture an implant that can assume a three-dimensional shape without assistance. The line in the outwardly curved half (24) indicated by the letters "AA" indicates the location of a cross-sectional view (32) of the outwardly curved half of the mold (24). The material (30) to be molded is clamped in the split metal mold.

[0050] Fig.9A is a diagram of a semi-ellipsoidal implant shape. Fig. 9B is a schematic diagram of an implant having cross-sectional dimensions of a three-dimensional shape defined by triaxial dimensions "a", "b" and "c".

[0051] Fig.10 is an illustration of an implant for breast reconstruction having a wide upper span (40) to facilitate sling support and embrace the breast mound, and an oversized bottom projection (42) to support the vertical pillars of the breast and shape the IMF. The two-dimensional implant shape is designed to minimize bunching or folding of the implant during breast reconstruction.

[0052] Fig.11 is an illustration of a two-dimensional implant for breast reconstruction designed to support the breast mound, characterized by a curved upper wire (54) to improve breast mound compliance, a short right-to-left span to anchor the scaffold to the breast mound, and an oblong lower protrusion (50) with rounded corners that supports vertical struts or folds beneath the IMF to provide shaping and support to the breast.

[0053] Fig.12 is a diagram of an implant (70) for breast reconstruction designed to support the breast mound and distribute loads to specific anchoring locations. The two-dimensional implant features a wide right-to-left flexion span (defined by width "W") that provides sling support, and an insert (74) between inferior anchoring tabs (72 and 76) that allows the implant to conform to the shape of the IMF without bunching.

[0054] Fig.13 An example of a two-dimensional crescent-shaped implant having a width (W) and a height (H) is shown.

[0055] Fig.14 Shows the width (W) and height (H 1 ) of a two-dimensional implant for breast reconstruction having a depression (110) for the nipple-areola complex, an option (112) for a mid-support, and protrusions (116) and (118) that allow the implant to spread over the breast mound without bunching.

[0056] Figures 15A to 15C Schematic diagram showing a three-dimensional implant for breast reconstruction. Fig.15A Shown is the partial dome shape of the implant, which is designed to conform to the contours of the breast mound and add shape to the breast mound. Fig. 15B The width (W) of a portion of the dome is shown, and (80) shows the dome crown or edge viewed from inside the dome. Fig. 15CThe height (H), depth (D) and angle (θ) between the base (or floor) (84) of the partial dome and the edge (82) of the partial dome at its highest point (86) are shown.

[0057] Figures 16A to 16D A three-dimensional dome-shaped implant is shown. Fig.16A A three-dimensional partial dome-shaped implant for breast reconstruction having three projections (90a, 90b, 90c) designed to conform to the contours of the breast mound and add shape to the breast mound is shown. Fig. 16B The width (W) of the partial dome and the arrangement of the protrusions (90a, 90b, 90c) are shown. Fig. 16C A view of the implant from above the partial dome is shown. Fig.16D The height (H), depth (D) and angle (θ) between the base (or floor) (92) of the partial dome and the edge (94) of the partial dome at its highest point are shown.

[0058] Fig.17A An example is shown of how a three-dimensional part dome shaped implant viewed from above may be reinforced by body ribs (100) around the edges of the implant and body ribs (102a and 102b) in the middle dome region. Fig. 17B Shown with Fig.17A The same three-dimensional implant, but viewed from above and partially inside the dome.

[0059] Fig.18A Showing unidirectional bending of the 3D implant. Fig.18B The bi-directional bending of the 3D implant is shown. Fig. 18C A peripheral support rib is shown with a reduced radius of the rib.

[0060] Fig.19A Shown is a custom mold that cuts the mesh and ribs to size and creates the 3 securing tabs. Fig.19B Shown is a custom mold that cuts the mesh and ribs to size and creates the 8 securing tabs. Fig.19C Shown is a custom mold that cuts the mesh and ribs to size and creates the 17 securing tabs. Fig.19DA plan view of a three-dimensional partial dome mesh implant (200) having eight fixation protrusions (204a to 204h) and uniform peripheral support ribs (100) made of polymer extrusion is shown, showing the upper portion with the ML distance (208) as a measure of the width of the device, the IMF-NAC (nipple-areola complex) NAC distance (210) as a measure of the height of the device, an orientation mark (202) located at the lower portion of the device, an outer protrusion (204a), an inner protrusion (204b), an IMF central protrusion (204c), additional protrusions (204d, 204e, 204f, 204g and 204h), and a rounded edge (206) to reduce stress in the implant. Fig.19E The device 200 is shown placed on a breast 400.

[0061] Fig. 20A is a diagram of a split metal template (300) for connecting a scaffold material (310) to an extrudate ring (320). The extrudate ring is placed in a semicircular groove (330) in one half of the split metal template. Fig. 20B is a diagram of a split metal template (350) having an inwardly curved half and a mating outwardly curved half for use in making an implant that can assume a three-dimensional shape without assistance. The material to be formed (360) is clamped in the split metal mold.

[0062] Fig.21 is a picture of a meniscus anchor made from PBS-malic acid copolymer by pultrusion and compression molding showing size 2 / 0 sutures passing through two holes in the anchor. DETAILED DESCRIPTION

[0063] Methods of making resorbable implants having prolonged strength retention comprising poly(butylene succinate) or copolymers thereof have been developed.

[0064] These implants preferably have a high initial strength and preferably contain less than 20 endotoxin units per device as determined by the Limulus amebocyte lysate (LAL) assay.

[0065] After implantation, the implant degrades slowly, providing adequate healing time before the implant loses strength.

[0066] In certain embodiments, the implant comprises micropores and / or is in the form of a scaffold, which allows tissue ingrowth to occur over an extended period of time due to prolonged strength retention.

[0067] The implant may contain one or more antimicrobial agents to prevent colonization of the implant by microorganisms and reduce or prevent infection after implantation in a patient. The implant may be designed to release the antimicrobial agent after implantation.

[0068] The implant may be coated on one or more surfaces to prevent adhesion formation on the coated surface.

[0069] In another embodiment, biomedical implants and other medical devices and articles can be coated with the compositions of poly(butylene succinate) or copolymers thereof as described herein.

[0070] In another embodiment, biomedical implants and other medical devices and articles (such as but not limited to stents, such as metal stents) are coated with a primer layer comprising poly(butylene succinate) or a copolymer thereof blended with one or more other polymers, optionally coated with a topcoat layer of a composition that may, for example, comprise poly(butylene succinate) or a copolymer thereof or the same as the primer layer. Optionally, the primer layer has a thickness of about 10 microns to about 50 microns, more preferably about 15 microns to about 25 microns. In one embodiment, the primer layer has a thickness of about 20 microns. Optionally, the topcoat layer has a thickness of about 10 microns to about 40 microns, preferably about 10 microns to 20 microns. In one embodiment, the topcoat layer has a thickness of about 15 microns. Preferably, the elongation at break of the primer layer and / or the topcoat layer is in the range of 10% to 50%, or at least in the range of 10% to 50%. Preferably, the Young's modulus of the primer layer and / or the topcoat layer is less than 5.0 GPa; and optionally at least or more than 600 MPa, at least or more than 700 MPa, at least or more than 800 MPa, at least or more than 1 GPa, or at least or more than 2 GPa, but less than 5 GPa. In one option, the primer layer and / or the topcoat layer, or the biomedical implant, device or article as a whole, is plastically expandable at body temperature.

[0071] Optionally, the biomedical implant of the invention (in one embodiment, at least in the case of a stent) does comprise a triblock copolymer comprising 1,4-butanediol, succinic acid and MPEG units.

[0072] In one embodiment, the implant may be delivered minimally invasively, and the implant may also be a three-dimensional implant with or without the ability to return to its original shape after being deformed for delivery.

[0073] The implants are particularly useful in procedures requiring prolonged strength retention, such as hernia repair (including abdominal hernia, ventral hernia, incisional hernia, umbilical hernia, inguinal hernia, femoral hernia, hiatal hernia and paraesophageal hernia), soft tissue reinforcement, breast reconstruction and augmentation, mastopexy, orthopedic repair (including ligament and tendon repair), wound management, resorbable wound closure materials (such as suture and staple materials), pelvic floor reconstruction, stress urinary incontinence treatment, stent implantation, heart valve surgery, dental surgery and other plastic surgery. Such implants of poly(butylene succinate) and its copolymers include, but are not limited to, the following implants:

[0074] (i) Made from oriented fibers, including monofilament and multifilament fibers:

[0075] (ii) made from films, including porous films, particularly films oriented in one or more directions; or

[0076] (iii) Made by 3D printing.

[0077] In a preferred embodiment, methods for implants of highly oriented fibers and meshes of poly(butylene succinate) and copolymers thereof have been developed. In this context, highly oriented fibers are fibers produced by methods that impart at least 2, 3, 4, 5, 6, 7, 8 or greater orientation ratios. A highly oriented mesh is a mesh comprising one or more highly oriented fibers or formed by one or more highly oriented fibers. Maintaining the highly oriented nature of these fibers and meshes is essential for their physical function in vivo.

[0078] The high degree of orientation of the fibers and meshes allows these devices to maintain strength for extended periods of time in vivo ("extended strength retention"), thus providing critical support to tissues during reconstruction and repair procedures.

[0079] If orientation is lost during the preparation of implants containing these fibers and meshes, the resulting product will have lower strength and strength retention and will not provide the necessary reinforcement and structure required for healing. For example, the use of many solvents to spray or dip coat oriented poly(butylene succinate) fibers may plasticize or dissolve the polymer and result in loss of fiber orientation and loss of strength retention.

[0080] Processes have been developed which allow the preparation of fibers and webs of poly(butylene succinate) and its copolymers without significant loss of fiber orientation and, therefore, strength and strength retention.

[0081] Optionally, these implants can also incorporate other bioactive agents, such as antibiotics, antimicrobial agents and anti-adhesion agents. For example, oriented resorbable implants made of PBS and copolymers thereof have been developed, which contain one or more antimicrobial agents to prevent implants from being colonized by microorganisms, and reduce or prevent infection after implantation in patients. These oriented implants are particularly suitable for operations that require extended strength retention and risk of infection, such as hernia repair, breast reconstruction and augmentation, mastopexy, orthopedic repair, wound management, pelvic floor reconstruction, pelvic organ prolapse treatment (including cystocele, urethrocele, uterine prolapse, vaginal misprolapse, enterocele and rectocele treatment), stent implantation, heart valve surgery, dental surgery and other plastic surgery.

[0082] In another preferred embodiment, methods for producing implants of poly(butylene succinate) and copolymers by 3D printing have been developed, and 3D printing includes free deposition modeling (including fused filament manufacturing, molten pellet deposition, and molten extrusion deposition), selective laser melting, and solution printing. A particularly preferred 3D printing method is fused filament manufacturing. In a preferred embodiment, the implant comprising poly(butylene succinate) and copolymers produced by 3D printing is porous, and in a particularly preferred embodiment, the implant can be a grid, including a mesh containing struts or fibers.

[0083] Methods have also been developed for preparing resorbable shells, bags, holders, covers, meshes, nonwovens, films, foams, clamshells, shells and other containers made of poly(butylene succinate) and copolymers thereof that partially or completely encapsulate, surround or contain implantable medical devices, and optionally wherein the poly(butylene succinate) and copolymers thereof contain and release one or more antimicrobial agents to prevent colonization of the implant and / or reduce or prevent infection. Implantable medical devices that may be partially or completely encapsulated include cardiac rhythm management (CRM) devices (including pacemakers, defibrillators and pulse generators), implantable access systems, neurostimulators, ventricular access devices, infusion pumps, devices for delivering drugs and hydration solutions, intrathecal delivery systems, pain pumps, breast implants, or other devices that provide drugs or electrical stimulation to a body part.

[0084] In one embodiment, the methods disclosed herein are based on the discovery that oriented implants and 3D printed implants of poly(butylene succinate) and copolymers thereof retain their strength longer than copolymers of glycolide and lactide and monofilament products made of polydioxanone (PDO). Oriented implants and 3D printed implants of poly(butylene succinate) and copolymers thereof can also be prepared to have high initial strength.

[0085] Methods for preparing resorbable implants comprising poly(butylene succinate) and copolymers thereof that can be used for soft and hard tissue repair, regeneration and replacement have also been developed. These implants include, but are not limited to, sutures, barbed sutures, braided sutures, monofilament sutures, mixed sutures of monofilament and multifilament fibers, braids, ligatures, knitted or woven meshes, surgical meshes for soft tissue implants for reinforcing soft tissue, surgical meshes for bridging fascial defects, surgical meshes for tracheal or other organ patches, surgical meshes for organ salvage, surgical meshes for dura mater graft materials, surgical meshes for wound or burn dressings, or surgical meshes for hemostatic packing, surgical meshes in the form of mesh plugs, knitted tubes, tubes suitable for passage of body fluids, catheters, monofilament meshes, multifilament meshes, patches (e.g., but not Limited to hernia mesh and / or repair mesh for the repair of abdominal and chest wall defects, inguinal hernia, para-colostomy hernia, ventral hernia, para-umbilical hernia, scrotal hernia or femoral hernia, mesh for muscle flap reinforcement, mesh for reinforcement of staple lines and long incisions, mesh for pelvic floor reconstruction, mesh for repair of pelvic floor prolapse (including rectal or vaginal prolapse, treatment of cystocele, urethrocele, uterine prolapse and enterocele), mesh for suture and staple pads, mesh for urinary or bladder repair, or mesh for cotton wool), soft tissue reinforcement implants, wound healing devices, bandages, wound dressings, burn dressings, ulcer dressings, skin substitutes, hemostatic agents, tracheal reconstruction devices, organ salvage devices, dura mater substitutes, dura mater Membrane patch, nerve guide, nerve regeneration or repair device, hernia repair device, hernia mesh, hernia plug, device for temporary wound or tissue support, tissue engineering device, tissue engineering scaffold, guided tissue repair / regeneration device, anti-adhesion membrane, adhesion barrier, tissue separation membrane, retention membrane, sling, device for pelvic floor reconstruction, urethral suspension device, device for treating urinary incontinence, device for treating vesicoureteral reflux, bladder repair device, sphincter repair device, sphincter expansion material for treating adult incontinence, injectable particles, injectable microspheres, microparticles, expansion or filling device, filler for filling defects in plastic surgery, bone marrow scaffold, clip, clamp, screw, bone screw, pin, nail, medullary cavity nails, bone plates, bone plugs, cranioplasty plugs, interference screws, tacks, fasteners, suture fasteners, rivets, staples, fixation devices for implants, bone graft substitutes, bone void fillers, bone putties, suture anchors, bone anchors, ligament repair devices, ligament augmentation devices, ligament grafts, anterior cruciate ligament repair devices, tendon repair devices, tendon grafts, tendon augmentation devices, rotator cuff repair devices, meniscus repair devices, meniscus regeneration devices, meniscus anchors, articular cartilage repair devices, osteochondral repair devices, spinal fusion devices, spinal fusion cages, interosseous wedges, intramedullary rods, antibiotic beads for treating or preventing bone infections, joint spacers, devices for treating osteoarthritis, adhesion promoters, stents (including coronary artery,cardiovascular, peripheral, ureteral, urethral, ​​urology, gastroenterology, nasal, ophthalmic or neurological stents), stent coatings, stent grafts, vascular application devices, cardiovascular patches, intracardiac patches or patches for closure after endarterectomy, catheter balloons, vascular closure devices, intracardiac septal defect repair devices (including but not limited to atrial septal defect repair devices and PFO (patent foramen ovale) closure devices), left atrial appendage (LAA) closure devices, pericardial patches, venous valves, heart valves, vascular grafts, myocardial regeneration devices, periodontal meshes, guided tissue regeneration membranes for periodontal tissue, ocular cell implants, imaging devices, cochlear implants, embolization devices, anastomosis devices, cell seeding devices, cell encapsulation devices, targeted delivery devices , diagnostic devices, rods, devices with biocompatible coatings, prostheses, controlled release devices, drug delivery devices, plastic surgery devices, breast lift devices, mastopexy devices, breast reconstruction devices, augmentation mammoplasty devices, breast reduction devices, devices for breast reconstruction after mastectomy with or without breast implants, facial reconstruction devices, forehead lift devices, brow lift devices, eyelid lift devices, face lift devices, wrinkle removal devices, thread lift devices to lift and support the face, brow and drooping neck areas, rhinoplasty devices, devices for zygomatic augmentation, otoplasty devices, neck lift devices, genioplasty devices, cosmetic repair devices, devices for facial scar repair, and foams. The present application also discloses the use of poly(butylene succinate) and its copolymers in preparing coatings for implants or other medical devices (e.g., any one or more of the implants listed above). In a particularly preferred embodiment, these implants comprise a polymer composition comprising 1,4-butanediol and succinic acid units copolymerized with one or more hydroxycarboxylic acid units, even more preferably wherein the hydroxycarboxylic acid units are malic acid, citric acid or tartaric acid. In a particularly preferred embodiment, these implants comprise succinic acid-1,4-butanediol-malic acid copolyesters. In another embodiment, the implant comprises a polymer composition comprising 1,4-butanediol and succinic acid units copolymerized with maleic acid, fumaric acid or a combination thereof. These polymer compositions may also comprise other monomers, including malic acid, citric acid or tartaric acid.

[0086] I. Definition

[0087] "Absorbable" is used herein to describe a polymer or device that undergoes hydrolysis and / or enzyme-driven chain scission, producing degradation products that are then absorbed by the body. The terms "resorbable," "degradable," "erodible," and "absorbable" are used somewhat interchangeably in the literature in this field, with or without the prefix "bio." Herein, these terms will be used interchangeably to describe a substance that breaks down and is gradually absorbed or eliminated by the body within five years, whether the degradation is primarily due to hydrolysis or mediated by metabolic processes.

[0088] "Biologically active agent" is used herein to refer to a therapeutic agent, a prophylactic agent, and / or a diagnostic agent. "Biologically active agent" includes a single such agent and is also intended to include the plural.

[0089] As generally used herein, "biocompatible" means that the biological response to a material or device is appropriate for the intended use of the device in vivo. Any metabolites or degradation products of these materials should also be biocompatible.

[0090] As generally used herein, "bicomponent" means a structure comprising two or more materials.

[0091] "Blend" as generally used herein means a physical combination of different polymers, as opposed to a copolymer composed of two or more different monomers.

[0092] Unless otherwise specified, "bursting strength" as used herein is determined using an MTS Q-Test Elite universal testing machine or similar equipment by a test method based on ASTM D6797-02 "Standard test method for bursting strength of fabrics constant rate of extension (CRE) ball burst test". However, the test fixture uses a 3 / 8 inch diameter ball and the opening is 1 / 2 inch diameter.

[0093] As generally used herein, "copolymers of poly(butylene succinate)" means any polymer of succinic acid monomers and 1,4-butanediol monomers incorporating one or more additional monomers. Examples of copolymers of poly(butylene succinate) include poly(butylene succinate-co-adipate), poly(butylene succinate-co-terephthalate), poly(butylene succinate-co-ethylene succinate), and poly(butylene succinate-co-propylene succinate). Poly(butylene succinate-co-adipate) can be made, for example, from succinic acid, adipic acid, and 1,4-butanediol by polycondensation. Copolymers of poly(butylene succinate) include polymers comprising (i) succinic acid and 1,4-butanediol units, and (ii) one or more of the following additional units, for example: chain extenders, crosslinking agents, and branching agents. Examples of these copolymers include: succinic acid-1,4-butanediol-malic acid copolyesters, succinic acid-1,4-butanediol-citric acid copolyesters, succinic acid-1,4-butanediol-tartaric acid copolyesters, succinic acid-1,4-butanediol-malic acid copolyesters also containing citric acid, tartaric acid or a combination thereof, succinic acid-adipic acid-1,4-butanediol-malic acid copolyesters, succinic acid-adipic acid-1,4-butanediol-citric acid copolyesters, succinic acid-adipic acid-1,4-butanediol-tartaric acid copolyesters, or succinic acid-adipic acid-1,4-butanediol-malic acid copolyesters also containing citric acid, tartaric acid or a combination thereof. Copolymers of poly(butylene succinate) also include polymers comprising succinic acid and 1,4-butanediol units and one or more hydroxycarboxylic acid units. Copolymers may also include maleic acid or fumaric acid units, or a combination thereof.

[0094] "Diameter" as generally used herein is determined according to the United States Pharmacopeia (USP) standard for diameter of surgical sutures (USP 861).

[0095] The "elongation" or "extensibility" of a material refers to the amount of increase in length resulting from the tension at which a specimen breaks, for example. It is usually expressed as a percentage of the original length. (Plastics Encyclopedia and Dictionary by Rosato, Oxford Univ. Press, 1993). Elongation at 16 N / cm is measured using ASTM D6797-15 Standard Test Method for Bursting Strength of Fabrics Constant-Rate-of-Extension (CRE) Ball Burst Test.

[0096] As used herein, "endotoxin content" refers to the amount of endotoxin present in a sample and is determined by the Limulus amebocyte lysate (LAL) assay.

[0097] Unless otherwise specified, "filament length" as used herein refers to the average length of the filaments in a monofilament fiber or a multifilament fiber.

[0098] As used herein, "full contour breast implant" refers to an implant that can be used to conform to the contours of the upper and lower poles of a breast, wherein at least a portion of the implant covers the upper and lower poles of the breast.

[0099] As used herein, "knot pull tensile strength" (or "knot strength") is determined using a universal mechanical tester according to the United States Pharmacopeia (USP) standard for testing tensile properties of surgical sutures (USP 881).

[0100] As generally used herein, "inferior pole" means the portion of the breast that is located between the inferior fibrous fold (IMF) and the nipple meridian coordinates and projects away from the chest wall.

[0101] As generally used herein, "inferior pole volume" means the volume of tissue in the inferior pole of the breast. The volume is contained within the boundaries defined by the inferior pole curve, chest wall, and nipple projection line.

[0102] As used herein, "mesh suture" means a device comprising a needle and mesh assembly that can be used to re-apply soft tissue. The mesh suture is designed to pass through soft tissue, and the mesh assembly is anchored under tension to re-apply the soft tissue. When compared to conventional monofilament and multifilament sutures, the mesh assembly helps prevent the suture from cutting through the tissue (suture pull-out or cheese wiring) and improves the strength of the repair.

[0103] As used herein, "micropores" refers to pores or voids that may be present in a polymer, particularly within the body of a fiber. Preferably, the term "micropores" does not refer to pores in a web, ie the areas between fibers in such a product.

[0104] Unless otherwise indicated, "molecular weight" as used herein refers to weight average molecular weight (Mw), not number average molecular weight (Mn), and is measured by gel permeation chromatography (GPC) in chloroform relative to polystyrene standards. Where number average molecular weight is used herein, this is measured by gel permeation chromatography (GPC) relative to polystyrene standards.

[0105] The "nipple meridian coordinate" is the plane that passes horizontally through the nipple to the chest wall.

[0106] The "nipple projection line" is a line drawn perpendicular to the chest wall and through the nipple.

[0107] As used herein, "nitrogen content" refers to the mass percentage of elemental nitrogen in a sample and is determined by the Kjeldahl nitrogen analysis method or other suitable analytical methods for trace element nitrogen analysis and is expressed in parts per million (ppm).

[0108] As generally used herein, "non-sacrificial elements, fibers, or struts" refers to elements, fibers, or struts of the implant that retain strength longer than sacrificial elements, fibers, or struts, however, the non-sacrificial elements, fibers, or struts may eventually break, stretch, or completely degrade.

[0109] As generally used herein, "orientation" refers to the alignment of polymer chains within a material or construct. For example, an oriented fiber means that some or all of the polymer chains within the fiber are aligned.

[0110] As used herein, "orientation ratio" is the ratio of the output speed to the input speed of two godet rolls (or rollers) used to orient the multifilament yarn or monofilament fiber. For example, if the output speed of the multifilament yarn or monofilament fiber is 6 meters per minute, and the input speed of the multifilament yarn or monofilament fiber is 2 meters per minute, the orientation ratio will be 3.

[0111] "PBS" as used herein means poly(butylene succinate).

[0112] As used herein, "phosphate buffered saline" is prepared by diluting 10× ultrapure grade phosphate buffered saline (product #J373-4L, from VWR) to 1× with deionized water and adding 0.05 wt% sodium azide (NaN3, product #14314, from Alfa Aesar) as an antimicrobial agent. The resulting 1× buffer solution contains 137 mM NaCl, 2.7 mM KCl, 9.8 mM phosphate, and 0.05 wt% sodium azide, and has a pH of 7.4 at 25°C. The prepared solution was filtered through a 0.45 μm filter (VWR product #10040-470) before use.

[0113] In one embodiment, "physiological conditions", "in vivo" and / or "physiological conditions in vivo" may refer to subcutaneous implantation in a subject (e.g., a human or animal). The animal may, for example, be a New Zealand white rabbit, and optionally, the steps for subcutaneous implantation and / or (if relevant) recovery of the implanted item may follow the steps shown in Example 15 of the present application. The same definitions may be applied to determine the characteristics of the item after "implantation".

[0114] As generally used herein, "poly(butylene succinate)" means an aliphatic polyester comprising succinic acid and 1,4-butanediol units, and may be made from succinic acid and 1,4-butanediol by polycondensation. Poly(butylene succinate) may be abbreviated as "PBS". Poly(butylene succinate) includes a polymer of (i) succinic acid and 1,4-butanediol units, and (ii) one or more additional monomers including: a chain extender, a crosslinker, and a branching agent.

[0115] “Aperture” as generally used herein is calculated using the open source 25 ImageJ software available at https: / / imagej.nih.gov / ij / index.html.

[0116] "Prepectoral" as used herein in the context of breast implant placement means that the implant is placed in the breast above the pectoral muscle.

[0117] As generally used herein, "resorbable" means that the material breaks down in the body and is ultimately eliminated from the body. The terms "resorbable," "degradable," "erodible," and "absorbable," with or without the prefix "bio," are used somewhat interchangeably in the literature of this field. Herein, these terms will be used interchangeably to describe a substance that breaks down and is gradually absorbed or eliminated by the body within five years, whether the degradation is primarily due to hydrolysis or mediated by metabolic processes.

[0118] As generally used herein, a "sacrificial element, fiber, or strut" refers to an implant element, fiber, or strut that is initially present in an implant but degrades, yields, or breaks prior to degradation, stretching, or breaking of non-sacrificial elements, fibers, or struts in the implant.

[0119] As used herein, "self-reinforcing" describes a property of an implant in which the outer edge is reinforced so that the implant can be squeezed, pulled, rolled, folded or otherwise temporarily deformed by a user to facilitate its insertion into the body and allow the implant to return to its original shape after insertion into the body.

[0120] As used herein, "shape memory" describes a property of an implant that allows a user to squeeze, pull, roll, fold, or otherwise temporarily deform the implant to facilitate insertion into the body, wherein the device resumes its pre-formed shape after insertion into the body.

[0121] In this article, "split metal template" can be used interchangeably with "split metal mold".

[0122] "Strength retention" refers to the amount of time a material retains a particular mechanical property after being implanted in a human or animal. For example, if the tensile strength of a resorbable fiber decreases by half within 3 months from when it was implanted in an animal, the fiber has a strength retention of 50% at 3 months.

[0123] "Subglandular" as used herein in the context of breast implant placement means that the implant is placed below the gland of the breast, but superficial to the pectoralis muscle.

[0124] "Subpectoral" as used herein in the context of breast implant placement means that the implant is placed beneath the pectoralis muscle of the breast.

[0125] As used herein, "suture pull-out strength" means that the implant cannot maintain the peak load (kg) of the suture. It is determined as follows: using a tensile tester by fixing the implant on a horizontal fixed plate, the suture is passed through the implant in a loop at a distance of 1cm from the implant edge, and the suture arm is fixed in the fiber clamp above the implant. Tested at a crosshead rate of 100mm / min, and the peak load (kg) is recorded. Suture is selected so that the implant will fail before the suture fails.

[0126] "Support rib" is used interchangeably herein with "rib" and "ring" to refer to a reinforcement around the edge of an implant.

[0127] "Taber Stiffness Unit" or (TSU) is defined as the bending moment when 1 / 5 gram is applied to a 1 1 / 2" (3.81 cm) wide specimen at a test length of 5 cm, causing it to bend to an angle of 15° and is measured using a Taber V-5 Stiffness Tester Model 150-B or 150-E. The V-5 Stiffness Tester Model 150-B or 150-E is used to evaluate the stiffness and resilience properties of materials up to 10,000 Taber Stiffness Units. This precision instrument provides ±1.0% accurate test measurements for specimens from 0.004" to 0.219" thick. One Taber Stiffness Unit is equal to 1 gram-cm (g cm) or 10.2 millinewtons meters (mN m). Taber Stiffness Units can be converted to Genuine Gurley Stiffness Units using the following formula: TM Stiffness unit: S T =0.01419S G -0.935, where S T is the stiffness in Taber stiffness units, S G The stiffness is measured in Gurley stiffness units. To convert Taber stiffness units to millinewtons, use the formula: X = S T0.098067, where X is the stiffness in millinewtons meters. This value can be used to determine the relative change in stiffness when the explant does not meet the size requirements of the Taber test due to limitations in the available test sizes for implantation in experimental animals or can provide a comparison value between samples of the same size.

[0128] As used herein, "tear strength" is measured using ASTM-D1938 (Standard Test Method for Tear Resistance of Plastic Film and Thin Sheeting by a Single-Tear Method).

[0129] "Tenac" means the strength of a yarn or filament for its given dimensions and is measured in grams of breaking force per unit of yarn or filament denier and expressed in grams per denier (gpd).

[0130] "Tensile modulus" is the ratio of stress to strain for a given material within its proportional limit.

[0131] As used herein, "tensile strength" means the maximum stress that a material can withstand before failing or breaking when stretched or pulled.

[0132] As generally used herein, "upper pole" means the top of the breast that protrudes from and away from the chest wall, between the nipple meridian coordinates and the location of the top of the breast.

[0133] As generally used herein, "upper pole volume" means the volume of tissue in the upper pole of the breast. The volume of tissue is contained within the boundaries defined by the upper pole curve, chest wall, and nipple projection line.

[0134] As used herein, "USP size" means suture sizes as defined by the United States Pharmacopeia.

[0135] As used herein, "yarn" means a continuous strand of textile fibers or filaments. Yarn can be twisted, untwisted, or substantially parallel strands.

[0136] Ⅱ. Composition

[0137] Methods have been developed to produce resorbable implants comprising poly(butylene succinate) and copolymers thereof.Resorbable implants can be used for soft and hard tissue repair, regeneration, and replacement.

[0138] In one embodiment, implant comprises the fiber with extended strength retention.Fiber can be monofilament or multifilament fiber, and is preferably oriented.Fiber preferably has at least 70% in vivo tensile strength retention at 4 weeks, more preferably has at least 80% or 90% tensile strength retention at 4 weeks.Fiber preferably has at least 50% in vivo tensile strength retention at 12 weeks, more preferably has at least 65% tensile strength retention at 12 weeks.These characteristics make fiber suitable for implants that need extended strength retention, such as hernia mesh, soft tissue strengthening implant, mesh, grid and textile, breast reconstruction mesh, resorbable wound closure material (such as suture and staple), sling for treating stress urinary incontinence, mesh suture and pelvic floor reconstruction device, including the device for treating pelvic organ prolapse (including treatment of cystocele, urethrocele, uterine prolapse, vaginal false prolapse, enterocele and rectocele). In addition to having extended strength retention, these fibers preferably have one or more of the following properties: (i) a tensile strength greater than 400 MPa, 500 MPa, 600 MPa, 700 MPa or 800 MPa but less than 2,000 MPa, more preferably 400 MPa to 1,200 MPa, (ii) a Young's modulus greater than 600 MPa, 700 MPa, 800 MPa, 900 MPa, 1 GPa or 2 GPa but less than 5 GPa, and (iii) an elongation at break of 10% to 150%, more preferably 10% to 50%.

[0139] Methods for producing implants comprising PBS or its copolymers have also been developed, which implants can partially or completely wrap, surround or contain implantable medical devices, and wherein the PBS or its copolymers release one or more antimicrobial agents to prevent the implantable medical device from being colonized by microorganisms and / or reduce or prevent infection in patients. Suitable implants comprising PBS or its copolymers include bags, retainers, covers, meshes (including but not limited to surgical meshes for soft tissue implants for strengthening soft tissue, surgical meshes for bridging fascial defects, surgical meshes for trachea or other organ patches, surgical meshes for organ salvage, surgical meshes for dura mater graft materials, surgical meshes for wound or burn dressings, or surgical meshes for hemostatic packing; or surgical meshes in the form of mesh plugs), nonwovens, grids, nets, films, clamshells, shells, and containers.

[0140] In another embodiment, the method for preparing the implant of relatively rigid implant that comprises PBS and copolymer thereof has been described.In one embodiment, the polymer composition of PBS and copolymer thereof can be used to prepare orthopedic implant.These implants have enough stiffness and torsional strength so that they are applicable to resorbable implants, for example interference screw, bone screw, suture anchor, bone anchor, clip, clamp, screw, pin, nail, intramedullary nail, bone plate, interference screw, tack, fastener, suture fastener, rivet, staple, implant fixture and bone void filler.

[0141] Also described is a method of processing PBS and its copolymers into resorbable implants by 3D printing. The method is particularly suitable for making meshes, void fillers, grids, tissue scaffolds and complex 3D shapes for use as implants.

[0142] A. Poly(butylene succinate) and copolymers

[0143] Resorbable implants and resorbable shells, bags, retainers, covers, meshes, nonwovens, nets, grids, films, clamshells, shells and other containers can generally be produced from poly(butylene succinate) and copolymers using the methods described herein. In addition to 1,4-butanediol and succinate monomers, the copolymers also include other diols and diacids, and may alternatively or additionally include branching agents, coupling agents, crosslinking agents and chain extenders. Examples of diols and diacids that may be included are: 1,3-propylene glycol, ethylene glycol, 1,5-pentanediol, 2,3-butanediol, glutaric acid, adipic acid, terephthalic acid, malonic acid and oxalic acid. In addition to 1,4-butanediol and succinic acid, the copolymers may also include one or more additional diols and diacids. Copolymers include, but are not limited to, poly(butylene succinate-co-adipate), poly(butylene succinate-co-terephthalate), poly(butylene succinate-co-butylene methyl succinate), poly(butylene succinate-co-butylene dimethyl succinate), poly(butylene succinate-co-ethylene succinate), and poly(butylene succinate-co-propylene succinate).

[0144] The resorbable implants described herein may be produced from poly(butylene succinate) and copolymers thereof, wherein the polymer or copolymer has been produced using one or more of the following: a chain extender or coupling agent, a crosslinking agent, and a branching agent. In a preferred embodiment, the poly(butylene succinate) has been prepared using a chain extender, and greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% of the polymer chains have been chain extended using a chain extender. The poly(butylene succinate) or copolymers thereof may be chain extended, branched, or crosslinked by adding one or more of the following: malic acid, trimethylolpropane, trimesic acid, citric acid, glycerol propoxylate, and tartaric acid. Particularly preferred substances for branching, chain extension, or crosslinking are hydroxycarboxylic acid units. Preferably, the hydroxycarboxylic acid unit has: two carboxyl groups and one hydroxyl group; two hydroxyl groups and one carboxyl group; three carboxyl groups and one hydroxyl group; or two hydroxyl groups and two carboxyl groups. In a preferred embodiment, the implant is prepared from poly(butylene succinate) comprising malic acid as a branching agent, chain extender or cross-linking agent. The composition may be referred to as poly(1,4-butylene succinate-co-succinic acid cross-linked or chain extended with malic acid, poly(butylene succinate) cross-linked or chain extended with malic acid, or succinic acid-1,4-butylene succinate-malic acid copolyester. In a preferred embodiment, the poly(butylene succinate) is chain extended with malic acid such that greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the poly(butylene succinate) polymer chains have been chain extended. It should be noted that malic acid can be dehydrated to maleic acid units or fumaric acid units at elevated temperatures, such as during melt extrusion. References herein to PBS copolymers comprising malic acid are intended to include implants wherein the malic acid in the PBS copolymer undergoes further reaction during processing, such as to form maleic acid or fumaric acid or another compound. Thus, an implant comprising a poly(butylene succinate)-malic acid copolymer refers to an implant prepared from a copolymer comprising succinic acid, 1,4-butanediol, and malic acid. The implant may comprise a composition of a poly(butylene succinate) copolymer wherein greater than 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the polymer chains of the composition have been extended with malic acid. In another preferred embodiment, malic acid may be used as a branching or crosslinking agent to prepare a copolymer of poly(butylene succinate) and adipic acid, which copolymer may be referred to as poly[(butylene succinate)-co-adipic acid crosslinked with malic acid]. The malic acid disclosed herein may be an L-enantiomer, a D-enantiomer, or a combination thereof, but in a preferred embodiment, L-malic acid is used to prepare poly(butylene succinate), making poly(1,4-butanediol-co-succinic acid) crosslinked or extended with L-malic acid a particularly preferred composition.

[0145] Substances that can be used to extend the chain of poly(butylene succinate) or its copolymers also include epoxides, isocyanates, diisocyanates, In one embodiment, the polymer composition of PBS and copolymer does not include the composition prepared with isocyanate or diisocyanate. In another embodiment, the polymer composition of PBS and copolymer does not include the composition prepared with urethane bond. In a particularly preferred composition, the polymer composition of PBS and copolymer used to prepare implants herein is only prepared by monomers with one or more of the following groups: hydroxyl and carboxylic acid group. In another embodiment, the polymer composition of PBS and copolymer does not include ether bond.

[0146] In a preferred embodiment, poly(butylene succinate) and copolymers thereof comprise at least 70 wt. %, more preferably 80 wt. %, even more preferably 90 wt. % of succinic acid and 1,4-butanediol units.

[0147] In another embodiment, poly(butylene succinate) and copolymers thereof disclosed herein include polymers and copolymers containing a small amount of unreacted or partially reacted monomers. For example, before the composition of poly(butylene succinate) and copolymers thereof is converted into a resorbable implant, succinic acid (or dimethyl succinate) and 1,4-butylene glycol units may be present in a small amount in poly(butylene succinate) and copolymers thereof. In some embodiments, poly(butylene succinate) and copolymers thereof may include one or more side reaction products derived from succinic acid or 1,4-butylene glycol, such as tetrahydrofuran. It is preferred to minimize the amount of unreacted monomers or side reaction products, particularly in polymers or copolymers before conversion into implants. In one embodiment, poly(butylene succinate) or copolymers thereof include up to 0.5 wt %, more preferably up to 0.2 wt % of succinic acid or dimethyl succinate. In another embodiment, the poly(butylene succinate) or copolymer thereof comprises up to 0.5 wt%, more preferably up to 0.2 wt% of 1,4-butanediol. In another embodiment, the poly(butylene succinate) or copolymer thereof comprises up to 0.5 wt%, more preferably up to 0.2 wt% of tetrahydrofuran. In yet another embodiment, the poly(butylene succinate) or copolymer thereof comprises up to 5 wt%, preferably up to 0.5 wt%, more preferably up to 0.1 wt% of malic acid.

[0148] In another embodiment, the poly(butylene succinate) and copolymers thereof disclosed herein include polymers and copolymers enriched with known hydrogen, carbon and / or oxygen isotopes. Hydrogen has three naturally occurring isotopes, including 1 H (hydrogen), 2 H (deuterium) and 3 H (tritium), the most common of which is 1 H isotope. The isotopic content of the polymer or copolymer can be enriched, for example, so that the polymer or copolymer contains a specific one or more isotopes above the natural proportion. The carbon and oxygen content of the polymer or copolymer can also be enriched to contain carbon and oxygen isotopes above the natural proportion, including but not limited to 13 C. 14 C. 17 O or 18 O. Other isotopes of carbon, hydrogen, and oxygen are known to those of ordinary skill in the art.

[0149] The preferred hydrogen isotope enriched in the poly(butylene succinate) or copolymer thereof is deuterium, i.e., deuterated poly(butylene succinate) or copolymer thereof. The deuteration percentage may be as high as at least 1% and as high as 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% or 85% or more.

[0150] Therefore, the present application discloses a composition comprising PBS or a copolymer thereof, and the use of such a composition according to other disclosures of the present application, wherein the isotopes of hydrogen, carbon and / or oxygen in the polymer have been enriched.

[0151] For example, the abundance of deuterium in PBS or its copolymer can exceed 0.0115% of all elemental hydrogen present in PBS or copolymer, and / or PBS or copolymer can contain tritium. Additionally or alternatively, the abundance of carbon-13 in PBS or copolymer can exceed 1.07% of all elemental carbon present in PBS or copolymer, and / or PBS or copolymer can contain carbon-14. Additionally or alternatively, the abundance of oxygen-17 in PBS or copolymer can exceed 0.038% of all elemental oxygen present in PBS or copolymer, and / or the abundance of oxygen-18 in PBS or copolymer exceeds 0.205%. Optionally, the abundance of deuterium in polymer exceeds 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80% or 85% of the elemental hydrogen present in PBS or copolymer.

[0152] Poly (butylene succinate) and copolymers thereof disclosed herein can be formed by monomers and additives that are themselves produced by chemical or biological methods. When using polymers to make implants, it is desirable that the polymer material has the lowest level of impurities as much as possible to prevent the body from reacting to the impurities or to minimize the body's reaction to the impurities. Related impurities include organic impurities. Purifying the polymer to a level suitable for implants involves a purification process that removes a series of impurities, including, for example, lipids, proteins, peptides, polysaccharides, nucleic acids, amino acids, and cell wall components. In the case of using biological processes to produce one or more monomers and additives, those processes may cause the monomers and additives to contain nitrogen-containing substances of a remaining amount, such as nitrogen-containing monomers, proteins, peptides, etc. In one embodiment, poly (butylene succinate) and copolymers thereof disclosed herein include polymers and copolymers wherein the nitrogen content is reduced to make it exist with 0 PPM or 0.01 PPM to 500 PPM. The nitrogen content is preferably up to 100 PPM, more preferably up to 50 PPM.

[0153] Preferred polymers and copolymers have a weight average molecular weight (Mw) of 10,000 to 400,000, more preferably 50,000 to 300,000, even more preferably 100,000 to 200,000 based on gel permeation chromatography (GPC) in chloroform solution relative to polystyrene standards. In a particularly preferred embodiment, the polymers and copolymers have a weight average molecular weight of 50,000 to 300,000, more preferably 130,000 to 250,000.

[0154] The polydispersity of the poly(butylene succinate) and copolymers thereof disclosed herein is preferably in the range of 1 to 10, such as in the range of 3 to 10 (eg, 4 to 7, or 3 to 8).

[0155] The number average molecular weight (Mn) of preferred polymers and copolymers is 1,000Da to 150,000Da, preferably 5,000Da to 100,000Da or 10,000Da to 100,000Da, even more preferably 10,000Da to 60,000Da or 20,000Da to 60,000Da. For example, the number average molecular weight (Mn) of polymers and copolymers can be 1,000Da to 50,000Da, 10,000Da to 70,000Da or 70,000Da to 150,000Da. In another embodiment, the number average molecular weight (Mn) of polymers and copolymers can be 1kDa to 150kDa based on gel permeation chromatography (GPC) relative to polystyrene standards, and PDI can be 2 to 10. In another embodiment, the polymers and copolymers have a number average molecular weight (Mn) of 20 kDa to 60 kDa and a PDI of 3 to 8 based on GPC relative to polystyrene standards.

[0156] In a preferred embodiment, the tensile strength of the non-oriented form of the poly(butylene succinate) or copolymer thereof used to make the implant should be at least 1 MPa, preferably 10 MPa, more preferably 35 MPa, and even more preferably up to 70 MPa or more. A particularly preferred tensile range for the non-oriented form is 35 MPa to 60 MPa. The Young's modulus of the non-oriented form of the poly(butylene succinate) or copolymer thereof used to make the implant should preferably be in the range of 30 MPa to 700 MPa, more preferably in the range of 300 MPa to 500 MPa, depending on its crystallinity. It is also preferred that the melting point of the polymer or copolymer is at least 80°C, preferably 90°C, and even more preferably greater than 100°C. In a preferred embodiment, the melting point of the poly(butylene succinate) or copolymer thereof used to make the implant is 115°C ± 20°C, more preferably 105°C to 120°C. Higher melting points (over 100°C) are preferred for providing improved stability to the implant, especially during sterilization, transportation and storage.

[0157] In a preferred embodiment, the poly(butylene succinate) or copolymer thereof used to make the implant has one or more, or all, of the following properties: 1.23 g / cm 3 Up to 1.26g / cm 3 The composite has a density of -31°C to -35°C, a glass transition temperature of 113°C to 117°C, a melt flow rate (MFR) of 2g / 10min to 10g / 10min at 190°C / 2.16kgf, and a tensile strength of 30MPa to 60MPa.

[0158] In yet another embodiment, the poly(butylene succinate) or copolymer thereof used to make the implant may comprise micropores. The average diameter of the micropores is generally in the range of 10 μm to 1 mm. Preferably, the average diameter of the micropores is greater than 50 μm or 75 μm to provide holes of appropriate size to promote tissue ingrowth. Optionally, the average diameter of the micropores is selected to be 50 μm to 500 μm.

[0159] For example, one object of the present invention is to manipulate the microporosity of poly(butylene succinate) or copolymers thereof in order to control the degradation rate of articles (particularly medical implants) formed from, comprising, consisting essentially of, or consisting of poly(butylene succinate) or copolymers thereof; and / or to control the degradation rate of components of those articles (particularly medical implants) made from poly(butylene succinate) or copolymers thereof.

[0160] Introducing micropores into a poly(butylene succinate) polymer or copolymer thereof can allow the polymer or copolymer to degrade more easily in the environment and / or in vivo (eg, following implantation).

[0161] Thus, the present invention also provides methods for making implants, particularly implants described elsewhere in this application, which increase the microporosity and / or exposed surface area of ​​poly(butylene succinate) polymers or copolymers thereof, thereby altering the degradability.

[0162] For example, microporous poly(butylene succinate) polymers or copolymers thereof can be made using methods that create pores, voids, or interstitial spaces, such as emulsion or spray drying techniques, or using methods that incorporate gaseous, liquid leachable, or freeze-dried particles into the polymer or copolymer. Examples include fibers (including monofilaments and multifilaments), foams, coatings, webs, microparticles, and other articles (e.g., as described elsewhere in this application).

[0163] Optionally, the degradation rate of an article formed from a poly(butylene succinate) polymer or a copolymer thereof can be increased by forming the article from such a polymer or copolymer that includes an additive that forms micropores therein.

[0164] Porosity formers are usually added as particles and include water-soluble compounds that can be removed by leaching, such as inorganic salts and sugars. However, gaseous or liquid pore formers can also be used. Suitable particles include salt crystals, proteins such as gelatin and agarose, starch, polysaccharides such as alginate and other polymers. The average diameter of the particles can be appropriately sized to provide micropores with an average diameter within the above range. Gaseous pore formers include carbon dioxide, steam or supercritical carbon dioxide or other gases and liquids, which can be added to polymers or molten polymers under pressure. After the pressure is released, the gaseous additive can expand and preferentially evaporate to leave holes in the polymer or device.

[0165] Pore ​​forming agents useful for producing microporous poly(butylene succinate) polymers or copolymers thereof can be lyophilizable. Lyophilizable liquids include water or dioxane, while lyophilizable solids include ammonium chloride or ammonium acetate.

[0166] Pore ​​formers for producing microporous poly(butylene succinate) polymers or copolymers thereof may be included, for example, in amounts of 0.01% to 90% by weight to volume, preferably at levels of 1% to 30% (w / w, polymer), to enhance micropore formation in the poly(butylene succinate) polymers or copolymers thereof.

[0167] In one option, after the poly(butylene succinate) polymer or copolymer thereof containing a pore former is formed, it can be treated to remove the pore former (e.g., by leaching, evaporation, or lyophilization) to produce a microporous poly(butylene succinate) polymer or copolymer thereof. Removal of the pore former can occur before, during, or after the poly(butylene succinate) polymer or copolymer thereof has been structurally configured into a form (e.g., shape, size, etc.) present in a finished medical implant.

[0168] In a particularly preferred embodiment, it is important that the poly(butylene succinate) or copolymer thereof has a low water content during processing and storage. This is necessary to ensure that an implant having high tensile strength, extended strength retention, and good shelf life can be produced. In a preferred embodiment, the water content of the polymers and copolymers used to prepare the implant is less than 1,000 ppm (0.1 wt %), less than 500 ppm (0.05 wt %), less than 300 ppm (0.03 wt %), more preferably less than 100 ppm (0.01 wt %), even more preferably less than 50 ppm (0.005 wt %).

[0169] The composition used to prepare the implant must have a low endotoxin content. The endotoxin content must be low enough so that the endotoxin content of the implant produced by poly(butylene succinate) or its copolymer is less than 20 endotoxin units / device as determined by the Limulus amebocyte lysate (LAL) assay. In one embodiment, the endotoxin content of the composition is <2.5EU / g PBS or its copolymer.

[0170] Optionally, resorbable implants and other articles produced by a polymer composition comprising a poly(butylene succinate) polymer or its copolymer can be implants and articles comprising a component made from the polymer composition, a component made from the polymer composition substantially, or a component made from the polymer composition. For example, the polymer composition can be present in resorbable implants and other articles of the present invention in an amount of at least or greater than about 5 wt %, 10 wt %, 15 wt %, 20 wt %, 30 wt %, 40 wt %, 50 wt %, 60 wt %, 70 wt %, 80 wt %, 85 wt %, 90 wt %, 95 wt %, 96 wt %, 97 wt %, 98 wt %, 99 wt %, or substantially 100 wt %, the remainder of which, if any, can be, for example, but not limited to, other components in resorbable implants and other articles, which other components can be other resorbable or non-resorbable parts, bioactive agents, or any other components of resorbable implants and other articles.

[0171] B. Additives and other polymers

[0172] Certain additives may be incorporated into the poly(butylene succinate) and copolymers thereof prior to converting them into resorbable implants. Preferably, these additives are incorporated during the compounding process to produce pellets that can subsequently be processed into implants. For example, the additive can be compounded with poly(butylene succinate) or its copolymer, the compounded poly(butylene succinate) or its copolymer is extruded into pellets, and the pellets are 3D printed or extruded into fibers suitable for making implantable surgical meshes (including but not limited to surgical meshes for soft tissue implants for strengthening soft tissue, surgical meshes for bridging fascial defects, surgical meshes for trachea or other organ patches, surgical meshes for organ repair, surgical meshes for dura mater graft materials, surgical meshes for wound or burn dressings, surgical meshes for breast reconstruction, surgical meshes for hernia repair, or surgical meshes for hemostatic packing; or surgical meshes in the form of mesh plugs), for example, by knitting, weaving or 3D printing. In another embodiment, a solution-based process can be used to incorporate the additive. In a preferred embodiment of the present invention, the additive is biocompatible, and even more preferably the additive is both biocompatible and resorbable.

[0173] In one embodiment of the invention, the additive can be a nucleating agent, a dye or a coloring agent, a processing aid and / or a plasticizer. These additives can be added in sufficient amounts to produce the desired result. Usually, these additives can be added in an amount of up to 20% by weight. Nucleating agents can be incorporated to improve the crystallization rate or increase the crystallization temperature of poly (butylene succinate) or its copolymer. Such material can be used for example to improve the mechanical properties of fiber and mesh and implant, and reduce the cycle time. Preferred nucleating agents include but are not limited to salts of organic acids such as calcium citrate, poly (butylene succinate) polymers and copolymers of polymers or oligomers, high melting point polymers such as polyglycolic acid and polylactic acid, alpha-cyclodextrin, talcum, micronized mica, calcium carbonate, ammonium chloride and aromatic amino acids such as tyrosine and phenylalanine or salts of these.

[0174] Plasticizers that can be incorporated into the composition include, but are not limited to, polyethylene glycol, polypropylene glycol, polybutylene glycol, copolymers of ethylene glycol, propylene glycol and or butylene glycol, di-n-butyl maleate, methyl laurate, dibutyl fumarate, di(2-ethylhexyl)(dioctyl) maleate, paraffin, dodecanol, olive oil, soybean oil, polytetramethylene glycol, methyl oleate, n-propyl oleate, tetrahydrofurfuryl oleate, epoxidized linseed oil, 2-ethylhexyl epoxy tall ester, triacetin, methyl linoleate, dibutyl fumarate, methyl acetylated castor oil, Oleic acid esters, acetyl tri(n-butyl) citrate, acetyl triethyl citrate, tri(n-butyl) citrate, triethyl citrate, bis(2-hydroxyethyl) dimer, butyl ricinoleate, glyceryl tri(acetyl ricinoleate), methyl ricinoleate, n-butyl acetyl ricinoleate, propylene glycol ricinoleate, diethyl succinate, diisobutyl adipate, dimethyl azelate, di(n-hexyl) azelate, tributyl phosphate, and mixtures thereof. Particularly preferred plasticizers are citrate esters.

[0175] In another preferred embodiment of the present invention, the additives are contrast agents, radiopaque markers and radioactive substances. These additives can also be incorporated into poly(butylene succinate) or its copolymers before or after preparing implants (e.g., fibers, meshes or 3D printed objects).

[0176] In another embodiment, the additive is a dye. Preferred dyes include D&C Blue No. 9 (7,16-dichloro-6,15-dihydro-5,9,14,18-dianthracene [1,2-1',2'] pyridazine-tetrone as defined in section 74.1109 of the U.S. Code of Federal Regulations (CFR)), D&C Green No. 5 (2,2'-[(9,10-dihydro-9,10-dioxo-1,4-anthracenediyl) diimino] bis-[5-methylbenzenesulfonic acid] (CAS Registry No. 4403-90-1 as defined in section 74.1205 of the CFR), FD&C Blue No. 2 (as defined in section 74.3102 of the CFR), D&C Blue No. 6 (as defined in section 74.3103 of the CFR). 74.3106, mainly [Δ2,2'-bisindoline]-3,3'-dione (CAS Reg. No. 482-89-3), D&C Green No. 6 (as defined in CFR 74.3206) and D&C Violet No. 2 (as defined in CFR 74.3602). In some embodiments, the dye is blended with the poly(butylene succinate) or copolymer thereof prior to melt processing or melt compounding. In some embodiments, the dye is dry blended with the poly(butylene succinate) or copolymer thereof (e.g., the dye is spread on polymer pellets), or the dye is melt compounded with the poly(butylene succinate) or copolymer thereof. In some embodiments, one or more dyes can be blended with the poly(butylene succinate) or copolymer thereof, and the dyed blend can be extruded to form a dyed fiber, such as a dyed monofilament or multifilament fiber, or the blend can be melt processed to form a dyed nonwoven, film, injection molded construct, foam, thermoform, laminate, pultruded construct, extruded tube, or 3D printed construct. In some embodiments, dyeing agent and poly (butylene succinate) or its copolymer can be carried out solution blending to form dyed object, such as dyed fiber or dyed nonwoven. In some embodiments, dye and poly (butylene succinate) or its copolymer solution can be carried out electrospinning to form dyed nonwoven. In some embodiments, dye and poly (butylene succinate) or its copolymer blend or mixing to form dye concentration is 0.001 % by weight to 1 % by weight, more preferably 0.01 % by weight to 0.08 % by weight blend, object or construct.

[0177] In yet another embodiment of the present invention, the additive is another polymer, preferably another resorbable polymer. Examples of other resorbable polymers that can be incorporated into the composition for making an implant are: polymers and copolymers of glycolic acid, lactic acid, 1,4-dioxanone, trimethylene carbonate, ε-caprolactone, 3-hydroxybutyrate, 4-hydroxybutyrate, including polyglycolic acid, polylactic acid, polydioxanone, polycaprolactone, poly-4-hydroxybutyrate and copolymers thereof, poly-3-hydroxybutyrate, copolymers of glycolic acid and lactic acid, for example polymer, and Polymers, and include poly(lactide-co-caprolactone); poly(orthoesters); polyanhydrides; poly(phosphazenes); synthetic or biologically produced polyesters; polycarbonates; tyrosine polycarbonate; polyamides (including synthetic and natural polyamides, polypeptides and poly(amino acids)); polyesteramides; poly(alkylene alkylates); polyethers (e.g., polyethylene glycol PEG and polyethylene oxide PEO); polypropylene glycol, polypropylene oxide and copolymers of ethylene and propylene oxide, polybutylene glycol, polytetrahydrofuran); polyvinyl pyrrolidone or PVP; polyurethanes; polyetheresters; polyacetals; polycyanoacrylates; poly(oxyethylene) / poly(oxypropylene) copolymers; polyacetals, polyketals; polyphosphates (polyp hosphate); (phosphorus-containing) polymers; polyphosphoesters; polyalkylene oxalates; polyalkylene succinates; poly(maleic acid); silk (including recombinant silk and silk derivatives and analogs); cellulose (including bacterial cellulose and recombinant cellulose); chitin; chitosan; modified chitosan; biocompatible polysaccharides; hydrophilic or water-soluble polymers, such as polyethylene glycol (PEG) or polyvinyl pyrrolidone (PVP), and blocks of other biocompatible or biodegradable polymers, such as poly(lactide), poly(lactide-co-glycolide) or polycaprolactone and copolymers thereof, including random copolymers and block copolymers thereof. In some embodiments, these polymers are blended with PBS or its copolymers so that the content of the polymer in PBS or its copolymers is 0.1 wt % to 99.9 wt %, more preferably 0.1 wt % to 30 wt %, and even more preferably 0.1 wt % to 20 wt %. In some embodiments, the polymer is blended with PBS or its copolymers by solution blending or melt blending. In one embodiment, the polymers are blended using a twin screw extruder.

[0178] In one embodiment, the polymer composition of PBS or a copolymer thereof is not blended with another polymer.

[0179] In another embodiment, the polymer composition of PBS or a copolymer thereof is not blended with polylactic acid (PLA), which may be poly-L-lactic acid (PLLA), poly-D-lactic acid (PDLA), or poly-D,L-lactic acid (PDLLA).

[0180] In another embodiment, the polymer composition of PBS or its copolymer can be blended with PLA (which can optionally be PLLA, PDLA or PDLLA), wherein it can be preferred that: (i) the blend contains no other polymers besides PBS or its copolymer and PLA; or (ii) the blend contains at least or greater than 40 wt%, 50 wt%, 60 wt%, 70 wt%, or 80 wt% PBS or its copolymer, for example greater than 85 wt%, 90 wt%, 95 wt%, 96 wt%, 97 wt%, 98 wt%, or 99 wt% PBS or its copolymer, the remainder of which can be PLA alone or together with any other components of the blend.

[0181] In another embodiment, the polymer composition of PBS or its copolymer is not blended with polycaprolactone (PCL) and / or if it is blended with PCL, the blend does not include polyanhydride and / or any other polymer.

[0182] In another embodiment, the polymer composition of PBS or its copolymer is not blended with chitosan and / or if it is blended with chitosan, the blend contains greater than 50 wt%, 60 wt%, 70 wt%, 80 wt%, 90 wt%, 95 wt%, 96 wt%, 97 wt%, 98 wt%, or 99 wt% PBS or its copolymer.

[0183] In one embodiment, a polymer composition of PBS or a copolymer thereof is blended with polyglycolic acid, and the blend comprises greater than 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% by weight of PBS or a copolymer thereof.

[0184] In one embodiment, a polymer composition of PBS or a copolymer thereof is blended with polydioxanone, and the blend comprises greater than 20 wt%, 30 wt%, 40 wt%, 50 wt%, 60 wt%, 70 wt%, 80 wt%, 90 wt%, 95 wt%, 96 wt%, 97 wt%, 98 wt%, or 99 wt% of PBS or a copolymer thereof.

[0185] In one embodiment, a polymer composition of PBS or a copolymer thereof is blended with a copolymer comprising glycolic acid and trimethylene carbonate, and the blend comprises greater than 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% by weight of PBS or a copolymer thereof.

[0186] In one embodiment, the polymer composition of PBS or its copolymer is blended with poly-4-hydroxybutyrate (P4HB), and the blend comprises greater than 5 wt %, 10 wt %, 20 wt %, 30 wt %, 40 wt %, 50 wt %, 60 wt %, 70 wt %, 80 wt %, 90 wt %, 95 wt %, 96 wt %, 97 wt %, 98 wt % or 99 wt % PBS or its copolymer. In some embodiments, PBS or its copolymer is blended with P4HB, and the blend comprises 0.1 wt % to 25 wt % PBS or its copolymer. It has been found that 0.1 wt % to 25 wt % PBS or its copolymer is blended with P4HB to improve the crystallization rate of P4HB, and to improve the crystallization temperature. These variations of crystallization rate and time can be used for melt processing in particular, for example the formation of fibers, which include monofilament and multifilament fibers, films, nonwovens and other textiles. In some embodiments, P4HB is blended with PBS or a copolymer thereof, and the blend comprises 0.1 wt % to 25 wt % P4HB. Blending 0.1 wt % to 25 wt % P4HB with PBS or a copolymer thereof can be used to increase the degradation rate of PBS or a copolymer thereof.

[0187] In one embodiment, a polymer composition of PBS or a copolymer thereof is blended with poly-3-hydroxybutyrate-co-4-hydroxybutyrate, and the blend comprises greater than 5 wt%, 10 wt%, 20 wt%, 30 wt%, 40 wt%, 50 wt%, 60 wt%, 70 wt%, 80 wt%, 90 wt%, 95 wt%, 96 wt%, 97 wt%, 98 wt%, or 99 wt% of PBS or a copolymer thereof.

[0188] In one embodiment, a polymer composition of PBS or a copolymer thereof is blended with a polymer comprising 3-hydroxybutyrate, and the blend comprises greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% by weight of PBS or a copolymer thereof.

[0189] In one embodiment, a polymer composition of PBS or a copolymer thereof is blended with a polymer comprising 3-hydroxybutyrate and 3-hydroxyhexanoate, and the blend comprises greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% by weight of PBS or a copolymer thereof.

[0190] In one embodiment, a polymer composition of PBS or a copolymer thereof is blended with a polymer comprising 3-hydroxyoctanoate, and the blend comprises greater than 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 95, 96, 97, 98, or 99 weight percent of PBS or a copolymer thereof.

[0191] In one embodiment, a polymer composition of PBS or a copolymer thereof is blended with a polymer comprising glycolic acid and ε-caprolactone, and the blend comprises greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% by weight of PBS or a copolymer thereof.

[0192] In one embodiment, the polymer composition of PBS or its copolymer is blended with a polymer comprising lactic acid, and the blend comprises greater than 5 wt %, 10 wt %, 20 wt %, 30 wt %, 40 wt %, 50 wt %, 60 wt %, 70 wt %, 80 wt %, 90 wt %, 95 wt %, 96 wt %, 97 wt %, 98 wt %, or 99 wt % PBS or its copolymer. In some embodiments, the polymer composition of PBS or its copolymer is blended with a copolymer comprising lactic acid, and the blend comprises greater than 5 wt %, 10 wt %, 20 wt %, 30 wt %, 40 wt %, 50 wt %, 60 wt %, 70 wt %, 80 wt %, 90 wt %, 95 wt %, 96 wt %, 97 wt %, 98 wt %, or 99 wt % PBS or its copolymer.

[0193] In one embodiment, a polymer composition of PBS or a copolymer thereof is blended with a polymer comprising glycolic acid and lactic acid, and the blend comprises greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% by weight of PBS or a copolymer thereof.

[0194] In some embodiments, the above polymers can be blended with PBS or its copolymers by solution blending or melt blending. In a preferred embodiment, a twin-screw extruder is used to prepare the blend.

[0195] In some embodiments, the additive is a hydrogel.

[0196] C. Bioactive Agents

[0197] If desired, implants of poly(butylene succinate) and / or copolymers thereof can incorporate one or more bioactive agents, including one or more drugs, for example, to form a drug delivery device.

[0198] Available bioactivators include, but are not limited to, physiology or pharmacologically active substances acting locally or systemically in vivo. Bioactivators are substances used for, for example, treatment, prevention, diagnosis, cure or alleviation of disease or illness, substances that affect body structure or function, or become more biologically active or more active prodrugs after being placed in a predetermined physiological environment. Bioactivators include biological, physiological or pharmacologically active substances acting locally or systemically in human or animal bodies, preferably include agents that promote host tissue healing and regeneration, and also include therapeutic agents for preventing, suppressing or eliminating infection. Examples may include, but are not limited to, small molecule drugs, peptides, proteins, antibodies, antimicrobials, antibiotics, antiparasitic agents, sugars, polysaccharides, nucleotides, oligonucleotides, hyaluronic acid and derivatives thereof, aptamers, siRNA, nucleic acids, and combinations thereof.

[0199] In certain exemplary embodiments, these bioactive agents may be added during the formulation process, during granulation or blending, or may be added after implantation.

[0200] In one embodiment, one or more bioactive agents or drugs are uniformly dispersed in the polybutylene succinate and / or copolymer.

[0201] The percentage load of one or more bioactive agents or drugs will depend on the specific treatment and the desired release kinetics. Polybutylene succinate polymers and / or copolymers are suitable for loading at least 33 % by weight of one or more bioactive agents or drugs (i.e., the polymer to drug ratio is 2:1). Higher loads up to 1:1 can also be used. The desired release kinetics will also depend on the specific treatment.

[0202] In a preferred embodiment, the device is characterized by linear or zero order release of one or more bioactive agents or drugs. In a more preferred embodiment, the device does not release one or more bioactive agents or drugs in a burst.

[0203] One or more bioactive agents or drugs will generally release over a period of at least 3 days, 7 days, 21 days, at least 1 month, at least 3 months, or at least 6 months. It is generally preferred that one or more bioactive agents or drugs are released linearly. The duration of one or more bioactive agents or drugs release can be controlled by selecting one or more bioactive agents or drugs, changing the load and / or shape and configuration of the device. The change of device porosity and / or microporosity can also be used to change the release kinetics of one or more bioactive agents or drugs. Optionally, after the device is incubated in vitro for 10 days at 37°C in a phosphate buffer of 0.1M, pH 7.4, release less than 5 wt%, 10 wt%, 20 wt%, 30 wt%, 40 wt%, 50 wt%, 60 wt%, 70 wt%, 80 wt%, or 90 wt% of one or more bioactive agents or drugs.

[0204] Examples of bioactive agents that can be incorporated into implants of poly(butylene succinate) or its copolymers include, but are not limited to, small molecule drugs, anti-inflammatory agents, immunomodulators, molecules that promote cell migration, molecules that promote or delay cell division, molecules that promote or delay cell proliferation and differentiation, molecules that stimulate cell phenotype modification, molecules that promote or delay angiogenesis, molecules that promote or delay blood vessel formation, molecules that promote or delay extracellular matrix distribution, signaling ligands, platelet-rich plasma, peptides, proteins, glycoproteins, anesthetics, hormones, antibodies, The invention relates to a method for implanting a fibroblastic implant comprising: injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, injecting a fibroblastic implant into a tissue sample, The hydrogel barrier is coated on the surface where tissue ingrowth is undesirable.Such an implant can be used, for example, in hernia repair to minimize tissue attachment of the implant to the visceral side after intra-abdominal placement.

[0205] Antimicrobial agents that can be incorporated into implants of poly(butylene succinate) and its copolymers include, but are not limited to, antibacterial, antiviral, antifungal, and antiparasitic agents. Antimicrobial agents include substances that kill or inhibit the growth of microorganisms, such as microbicides and microstatins. Antimicrobial agents that may be incorporated into implants of poly(butylene succinate) and copolymers thereof include, but are not limited to, rifampicin; minocycline and its hydrochloride, sulfate or phosphate salts; triclosan; chlorhexidine; vancomycin and its hydrochloride, sulfate or phosphate salts; tetracycline and its hydrochloride, sulfate or phosphate salts, and derivatives; gentamicin; cephalosporin microbial agents; aztreonam; cefotetan and its disodium salt; loracarbef; cefoxitin and its sodium salt; cefazolin and its sodium salt; cefaclor; ceftibuten and its sodium salt; ceftizoxime; ceftizoxime sodium salt; cefoperazone and its sodium salt; cefuroxime and its sodium salt; cefuroxime axetil; cefprozil; ceftazidime; cefotaxime and its sodium salt; cefadroxil; ceftazidime chloramphenicol; chloramphenicol sodium; chloramphenicol sodium; chloramphenicol and its hydrochloride, sulfate or phosphate; chloramphenicol and its sodium salt ... azoles; polymyxin E mesylate and its sodium salt; quinupristin; dalfopristin; amoxicillin; ampicillin and its sodium salt; clavulanic acid and its sodium or potassium salt; penicillin G; benzathine penicillin G or procaine salt; penicillin G sodium or potassium salt; carbenicillin and its disodium salt or indane disodium salt; piperacillin and its sodium salt; ticarcillin and its disodium salt; sulbactam and its sodium salt; moxifloxacin; ciprofloxacin; ofloxacin; levofloxacin; norfloxacin; gatifloxacin; trovafloxacin mesylate; alatrofloxacin mesylate; trimethoprim; sulfamethoxazole azole; demeclocycline and its hydrochloride, sulfate or phosphate; doxycycline and its hydrochloride, sulfate or phosphate; oxytetracycline and its hydrochloride, sulfate or phosphate; chlortetracycline and its hydrochloride, sulfate or phosphate; metronidazole; dapsone; atovaquone; rifabutin; linezolid; polymyxin B and its hydrochloride, sulfate or phosphate; sulfacetamide and its sodium salt; clarithromycin; and silver ions, salts and complexes. In a preferred embodiment, the antimicrobial agent incorporated into the implant is (i) rifampicin and (ii) minocycline and its hydrochloride, sulfate or phosphate. In a particularly preferred embodiment, the implant of poly(butylene succinate) and its copolymers contains rifampicin and minocycline, or their hydrochloride, sulfate or phosphate.

[0206] The method for preparing oriented resorbable implants has been developed, and the implant comprises one or more antimicrobial agents to prevent the colonization of the implant, and reduces or prevents infection after implantation in the patient. The implant is designed to release the antimicrobial agent after implantation. The resorbable implant comprises oriented PBS and / or its copolymer. In one embodiment, the implant releases the antimicrobial agent for at least 2 days to 3 days. The implant is particularly suitable for operations with risk of infection, such as hernia repair, breast reconstruction and enlargement, mastopexy, orthopedic repair, wound management, pelvic floor reconstruction, including pelvic organ prolapse treatment (including the treatment of cystocele, urethrocele, uterine prolapse, vaginal misprolapse, enterocele and rectocele), for the surgical treatment of incontinence, stent implantation, heart valve surgery, dental surgery and other surgical procedures or plastic surgery. In a preferred embodiment, the method for producing a medical implant has been developed, and the implant comprises highly oriented fibers, meshes and / or films or other PBS and / or its copolymer products containing antimicrobial agents. The high degree of orientation of maintaining these fibers, meshes and / or films may be crucial for its physical function in vivo. The high degree of orientation of fibers, meshes and / or films allows these devices to maintain strength for a prolonged period of time in vivo ("extended strength retention"), therefore providing key support for tissue during reconstruction and repair steps. If orientation is lost during the preparation of fibers and meshes containing antimicrobials, the resulting products will have lower strength and strength retention, and necessary reinforcement and construction required for healing can not be provided. For example, using many solvents to spray or dip-coat oriented fibers may cause fiber orientation to be lost and strength retention to be lost. Developed a method that allows the preparation of PBS and copolymers thereof containing antimicrobials without significantly losing fiber orientation and therefore without significantly losing strength and strength retention.

[0207] Methods have also been developed for preparing resorbable shells, bags, holders, covers, meshes, nonwovens, films, clamshells, shells and other containers made of PBS and its copolymers that partially or completely encapsulate, surround or contain implantable medical devices, and wherein the PBS and its copolymers contain and release one or more antimicrobial agents to prevent colonization of the implant and / or reduce or prevent infection. Implantable medical devices that may be partially or completely encapsulated include cardiac rhythm management (CRM) devices (including pacemakers, defibrillators and pulse generators), implantable access systems, neurostimulators, ventricular access devices, infusion pumps, devices for delivering drugs and hydration solutions, intrathecal delivery systems, pain pumps, and other devices that provide drugs or electrical stimulation to body parts.

[0208] In one embodiment, the method disclosed herein is based on the following discovery: certain solvents and solvent mixtures can be used to apply antimicrobial agents to oriented constructs of PBS and its copolymers, such as fibers and meshes, without causing the deorientation of the construct. Solvents and solvent mixtures are essentially non-solvents or poor solvents for oriented constructs of PBS and its copolymers, but can dissolve antimicrobial agents. In addition, after being applied to the construct of PBS and its copolymers, the solvent: evaporates, can be removed by washing with another non-solvent of the construct; or can be easily dried and leave the antimicrobial agent on the construct. Therefore, the suitable solvent for applying antimicrobial agents to the oriented construct of PBS and its copolymers must be (i) a non-solvent or poor solvent for the construct, (ii) able to dissolve the antimicrobial agent at a suitable concentration, (iii) volatile or easy to remove from the construct using, for example, low heat or another non-solvent of the construct, and (iv) non-reactive and nontoxic. Examples of suitable non-solvents include hexane, ethyl acetate, methanol, ethanol, isopropanol, water, and combinations thereof.

[0209] Therefore, the application also provides: comprise the oriented form of PBS or its copolymer and the implant of one or more antimicrobial agents.In one embodiment, the oriented form can comprise fiber, mesh, woven fabric, nonwoven fabric, film, patch, pipe, laminate or pultruded profile.Optionally, fiber is monofilament, multifilament, braided or barbed.Optionally, mesh, woven fabric and nonwoven form are knitted mesh, woven mesh, monofilament mesh or multifilament mesh. Without limitation, the antimicrobial agent may be selected from one or more of the following: rifampicin; minocycline and its hydrochloride, sulfate or phosphate; triclosan; chlorhexidine; vancomycin and its hydrochloride, sulfate or phosphate; tetracycline and its hydrochloride, sulfate or phosphate, and derivatives; gentamicin; cephalosporin microbial agents; aztreonam; cefotetan and its disodium salt; loracarbef; cefoxitin and its sodium salt; cefazolin and its sodium salt; cefaclor; cefbutan and its sodium salt; ceftizoxime; ceftizoxime sodium salt; cefoperazone and its sodium salt; cefuroxime and its sodium salt; cefuroxime axetil; cefprozil; ceftazidime; cefotaxime and its sodium salt; cefadroxil; ceftazidime and its sodium salt; Cefalexin; Cefmandole sodium; Cefepime and its hydrochloride, sulfate and phosphate; Cefdinir and its sodium salt; Ceftriaxone and its sodium salt; Cefixime and its sodium salt; Cefpodoxime proxetil; Meropenem and its sodium salt; Imipenem and its sodium salt; Cilastatin and its sodium salt; Azithromycin; Clarithromycin; Dirithromycin; Erythromycin and its hydrochloride, sulfate or phosphate; Ethyl succinate and its stearate form; Clindamycin; Clindamycin hydrochloride, sulfate or phosphate; Lincomycin and its hydrochloride, sulfate or phosphate; Tobramycin and its hydrochloride, sulfate or phosphate; Streptomycin and its hydrochloride, sulfate or phosphate; Neomycin and its hydrochloride, sulfate or phosphate; Sulfadiazine azoles; polymyxin E mesylate and its sodium salt; quinupristin; dalfopristin; amoxicillin; ampicillin and its sodium salt; clavulanic acid and its sodium or potassium salt; penicillin G; benzathine penicillin G or procaine salt; penicillin G sodium or potassium salt; carbenicillin and its disodium salt or indane disodium salt; piperacillin and its sodium salt; ticarcillin and its disodium salt; sulbactam and its sodium salt; moxifloxacin; ciprofloxacin; ofloxacin; levofloxacin; norfloxacin; gatifloxacin; trovafloxacin mesylate; alatrofloxacin mesylate; trimethoprim; sulfamethoxazole azoles; demeclocycline and its hydrochloride, sulfate or phosphate; doxycycline and its hydrochloride, sulfate or phosphate; oxytetracycline and its hydrochloride, sulfate or phosphate; chlortetracycline and its hydrochloride, sulfate or phosphate; metronidazole; dapsone; atovaquone; rifabutin; linezolid; polymyxin B and its hydrochloride, sulfate or phosphate; sulfacetamide and its sodium salt; clarithromycin; and silver ions, salts and complexes.

[0210] Optionally, the oriented form may be already uniaxially or biaxially oriented, and more preferably, the oriented form may have one or more of the following properties: a tensile strength of 400 to 1200 MPa, a Young's modulus of less than 5.0 GPa (e.g., at least 600 MPa, at least 1 GPa, or at least 2 GPa, but less than 5 GPa), an elongation at break of 15% to 50%, a melting temperature of 105° C. to 120° C. In one option, the implant may comprise rifampicin and minocycline, or hydrochloride, sulfate or phosphate salts thereof.

[0211] One or more antimicrobial agents can for example release at least 2 days from implant.In some embodiments, implant can be the monofilament mesh with one or more of the following characteristics: at least 10N or at least 20N suture pull-out strength, at least 22lb power, the ball bursting strength of using 3 / 8 inch ball measurement, 10 μm to 1mm fiber diameter, at least 50 μm aperture and 0.01 Taber deflection unit to 10 Taber deflection units or 0.1 Taber deflection unit to 1 Taber deflection unit ...Optionally, the implant is selected from the group consisting of a suture, a barbed suture, a wound closure device, a patch, a wound healing device, a wound dressing, a burn dressing, an ulcer dressing, a skin substitute, a hemostatic agent, a tracheal reconstruction device, an organ salvage device, a dura mater patch or substitute, a nerve regeneration or repair device, a hernia repair device, a hernia mesh, a hernia plug, a device for temporary wound or tissue support, a tissue engineering scaffold, a guided tissue repair / regeneration device, an anti-adhesion membrane or barrier, a tissue separation membrane, a retention membrane, a sling, a device for pelvic floor reconstruction (including pelvic organ prolapse treatment, including bladder devices for the treatment of urethral prolapse, urethral prolapse, uterine prolapse, vaginal prolapse, enterocele and rectocele), urethral suspension devices, devices for the treatment of urinary incontinence, bladder repair devices, expansion or filling devices, bone marrow scaffolds, bone plates, fixation devices for implants, ligament repair devices or augmentation devices, anterior cruciate ligament repair devices, tendon repair devices or augmentation devices, rotator cuff repair devices, meniscus repair or regeneration devices, articular cartilage repair devices, osteochondral repair devices, spinal fusion devices, cardiovascular patches, catheter balloons, vascular closure devices, intracardiac septal defect repair devices devices, including but not limited to atrial septal defect repair devices and PFO (patent foramen ovale) closure devices, left atrial appendage (LAA) closure devices, pericardial patches, venous valves, heart valves, vascular grafts, myocardial regeneration devices, periodontal meshes, guided tissue regeneration membranes for periodontal tissue, ocular cell implants, imaging devices, cochlear implants, anastomotic devices, cell seeding devices, cell encapsulation devices, controlled release devices, drug delivery devices, plastic surgery devices, breast lift devices, mastopexy devices, breast reconstruction devices, augmentation mammoplasty devices (including devices for use with breast implants), devices for the removal, reshaping and reorientation of breast tissue), breast reduction devices (including devices for the removal, reshaping and reorientation of breast tissue), devices for breast reconstruction after mastectomy with or without the aid of breast implants, facial reconstruction devices, forehead lift devices, brow lift devices, eyelid lift devices, face lift devices, rhytidectomy devices, thread lift devices (to lift and support sagging areas of the face, brow and neck), rhinoplasty devices, devices for cheekbone augmentation, otoplasty devices, neck lift devices, genioplasty devices, cosmetic repair devices, and devices for facial scar repair. Optionally, the implant further comprises one or more of the following: a processing aid, a plasticizer, a nucleating agent, a dye, a medical marker, a therapeutic agent, a diagnostic agent, a prophylactic agent, a protein, a peptide, a polysaccharide, a glycoprotein, a lipid, a lipoprotein, a nucleic acid molecule, an inorganic or organic synthetic molecule, a contrast agent, a radiopaque marker, a radioactive material, hyaluronic acid or a derivative thereof, collagen, hydroxyapatite, or a resorbable polymer comprising one or more of the following monomer units: glycolic acid, lactic acid, trimethylene carbonate, dioxanone, and caprolactone.In some embodiments, the PBS or its copolymer is oriented in a form that is designed to partially or completely wrap, surround or contain a resorbable shell, bag, holder, cover, mesh, nonwoven, membrane, clamshell, shell and other container of an implantable medical device, and wherein the implantable medical device that can be partially or completely wrapped is selected from one of the following: cardiac rhythm management (CRM) devices (including pacemakers, defibrillators and generators), implantable access systems, neurostimulators, ventricular access devices, infusion pumps, devices for delivering drugs and hydration solutions, intrathecal delivery systems, pain pumps, or other devices that provide drugs or electrical stimulation to a body part. Optionally, the implant contains rifampicin and minocycline, or its hydrochloride, sulfate or phosphate, and also optionally, the antimicrobial agent can be released from the implant for at least 2 days.

[0212] In one embodiment, the bioactive agent can be applied as a coating with several layers, for example, a plurality of different layers are sprayed onto the device or on the selected area of ​​the device, or a layer-by-layer method using an alternating bioactive agent layer, coating or additive layer is used by application. These layers can be different in terms of the amount or concentration of the additive, or in terms of the type of coating material, or in terms of the counterion or charge of the coating material or additive. In a preferred embodiment, the layer is designed to degrade, dissolve or erode in a controlled manner, thereby extending the release time of the activating agent or the release kinetics of the activating agent. For example, a plurality of alternating layers of charged polymers (for example, positively charged polylysine and negatively charged polyaspartic acid) can be used to produce a coating comprising a bioactive agent by a layer-by-layer method. The release of the bioactive agent will depend on the degradation, dissolution or erosion rate of the layer in the target tissue.

[0213] D. Reactive Blending

[0214] In some embodiments, implant or the composition forming implant is prepared by reactive blending of PBS or its copolymer. In some embodiments, PBS or its copolymer comprises residual active catalyst from its preparation, or active catalyst is added to PBS or its copolymer to catalyze reactive blending. When blending with another polyester, oligomer or monomer, residual active catalyst or added catalyst can catalyze reactive blending of polyester, oligomer or monomer and PBS or its copolymer, causing transesterification between polyester, oligomer or monomer and PBS or its copolymer. Reactive blending in this way can be used to produce block copolymers of polyester and PBS or its copolymer or introduce new monomer units. In some embodiments, reactive blending is used to catalyze transesterification of PBS or its copolymer and another polyester, oligomer or monomer. In other embodiments, reactive blending is used to catalyze esterification or transesterification of PBS or its copolymer and one or more of the following: another polyester, oligomer or monomer containing ester group or hydroxyl group or monomer existing as lactone.

[0215] In some embodiments, the catalyst for reactive blending is a metal-based catalyst. When using a metallic compound as a reactive blending catalyst, the amount of the catalyst for preparing the blend of poly (butylene succinate) or its copolymer is preferably 0.1ppm or greater, preferably 0.5ppm or greater, more preferably 1ppm or greater, and less than 30,000ppm, preferably less than 1,000ppm, more preferably less than 250ppm, more preferably less than 130ppm. In some embodiments, the catalyst comprises one or more of the following metals: scandium, yttrium, titanium, zirconium, vanadium, molybdenum, tungsten, zinc, iron, tin and germanium. Preferred catalysts for reactive blending include titanium catalysts. A particularly preferred catalyst for reactive blending is titanium alkoxide. The titanium catalyst can be present in the PBS polymer or copolymer with a residual amount, or can be added to the polymer or copolymer.

[0216] In some embodiments, units or blocks of polymers, oligomers or monomers that are more susceptible to hydrolysis and degradation are introduced into the polymer backbone of PBS or its copolymer by reactive blending to improve the degradation rate of PBS polymers or copolymers. In some embodiments, the blend prepared by reactive blending of PBS or its copolymers comprises hydrolytically degradable polymers, oligomers or monomers. In some embodiments, the hydrolytically degradable polymers or oligomers are polyesters. In some embodiments, the hydrolytically degradable polymers, oligomers or monomers may comprise one or more of the following monomers: glycolic acid, lactic acid, p-dioxanone, trimethylene carbonate, 4-hydroxybutyric acid or its ester, 3-hydroxybutyric acid or its ester and ε-caprolactone. In some embodiments, the blend of PBS or its copolymer is formed by reactive blending of PBS or its copolymer with one or more of the following polyesters: polyglycolic acid, polylactic acid, polyglycolic acid-co-lactic acid, polydioxanone, poly-4-hydroxybutyrate, poly-3-hydroxybutyrate, copolymers comprising glycolic acid and ε-caprolactone, and poly-ε-caprolactone. In some embodiments, the blend of PBS or its copolymer formed by reactive blending comprises 1 wt % to 99 wt % of a hydrolytically degradable polymer, oligomer or monomer, more preferably, the blend comprises greater than 20 wt %, 30 wt %, 40 wt %, 50 wt %, 60 wt %, 70 wt %, 80 wt %, 90 wt %, 95 wt %, 96 wt %, 97 wt %, 98 wt % or 99 wt % of PBS or its copolymer. In some embodiments, the blend of PBS or its copolymer formed by reactive blending comprises 1 wt % to 99 wt % of a polymer, oligomer or monomer comprising one or more of the following monomers: glycolic acid, lactic acid, p-dioxanone, trimethylene carbonate, 4-hydroxybutyric acid, 3-hydroxybutyric acid and ε-caprolactone. In some embodiments, the blend formed by reactive blending further comprises a metal catalyst, preferably a titanium catalyst. In some embodiments, the blend of PBS or its copolymer formed by reactive blending comprises a titanium catalyst and 1 wt % to 99 wt % of a polymer comprising one or more of the following monomers: glycolic acid, lactic acid, p-dioxanone, trimethylene carbonate, 4-hydroxybutyric acid, 3-hydroxybutyric acid and ε-caprolactone. In some embodiments, the blend of PBS or its copolymers formed by reactive blending comprises a titanium catalyst and 1 wt % to 99 wt % of a combination of polymers, oligomers, and monomers comprising one or more of the following monomers: glycolic acid, lactic acid, p-dioxanone, trimethylene carbonate, 4-hydroxybutyric acid, 3-hydroxybutyric acid, and ε-caprolactone.

[0217] In some embodiments, blends of PBS or its copolymers with other polymers (including those listed in Section II.B) can be prepared by reactive blending with a free radical initiator. Suitable free radical initiators are organic peroxides, azo compounds or organic peroxy compounds. In some embodiments, the free radical initiator is dicumyl peroxide, di-(2-tert-butyl-isopropyl peroxide) benzene or azobisisobutyronitrile (AIBN). Suitable concentrations of the initiator include 0.01 phr (parts per hundred) to 1 phr, more preferably 0.1 phr to 0.5 phr.

[0218] Thus, in the context of reactive blending of PBS or copolymers thereof, the invention also provides the subject matter defined by the following numbered paragraphs:

[0219] Paragraph 1. An implant comprising a polymer composition comprising 1,4-butanediol units and succinic acid units, wherein the implant is formed by a process comprising reactive blending, wherein the polymer composition is reactively blended with another polyester, oligomer, or monomer, wherein the polymer composition further comprises residual catalyst or added catalyst, and wherein the oligomer or monomer comprises one or more hydroxyl, ester, or lactone groups.

[0220] Paragraph 2. The implant of Paragraph 1, wherein the catalyst used for reactive blending is a metal-based catalyst.

[0221] Paragraph 3. The implant of paragraph 2, wherein the metal-based catalyst comprises one or more of the following metals: scandium, yttrium, titanium, zirconium, vanadium, molybdenum, tungsten, zinc, iron, tin, and germanium.

[0222] Paragraph 4. The implant of Paragraph 3, wherein the metal-based catalyst is a titanium catalyst, including a titanium alkoxide.

[0223] Paragraph 5. The implant of Paragraph 3, wherein the catalyst is present in the polymer composition as a residual amount or is added to the polymer composition.

[0224] Paragraph 6. The implant of paragraphs 2 to 5, wherein the metal catalyst is present in the polymer composition at a level of 0.1 ppm or greater, preferably 0.5 ppm or greater, more preferably 1 ppm or greater, and less than 30,000 ppm, preferably less than 1,000 ppm, more preferably less than 250 ppm, more preferably less than 130 ppm.

[0225] Paragraph 7. The implant of Paragraphs 1 to 6, wherein the polyester, oligomer or monomer reactively blended with the polymer composition is hydrolytically degradable.

[0226] Paragraph 8. The implant of Paragraph 7, wherein the polyester, oligomer or monomer comprises one or more of glycolic acid, lactic acid, glycolide, lactide, p-dioxanone, trimethylene carbonate, 4-hydroxybutyric acid or its ester, 3-hydroxybutyric acid or its ester and ε-caprolactone.

[0227] Paragraph 9. The implant of Paragraph 7, wherein the polyester is selected from one or more of the following: polyglycolic acid, polylactic acid, polyglycolic acid-co-lactic acid, polydioxanone, poly-4-hydroxybutyrate, poly-3-hydroxybutyrate, a copolymer comprising glycolic acid and ε-caprolactone, and poly-ε-caprolactone.

[0228] Paragraph 10. The implant of Paragraphs 1 to 9, wherein the implant is formed by reactive blending and comprises 1 wt % to 99 wt % of a hydrolytically degradable polymer, oligomer or monomer, and more preferably, the reactive blend comprises greater than 20 wt %, 30 wt %, 40 wt %, 50 wt %, 60 wt %, 70 wt %, 80 wt %, 90 wt %, 95 wt %, 96 wt %, 97 wt %, 98 wt % or 99 wt % of PBS or a copolymer thereof.

[0229] Paragraph 11. The implant of paragraph 10, wherein the implant is formed by reactive blending with 1 wt % to 99 wt % of a polyester, oligomer or monomer comprising one or more of the following monomers: glycolic acid, lactic acid, glycolide, lactide, p-dioxanone, trimethylene carbonate, 4-hydroxybutyric acid, 3-hydroxybutyric acid and ε-caprolactone.

[0230] Paragraph 12. The implant of Paragraphs 1 to 11, wherein the reactive blend comprises a blend of PBS or a copolymer thereof, a titanium catalyst, and 1 wt % to 99 wt % of a polymer comprising one or more of the following monomers: glycolic acid, lactic acid, glycolide, lactide, p-dioxanone, trimethylene carbonate, 4-hydroxybutyric acid, 3-hydroxybutyric acid, and ε-caprolactone.

[0231] Paragraph 13. The implant of Paragraphs 1 to 11, wherein the reactive blend comprises a blend of PBS or a copolymer thereof, a titanium catalyst, and 1 wt % to 99 wt % of one or more polyesters, oligomers, and monomers comprising one or more of the following monomers: glycolic acid, lactic acid, glycolide, lactide, p-dioxanone, trimethylene carbonate, 4-hydroxybutyric acid, 3-hydroxybutyric acid, and ε-caprolactone.

[0232] Paragraph 14. The implant of paragraph 1, wherein the method further comprises adding a free radical initiator.

[0233] E. Combinations of PBS or its copolymers with catalysts to increase the weight average molecular weight of polymers or copolymers during melt processing

[0234] Preventing the weight average molecular weight loss of PBS or its copolymer during melt processing is important for making the tensile strength and the strength retention of the implant derived from these polymers maximized. Found that some compositions of PBS or its copolymer can be melt processed without losing weight average molecular weight, in fact can produce the compositions of PBS or its copolymer that wherein the weight average molecular weight of polymer improves during melt processing. In some implant applications, the raising of molecular weight can be particularly advantageous. For example, raising weight average molecular weight can make the strength retention of implant extend. In some embodiments, implant is formed by the chain extension of PBS or its copolymer during melt processing.

[0235] In some embodiments, there is provided a composition of such PBS or its copolymer, wherein when the polymer or copolymer is melt processed to form an implant, the weight average molecular weight of the PBS or its copolymer is increased. In some embodiments, these compositions include a catalyst. The catalyst may be a residual catalyst remaining in the polymer after the polymer is synthesized, or a catalyst may be added to the composition of the PBS or its copolymer. In some embodiments, the catalysis may include one of the following metals: scandium, yttrium, titanium, zirconium, vanadium, molybdenum, tungsten, zinc, iron, tin and germanium. A preferred catalyst includes titanium. A particularly preferred catalyst is titanium alkoxide. In some embodiments, the catalyst is present in the PBS or copolymer at a level of 0.1ppm to 1,000ppm, more preferably 1ppm to 1,000ppm, even more preferably 1ppm to 100ppm or 5ppm to 100ppm. In some embodiments, the weight average molecular weight of the PBS or its copolymer comprising the catalyst increases by 1% to 100%, more preferably 2% to 60%, even more preferably 2% to 31% during melt processing. In some embodiments, the weight average molecular weight of the PBS or copolymer thereof containing the catalyst increases during melt processing at a temperature of 150°C to 250°C, more preferably 180°C to 230°C. In some embodiments, a composition comprising PBS or copolymer thereof and 1 ppm to 100 ppm of a titanium catalyst is melt processed at a temperature in the range of 100°C to 250°C or 100°C to 230°C to form an implant, wherein the weight average molecular weight of the PBS or copolymer thereof in the implant is higher than the weight average molecular weight of the PBS or copolymer thereof before melt processing. In some embodiments, the thermal processing range reaches a peak temperature of 180°C to 250°C or 180°C to 230°C. In some embodiments, the compositions can be processed by melt processing methods including melt extrusion, injection molding, melt foaming, film melt extrusion, melt blowing, melt spinning, compression molding, lamination, thermoforming, molding, spunbonding, nonwoven fabrication, tube melt extrusion, fiber melt extrusion, 3D printing by melt extrusion deposition (MED), melt pellet deposition (FPD), fused filament fabrication (FFF), and selective laser melting (SLM).Implants that can be formed from these compositions include fibers, meshes including meshes for hernia repair and for breast reconstruction and breast lift, breast implants, scaffolds, monofilament fibers, multifilament fibers, nonwovens, films, injection molded implants, 3D printed implants, tubes, foams, screws, bone screws, interference screws, pins, ACL screws, clips, clamps, nails, intramedullary nails, bone plates, bone substitutes, tacks, fasteners, suture fasteners, rivets, staples, fixation devices, suture anchors, bone anchors, meniscus anchors, meniscus implants, intramedullary rods and nails, joint spacers, interosseous wedge implants, osteochondral repair devices, spinal fusion devices, spinal fusion cages, bone plugs, cranioplasty plugs, and plugs to fill or cover trephine drill holes, and other orthopedic implants. In one embodiment, the implant comprising PBS and its copolymers can be formed by melt processing and has a weight average molecular weight that is 1% to 100% higher, more preferably 1% to 50%, and even more preferably 5% to 30% higher than the weight average molecular weight of the PBS or its copolymers used to prepare the implant.

[0236] The increase in weight average molecular weight of a PBS copolymer containing a titanium catalyst during melt processing is described in Example 18, and the results are shown in Table 17. In this example, the PBS copolymer contains 56 ppm titanium and has a starting weight average molecular weight of 160.4 kDa. When the copolymer is processed at a temperature of 100°C to 230°C with a peak temperature of 180°C to 230°C, the weight average molecular weight of the implant formed by melt processing of the copolymer is 164.5 kDa to 209.4 kDa, representing an increase in weight average molecular weight of up to 31%.

[0237] Thus, in the context of a composition of a PBS or copolymer thereof with a catalyst to increase the weight average molecular weight of a polymer or copolymer during melt processing, the present invention also provides the subject matter defined by the following numbered paragraphs:

[0238] Paragraph 1. An implant comprising a polymer composition comprising 1,4-butanediol units and succinic acid units, wherein the implant is formed by melt processing, and wherein the weight average molecular weight of the polymer composition increases during melt processing.

[0239] Paragraph 2. The implant of Paragraph 1, wherein the polymer composition further comprises a catalyst prior to melt processing.

[0240] Paragraph 3. The implant of paragraph 2, wherein the catalyst comprises one or more of the following metals: scandium, yttrium, titanium, zirconium, vanadium, molybdenum, tungsten, zinc, iron, tin, and germanium.

[0241] Paragraph 4. The implant of Paragraph 3, wherein the catalyst is a titanium alkoxide.

[0242] Paragraph 5. The implant of Paragraphs 3 and 4, wherein the catalyst is present at a level of 0.1 ppm to 1,000 ppm.

[0243] Paragraph 6. The implant of Paragraph 1, wherein the weight average molecular weight increases by 1% to 100% during melt processing.

[0244] Paragraph 7. The implant of Paragraph 1, wherein the polymer composition is heated to a temperature of 150°C to 250°C during melt processing.

[0245] Paragraph 8. The implant of Paragraph 1, wherein the implant is melt processed by melt extrusion, injection molding, melt foaming, film extrusion, melt blowing, melt spinning, compression molding, lamination, thermoforming, molding, spunbonding, nonwoven manufacturing, tube extrusion, fiber extrusion, 3D printing via extrusion deposition, melt pellet deposition, fused filament manufacturing, and selective laser melting.

[0246] Paragraph 9. The implant of Paragraph 1, wherein the implant is a fiber, a suture, a mesh, including meshes for hernia repair, breast reconstruction and breast lift, breast implants, tissue scaffolds, monofilament fibers, multifilament fibers, nonwovens, films, injection molded implants, 3D printed implants, tubes, foams, screws, bone screws, interference screws, pins, ACL screws, clips, clamps, nails, intramedullary nails, bone plates, bone substitutes, tacks, fasteners, suture fasteners, rivets, staples, fixation devices, suture anchors, bone anchors, meniscus anchors, meniscus implants, intramedullary rods and nails, joint spacers, interosseous wedge implants, osteochondral repair devices, spinal fusion devices, spinal fusion cages, bone plugs, cranioplasty plugs, and plugs for filling or covering trephine holes.

[0247] Paragraph 10. The implant of paragraph 1, wherein the polymer composition is melt processed to form fibers, and wherein the fibers have one or more of the following properties: (i) a tensile strength of 400 MPa to 2,000 MPa, (ii) a Young's modulus of 600 MPa to 5 GPa, and (iii) an elongation at break of 10% to 150%.

[0248] Paragraph 11. The implant of paragraph 10, wherein the fibers are knitted, woven, or braided.

[0249] Paragraph 12. The implant of paragraph 11, wherein the implant is a mesh.

[0250] Paragraph 13. A method of forming an implant as described in any of paragraphs 1 to 12, wherein the implant is produced by a method comprising the following steps: (a) preparing a polymer composition comprising a polymer or copolymer of 1,4-butanediol units, succinic acid units, and a metal catalyst, wherein the metal catalyst comprises scandium, yttrium, titanium, zirconium, vanadium, molybdenum, tungsten, zinc, iron, tin or germanium, and (b) forming the implant by a process comprising melt processing of the polymer composition.

[0251] Paragraph 14. The method of paragraph 13, wherein the catalyst is present at a level of 0.1 ppm to 1,000 ppm.

[0252] Paragraph 15. The method described in paragraph 13, wherein the implant is formed by a process comprising one of the following melt processing processes: melt extrusion, injection molding, melt foaming, film extrusion, melt blowing, melt spinning, compression molding, lamination, thermoforming, molding, spunbonding, nonwoven manufacturing, tube extrusion, fiber extrusion, 3D printing via melt extrusion deposition, melt pellet deposition, fused filament manufacturing and selective laser melting.

[0253] Paragraph 16. The method of paragraph 13, wherein the polymer composition is heated to a temperature of 150° C. to 250° C. during melt processing.

[0254] Paragraph 17. The method of Paragraph 13, wherein the weight average molecular weight is increased by 1% to 100% during melt processing.

[0255] Paragraph 18. The method of paragraph 13, wherein the implant is a fiber, a suture, a mesh, including meshes for hernia repair, breast reconstruction and breast lift, breast implants, tissue scaffolds, monofilament fibers, multifilament fibers, nonwovens, films, injection molded implants, 3D printed implants, tubes, foams, screws, bone screws, interference screws, pins, ACL screws, clips, clamps, nails, intramedullary nails, bone plates, bone substitutes, tacks, fasteners, suture fasteners, rivets, staples, fixation devices, suture anchors, bone anchors, meniscus anchors, meniscus implants, intramedullary rods and nails, joint spacers, interosseous wedge implants, osteochondral repair devices, spinal fusion devices, spinal fusion cages, bone plugs, cranioplasty plugs, and plugs for filling or covering trephine holes.

[0256] Paragraph 19. The method of paragraph 13, wherein the polymer composition is melt processed to form fibers, and wherein the fibers have one or more of the following properties: (i) a tensile strength of 400 MPa to 2,000 MPa, (ii) a Young's modulus of 600 MPa to 5 GPa, and (iii) an elongation at break of 10% to 150%.

[0257] Paragraph 20. The implant of paragraph 13, wherein the fibers are knitted, woven, braided, or formed into a mesh.

[0258] III. Synthesis and processing of implants of poly(butylene succinate) and its copolymers

[0259] A. Poly(butylene succinate) and its copolymers

[0260] Poly(butylene succinate) and copolymers thereof can be synthesized by any suitable method. Suitable methods must provide biocompatible polymer compositions of PBS and copolymers thereof. In one embodiment, poly(butylene succinate) can be synthesized by (i) condensing or esterifying succinic acid and 1,4-butanediol or transesterifying dimethyl succinate and 1,4-butanediol to obtain oligomers, and (ii) polycondensing the oligomers to form high weight average molecular weight poly(butylene succinate).

[0261] In one method, poly(butylene succinate) can be prepared by charging succinic acid (or dimethyl succinate) and 1,4-butanediol (or a small excess of 1,4-butanediol) in a 1:1 ratio into a suitable container. The reactants are heated to 130°C to 190°C, more preferably 160°C to 190°C under an inert atmosphere to melt the acid component and distill off water (or methanol). Once the distillation is complete, a high vacuum is used to reduce the pressure in the container and produce a suitable high weight average molecular weight poly(butylene succinate) by polycondensation, preferably at a temperature of 220°C to 240°C in the presence of a catalyst with or without the addition of a co-catalyst.

[0262] Suitable catalysts for the synthesis of poly(butylene succinate) include p-toluenesulfonic acid, tin(II) chloride, monobutyltin oxide, tetrabutyl titanate, titanium isopropoxide, tetraisopropyl titanate, lanthanide triflate and distannoxane. The catalyst may include a metal element from Groups 1 to 14 of the periodic table. Preferred catalysts have the metal elements scandium, yttrium, titanium, zirconium, vanadium, molybdenum, tungsten, zinc, iron and germanium. Titanium catalysts and zirconium catalysts are particularly preferred for the preparation of poly(butylene succinate) and copolymers thereof. Tetraalkyl titanates are preferred catalysts. Specifically, tetra-n-propyl titanate, tetra-isopropyl titanate, tetra-n-butyl titanate, tetra-tert-butyl titanate, tetraphenyl titanate, tetracyclohexyl titanate, tetrabenzyl titanate, and mixed titanates thereof are preferred. In addition, (oxy) acetylacetonate titanium, tetraacetylacetonate titanium, (diisopropyl alcohol) acetylacetonate titanium, bis(lactate ammonium) titanium dihydroxide, bis(ethylacetoacetate) titanium diisopropylate, (triethanol amination) titanium isopropylate, polyhydroxy stearic acid titanium, lactic acid titanium, triethanol amination titanium, butyl titanate dimer is also a preferred catalyst. Among them, tetra-n-propyl titanate, tetraisopropyl titanate, and tetra-n-butyl titanate, (oxy) acetylacetonate titanium, tetraacetylacetonate titanium, bis(lactate ammonium) titanium dihydroxide, polyhydroxy stearic acid titanium, lactic acid titanium, and butyl titanate dimer are preferred, and tetra-n-butyl titanate, (oxy) acetylacetonate titanium, tetraacetylacetonate titanium, polyhydroxy stearic acid titanium, lactic acid titanium, and butyl titanate dimer are more preferred. In some embodiments, the preferred catalyst is titanium alkoxide. The zirconium catalyst that can be used for preparing polymer or copolymer includes zirconium tetraacetate, zirconium acetate hydroxide, three (butoxy) zirconium stearate, zirconium diacetate, zirconium oxalate, zirconium oxalate, potassium zirconium oxalate, polyhydroxy zirconium stearate, zirconium ethanol, zirconium tetra-propanol, zirconium tetra-isopropanol, zirconium tetra-n-butanol, zirconium tetra-tert-butanol, zirconium tributoxy acetylacetonate and mixture thereof. Wherein, zirconium diacetate, three (butoxy) zirconium stearate, zirconium tetraacetate, zirconium acetate hydroxide, zirconium ammonium oxalate, zirconium potassium oxalate, zirconium polyhydroxy stearate, zirconium tetra-n-propoxide, zirconium tetraisopropoxide, zirconium tetra-n-butoxide and zirconium tetra-tert-butoxide are preferred, and zirconium diacetate, zirconium tetraacetate, zirconium acetate hydroxide, three (butoxy) zirconium stearate, zirconium ammonium oxalate, zirconium tetra-n-propoxide and zirconium tetra-n-butoxide are more preferred.Especially, three (butoxy) zirconium stearate is preferred.Operable germanium catalyst comprises inorganic germanium compound such as germanium oxide and germanium chloride, and organic germanium compound such as tetraalkoxy germanium.Germanium oxide, tetraethoxy germanium, tetrabutoxy germanium etc. are preferred.Other metal-containing catalysts that can be used include scandium compounds such as scandium carbonate, scandium acetate, scandium chloride and scandium acetylacetonate, yttrium compounds such as yttrium carbonate, yttrium chloride, yttrium acetate and yttrium acetylacetonate, vanadium compounds such as vanadium chloride, vanadium oxychloride, vanadium acetylacetonate and vanadium acetylacetonate, molybdenum compounds such as molybdenum chloride and molybdenum acetate, tungsten compounds such as tungsten chloride, tungsten acetate, tungstic acid, and lanthanide compounds such as cerium chloride, samarium chloride and ytterbium chloride.

[0263] When a metal compound is used as a catalyst, the amount of the catalyst used to prepare poly(butylene succinate) or its copolymer is preferably 0.1 ppm or greater, preferably 0.5 ppm or greater, more preferably 1 ppm or greater, and less than 30,000 ppm, preferably less than 1,000 ppm, more preferably less than 250 ppm, more preferably less than 130 ppm.

[0264] In some embodiments, a phosphorus compound may be included in the polymerization process. In some embodiments, the phosphorus compound may be a cocatalyst. In some embodiments, a phosphorus compound may be a heat stabilizer. In some embodiments, the phosphorus compound may be a proton-releasing compound. In some embodiments, the phosphorus compound may be an organic phosphinic acid, an organic phosphonic acid, an inorganic phosphoric acid or a hydrogen phosphate. In some embodiments, the phosphorus compound may be: polyphosphoric acid, phosphoric acid, hypophosphorous acid, pyrophosphorous acid, phosphorous acid, metaphosphoric acid, superphosphoric acid, ammonium hydrogen phosphate, magnesium hydrogen phosphate, calcium hydrogen phosphate, ammonium polyphosphate, magnesium hydrogen phosphate, calcium hydrogen polyphosphate, tributyl phosphate, triphenyl phosphate, phenylphosphonic acid, benzylphosphonic acid, methylphosphonic acid, n-butylphosphonic acid, cyclophosphonic acid, diphenylphosphinic acid, phenylphosphinic acid, benzylphosphinic acid, methylphosphinic acid, n-butylphosphinic acid, cyclohexylphosphinic acid, sodium phenylphosphinate. In some embodiments, the phosphorus-containing compound is present in the PBS or its copolymer at a concentration of 0.001 wt % to 10 wt %, more preferably 0.001 wt % to 1 wt %, even more preferably 0.01 wt % to 0.1 wt %. In some embodiments, a phosphorus promoter is used with a metal catalyst to produce a PBS or its copolymer, wherein the atomic ratio P / M of phosphorus (P) to metal (M) is 0.01 to 0.8, more preferably 0.2 to 0.5.

[0265] After polycondensation is complete, the polymer can be purified by being dissolved in a solvent, filtered and separated out. For example, the polymer can be dissolved in chloroform, filtered, and separated out with an alcohol such as methanol or ethanol. If desired, the polymer can be further purified by washing, for example, with diethyl ether. Preferably, the amount of the metal in poly(butylene succinate) or its copolymer is less than 100ppm, more preferably less than 50ppm. Preferred metal content in poly(butylene succinate) or its copolymer is 0.1ppm to 100ppm, more preferably 1ppm to 50ppm.

[0266] After the polycondensation is complete, the polymer can be purified by washing with a non-solvent (e.g., methanol, ethanol, isopropanol, butanol, ethyl acetate, water, or a mixture thereof) to remove side reaction products such as tetrahydrofuran, unreacted monomers or oligomers. For example, the polymer can be suspended in methanol, ethanol, water, or a mixture thereof for a period of time at ambient temperature or an elevated temperature, and then collected by a solid-liquid separation step such as filtering or centrifugation. Residual washing solvent can be removed by drying, evaporation, or under vacuum. Such washing steps can also be performed to remove, hydrolyze, or deactivate residual catalysts.

[0267] In one embodiment, the polymer composition of PBS and copolymers thereof for the preparation of implants comprises one or more of the following from 1ppm to 500ppm: silicon, titanium and zinc. Preferably, the polymer composition comprises silicon, titanium and zinc that are less than 100ppm or that are less than 50ppm. In another embodiment, except silicon, titanium and zinc, or with the amount that can be detected by PIXE analysis or the catalyst and the co-catalyst of the amount that can be detected by ICP-MS analysis higher than 10ppm, the polymer composition for the manufacture of implants does not comprise metal. In a particularly preferred embodiment, the polymer composition for the manufacture of implants does not comprise tin.

[0268] Copolymers of poly(butylene succinate) can be formed by copolymerizing with different comonomer units, preferably dicarboxylic acids and diols, including, for example, adipic acid, terephthalic acid, fumaric acid, ethylene glycol, and 1,3-propylene glycol. Other suitable diol and dicarboxylic acid comonomer units include 1,2-propylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, 1,3-butylene glycol, 2,3-butylene glycol, 1,5-pentanediol, 1,2-pentanediol, 2,4-pentanediol, 1,6-hexanediol, 1,2-hexanediol, malonic acid, glutaric acid, suberic acid, sebacic acid, azelaic acid, decanedicarboxylic acid, dodecanedicarboxylic acid, and octadecanedicarboxylic acid. In a preferred embodiment, the content of the comonomer units is less than 30%, more preferably less than 20%, and even more preferably less than 15%. In another preferred embodiment, the comonomer content of the copolymer is less than 15%, and the melting point of the copolymer is greater than 100°C. Preferably, the melting point of the PBS copolymer is from 105°C to 120°C.

[0269] In yet another embodiment, the polymers and copolymers of succinic acid and 1,4-butanediol may contain a chain branching agent or chain extender, most preferably a chain branching agent or chain extender formed from an aliphatic hydroxycarboxylic acid. Preferred chain branching agents and / or chain extenders are trifunctional aliphatic hydroxycarboxylic acids and tetrafunctional aliphatic hydroxycarboxylic acids. Preferred trifunctional hydroxycarboxylic acid chain branching agents and / or chain extenders may have (i) two carboxyl groups and one hydroxyl group in the same molecule (e.g., malic acid), or (ii) one carboxyl group and two hydroxyl groups in the same molecule. Preferred tetrafunctional hydroxycarboxylic acid chain branching agents and / or chain extenders may have (i) three carboxyl groups and one hydroxyl group in the same molecule (e.g., citric acid), (ii) two carboxyl groups and two hydroxyl groups in the same molecule (e.g., tartaric acid), or (iii) three hydroxyl groups and one carboxyl group in the same molecule. Other chain branching agents and / or chain extenders that may be incorporated include hydroxyglutaric acid, hydroxymethylglutaric acid, hydroxyisophthalic acid, and hydroxyterephthalic acid. Malic acid, tartaric acid and citric acid are particularly preferred chain branching agents and / or chain extenders. Chain branching agents, crosslinking agents, coupling agents and chain extenders are preferably incorporated into poly(butylene succinate) and copolymers thereof in an amount of 0.001 mol% to 5.0 mol%, or 0.01 mol% to 5.0 mol%, more preferably 0.01 mol% to 2.5 mol%, most preferably 0.01 mol% to 0.5 mol% or 0.1 mol% to 0.5 mol%. In one embodiment, the chain branching agent and / or chain extender is malic acid. In a preferred embodiment, malic acid is incorporated into the poly(butylene succinate) or copolymer in an amount of 0.001 mol% to 5.0 mol% or 0.01 mol% to 5.0 mol%, more preferably 0.01 mol% to 0.5 mol% or 0.1 mol% to 0.5 mol%, or in an amount of 0.01 to 1 part by weight, more preferably 0.1 to 0.5 parts by weight. In a preferred embodiment, greater than 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% of the poly(butylene succinate) polymer chains are extended with malic acid. When malic acid is used as the trifunctional hydroxycarboxylic acid serving as a copolymerizable component, the example of copolyester includes succinic acid-1,4-butanediol-malic acid copolyester, succinic acid-adipic acid-1,4-butanediol-malic acid copolyester, succinic acid-1,4-butanediol-malic acid-tartaric acid copolyester, succinic acid-adipic acid-1,4-butanediol-malic acid-tartaric acid copolyester, succinic acid-1,4-butanediol-malic acid-citric acid copolyester and succinic acid-adipic acid-1,4-butanediol-malic acid-citric acid copolyester. Malic acid can exist as L-enantiomer, D-enantiomer, or both, but L-malic acid is preferred. During exposure to heat or further processing, the malic acid monomer in the copolymer can be dehydrated to produce fumaric acid monomer and / or maleic acid monomer in the copolymer.Therefore, the implants disclosed herein may also comprise fumaric acid units and maleic acid units, or a combination thereof.

[0270] Polymer chain branching, chain extension, and cross-linking can be detected and quantified using methods known in the art, such as laser light scattering.

[0271] B. Spinning of poly(butylene succinate) and its copolymers

[0272] Poly(butylene succinate) and copolymers thereof can be processed and oriented to provide implants with high tensile strength and extended strength retention. The polymer can be processed as a melt or in solution. In a preferred embodiment, poly(butylene succinate) and copolymers thereof are melt processed.

[0273] In melt processing of poly(butylene succinate) and copolymers thereof, it is important to prevent the polymer from hydrolysis due to residual moisture. Therefore, it is important to dry the polymer prior to melt processing. In a preferred embodiment, poly(butylene succinate) and copolymers are dried prior to melt processing to a water content of less than 0.1 wt. %, preferably less than 0.05 wt. %, more preferably less than 0.01 wt. %, and even more preferably less than 0.005 wt. %. The polymer may be dried with hot air and under vacuum prior to melt processing. In a preferred embodiment, the polymer is dried under vacuum at 30° C. to 90° C., more preferably 60° C. to 90° C. In addition, to prevent moisture absorption after drying, it is important to protect the polymer from exposure to moisture during processing and to process the polymer under dry conditions. Preferably, the polymer is kept under a blanket of dry, inert gas prior to and during extrusion and at the extruder outlet.

[0274] In order to obtain implants with high tensile strength and extended strength retention, it is important to prevent weight average molecular weight loss of poly(butylene succinate) and its copolymers during melt processing. At temperatures exceeding 200°C, the shear viscosity of poly(butylene succinate) may be significantly reduced. The magnitude of the loss increases as the temperature rises to above 200°C and as the exposure time increases. In order to manufacture implants with the highest tensile strength and extended strength retention, it is important to minimize the time the polymer is exposed to high processing temperatures and the presence of moisture in the polymer. In one embodiment, the implant is melt extruded at a temperature spectrum of 60°C to 230°C, more preferably 80°C to 180°C, and even more preferably 80°C to 170°C.

[0275] Examples 1 and 2 described herein compare two different methods of melt extruding poly(butylene succinate) and copolymers thereof. In some embodiments, the fibers are melt extruded using a standard thermal convection chamber as described in Example 1. In this embodiment, the monofilament fibers are oriented in 2 to 6 orientation stages, more preferably in 3, 4, or 5 orientation stages. In this embodiment (i.e., oriented using a standard thermal convection chamber), the fibers can be oriented in an ordered manner at least one day after extrusion (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 days after extrusion), or preferably in a disordered orientation.

[0276] Furthermore, it has been found that the method disclosed in Example 2 produces fibers having a tensile strength significantly higher than that of the fibers obtained by the method described in Example 1. Therefore, when fibers having high tensile strength and prolonged strength retention are desired, the method disclosed in Example 2 is preferably used to manufacture implants comprising the fibers.

[0277] For the same filament diameter, fibers with tensile strengths of 779 MPa to 883 MPa were obtained using the method disclosed in Example 2, compared to tensile strengths of 434 MPa to 518 MPa produced by the method disclosed in Example 1. The use of multi-stage incremental orientation of the fibers and the use of a conduction chamber rather than the standard thermal convection chamber used in Example 1 produced fibers with unexpectedly higher tensile strengths compared to the method of Example 1. Preferably, the filament fibers are oriented in 2 to 6 orientation stages, more preferably in 3, 4 or 5 orientation stages.

[0278] In a preferred embodiment, monofilament or multifilament fibers comprising poly(butylene succinate) and copolymers thereof are produced by a process comprising the steps of: (a) spinning a multifilament or multifilament fiber comprising a polymer composition, (b) drawing the multifilament or multifilament fiber in one or more stages at a temperature of 50° C. to 70° C. with an orientation ratio of at least 3.5, (c) drawing the multifilament or multifilament fiber in one or more stages at a temperature of 65° C. to 75° C. with an orientation ratio of at least 2.0, and (d) drawing the multifilament or multifilament fiber at an orientation ratio greater than 1.0 at a temperature of 70° C. to 75° C. Preferably, the sum of the orientation ratios exceeds 6.0, 6.5, 7.0, 7.5 or 8.0.

[0279] In an even more preferred embodiment, the fiber is drawn in a conducting liquid chamber. Before drawing the fiber, the melt-extruded polymer is preferably quenched in a conducting liquid bath. The temperature of the bath is preferably 50°C to 70°C. It may be necessary to further cool the fiber after quenching, and this can be achieved by passing the fiber between two godet rollers. In one embodiment, the temperature range for extruding PBS or its copolymer to form a high-strength fiber is 60°C to 230°C or 75°C to 220°C, but more preferably 75°C to 200°C, 80°C to 180°C, 80°C to 175°C, or 80°C to 170°C. Example 3 discloses a specific example of a method for preparing multifilament fibers of PBS and its copolymers using multi-stage incremental orientation and using a conducting chamber. Examples of multifilament fibers with a tenacity of 8.3g / d to 12.5g / d are shown. Preferably, the monofilament fiber is oriented in 2 to 6 orientation stages, more preferably in 3, 4 or 5 orientation stages.

[0280] If desired, the oriented fibers may be annealed. In one embodiment, the oriented fibers may be annealed using a temperature of 80°C to 120°C, more preferably 105°C ± 10°C.

[0281] In one embodiment, the diameter of the oriented monofilament fiber is 0.01 mm to 1.00 mm. In a particularly preferred embodiment, the diameter of the monofilament fiber is 0.07 mm to 0.7 mm. In another embodiment, the monofilament fiber may optionally meet the USP standard for an absorbable monofilament suture.

[0282] In one embodiment, the monofilament fiber of PBS and its copolymer has a tensile strength of 400MPa to 2,000MPa, more preferably, a tensile strength of greater than 500MPa, 600MPa, 700MPa or 800MPa but less than 1,200MPa. In another embodiment, the Young's modulus of the monofilament fiber of PBS and its copolymer is at least 600MPa and less than 5GPa, but more preferably greater than 800MPa, 1GPa, 1.5GPa and 2GPa. In another embodiment, the elongation at break of the monofilament fiber of PBS and its copolymer is 10% to 150%, more preferably 10% to 50%. In another embodiment, the monofilament fiber of PBS and its copolymer has a knot tensile strength of 200MPa to 1,000MPa, more preferably greater than 300MPa, 400MPa and 500MPa but less than 800MPa. In an even more preferred embodiment, the knot tensile strength of the monofilament fibers of PBS and its copolymers is from 300 MPa to 600 MPa.

[0283] In yet another embodiment, the tenacity of the multifilament fiber of PBS and its copolymers is greater than 4 g / denier but less than 14 g / denier. Preferably, the elongation at break of the multifilament fiber is from 15% to 50%.

[0284] Yarns and monofilament fibers of poly(butylene succinate) and copolymers thereof can be used to prepare knitted and woven meshes, nonwoven meshes, suture tapes, mesh sutures, surgical meshes (including but not limited to surgical meshes for soft tissue implants for reinforcing soft tissue, surgical meshes for bridging fascial defects, surgical meshes for trachea or other organ patches, surgical meshes for organ repair, surgical meshes for dura mater graft materials, surgical meshes for wound or burn dressings, surgical meshes for breast reconstruction, surgical meshes for hernia repair, or surgical meshes for hemostatic packing; or mesh Surgical mesh in the form of a material plug), mesh, patch (for example, but not limited to, hernia mesh and / or repair mesh for repairing abdominal and chest wall defects, inguinal hernia, para-colostomy hernia, ventral hernia, para-umbilical hernia, scrotal hernia or femoral hernia, mesh for muscle flap reinforcement, mesh for reinforcing staple lines and long incisions, mesh for pelvic floor reconstruction, mesh for treatment of pelvic organ prolapse (including treatment of cystocele, urethrocele, uterine prolapse, enterocele, repair of rectal or vaginal misprolapse), mesh for suture and staple pads, mesh for urinary or bladder repair, or mesh for cotton wool), and resorbable wound closure materials such as sutures and suture materials. These mesh, net and patch products are particularly useful for soft tissue repair, hernia repair, breast lift, breast reconstruction, face and neck lift, pelvic floor reconstruction, including pelvic organ prolapse treatment (including treatment of cystocele, urethrocele, uterine prolapse, vaginal misalignment prolapse, enterocele and rectocele), stress urinary incontinence treatment, organ salvage, lifting and suspension procedures, and can be used to make housings, pouches, retainers, covers, clamshells and cases to house implantable medical devices.

[0285] In one embodiment, the total filament length of a mesh, net or patch made using yarn or monofilament fibers of poly(butylene succinate) or its copolymers may be 10 cm / cm 2 Mesh, net or patch up to 400cm / cm 2 Mesh, net or patch, e.g. 20cm / cm 2 Mesh, net or patch up to 100cm / cm 2In another embodiment, the total length of a mesh, net or patch made using a yarn or monofilament fiber of poly(butylene succinate) or a copolymer thereof can be from 3 meters to 1,200 meters. The filament length can be measured, for example, by winding the fiber on a bobbin having a counter that measures its length (e.g., the number of revolutions of the bobbin).

[0286] The meshes, nets and patches described herein may comprise monofilament and / or multifilament fibers, wherein each fiber has an outer surface, thereby affecting the total fiber surface area. In one embodiment, the total fiber surface area in such a mesh, net or patch is 0.1 cm 2 / cm 2 Mesh, net or patch up to 125cm 2 / cm 2 Mesh, net or patch, e.g. 1cm 2 / cm 2 Mesh, net or patch up to 10cm 2 / cm 2 A mesh, net or patch.

[0287] In view of their mechanical properties, the yarns and monofilament fibers disclosed herein can also be used to prepare medical devices, including sutures, braided sutures, hybrid sutures of monofilament and multifilament fibers, barbed sutures, suture tapes, mesh sutures, surgical meshes (including but not limited to surgical meshes for soft tissue implants for reinforcing soft tissue, surgical meshes for bridging fascial defects, surgical meshes for tracheal or other organ patches, surgical meshes for organ repair, surgical meshes for dura mater graft materials, surgical meshes for wound or burn dressings, surgical meshes for breast reconstruction, surgical meshes for hernia repair, or surgical meshes for hemostatic packing. mesh; surgical mesh in the form of mesh plugs), braids, ligatures, tapes, knitted or woven meshes, knitted tubes, tubes suitable for the passage of body fluids, multifilament meshes, patches (such as, but not limited to, hernia patches and / or repair patches for the repair of abdominal and chest wall defects, inguinal hernias, paracolostomy hernias, ventral hernias, paraumbilical hernias, scrotal hernias or femoral hernias, patches for muscle flap reinforcement, patches for reinforcement of staple lines and long incisions, patches for pelvic floor reconstruction, patches for the repair of rectal or vaginal prolapse and the treatment of pelvic organ prolapse (including the treatment of cystocele, urethrocele, uterine prolapse and enterocele), patches for suture and staple pads, patches for urinary or bladder repair,or patch for cotton wool), wound healing device, bandage, wound dressing, burn dressing, ulcer dressing, skin substitute, hemostatic agent, tracheal reconstruction device, organ salvage device, dura mater substitute, dura mater patch, nerve regeneration or repair device, hernia repair device, hernia mesh, hernia plug, device for temporary wound or tissue support, tissue engineering device, tissue engineering scaffold, guided tissue repair / regeneration device, anti-adhesion membrane, adhesion barrier, tissue separation membrane, retention membrane, sling, device for pelvic floor reconstruction, urethral suspension device, device for treating urinary incontinence (including stress urinary incontinence), device for treating vesicoureteral reflux, Bladder repair device, sphincter repair device, sphincter expansion material for treating adult incontinence, suture anchor, soft suture anchor, bone anchor, ligament repair device, ligament enhancement device, ligament graft, anterior cruciate ligament repair device, tendon repair device, tendon graft, tendon enhancement device, rotator cuff repair device, meniscus repair device, meniscus regeneration device, articular cartilage repair device, osteochondral repair device, spinal fusion device, spinal fusion device, stent (including coronary, cardiovascular, peripheral, ureteral, urethral, ​​urology, gastroenterology, nasal, eye or neural stent), stent graft, vascular application device, cardiovascular patch, intracardiac patch, for animal Patches for closure after endarterectomy, vascular closure devices, intracardiac septal defect repair devices (including but not limited to atrial septal defect repair devices and PFO (patent foramen ovale) closure devices), left atrial appendage (LAA) closure devices, pericardial patches, venous valves, heart valves, vascular grafts, myocardial regeneration devices, periodontal meshes, guided tissue regeneration membranes for periodontal tissue, embolization devices, anastomotic devices, cell seeding devices, controlled release devices, drug delivery devices, plastic surgery devices, breast lift devices, mastopexy devices, breast reconstruction devices, augmentation mammoplasty devices (including devices used with breast implants), breast reduction devices (including Devices for removing, reshaping and reorienting breast tissue), devices for breast reconstruction after mastectomy with or without breast implants, facial reconstruction devices, forehead lift devices, brow lift devices, eyelid lift devices, face lift devices, rhytidectomy devices, thread lift devices (lift and support sagging facial, brow and neck areas), rhinoplasty devices, devices for cheekbone augmentation, otoplasty devices, neck lift devices, genioplasty devices, buttocks lift devices, cosmetic repair devices, devices for facial scar repair, and housings, pouches, retainers, covers, clamshells, cases for housing implantable medical devices.

[0288] C. 3D printing of implants

[0289] In another preferred embodiment, the implant can be prepared by 3D printing. Methods that can be used for 3D printing of poly(butylene succinate) and its copolymers include fused filament fabrication (FFF), fused deposition modeling, fused pellet deposition, melt extrusion deposition (MED), selective laser melting, and solution printing. A particularly preferred method for 3D printing implants is melt extrusion deposition.

[0290] In some embodiments, a method of 3D printing poly(butylene succinate) and copolymers thereof is to feed a filament of the polymer or copolymer into an FFF printer. In FFF of poly(butylene succinate) and copolymers, it is important to prevent the polymer from hydrolyzing due to residual moisture. Therefore, it is important that the filament used for FFF has a low water content of preferably less than 0.1 wt%, preferably less than 0.05 wt%, more preferably less than 0.01 wt%, and even more preferably less than 0.005 wt%. The filament can be dried with hot air and under vacuum before printing. In a preferred embodiment, the polymer is dried under vacuum at 30°C to 90°C, more preferably 60°C to 90°C. Preferably, the polymer is kept dry, the filament is protected from moisture, and moisture reabsorption is prevented during processing.

[0291] In order to obtain 3D printed implants with high tensile strength and extended strength retention, it is important to prevent the loss of weight average molecular weight during melt processing of poly(butylene succinate) and its copolymers. The magnitude of molecular weight loss increases as the temperature rises above 200°C and as the exposure time increases. In order to manufacture implants with the highest tensile strength and extended strength retention, it is therefore important to minimize the time the polymer is exposed to high processing temperatures during 3D printing and the moisture present in the polymer or copolymer. The temperature of the hot end, including the printer nozzle, can be set to a temperature of 120°C to 300°C, more preferably 130°C to 230°C, and even more preferably 150°C to 200°C.

[0292] The 3D printing method of PBS and its copolymers is shown in Examples 9 and 10. The 3D printing of PBS-malic acid copolymers by MED using different thermal conditions is shown in Example 18, and the properties of the obtained implants are shown in Table 17. Unexpectedly, it was found that the weight average molecular weight of the PBS polymer increased as the processing temperature rose from 180°C to 220°C. (At 230°C, the weight average molecular weight decreased from the peak value of 220°C.) In some embodiments, the 3D printed implant is formed with a chain extension of PBS or its copolymer during 3D printing. In some implant applications, the increase in molecular weight may be particularly beneficial. For example, increasing the weight average molecular weight can result in an extended strength retention rate of the implant. In one embodiment, an implant comprising PBS and its copolymer is produced, and its weight average molecular weight exceeds the weight average molecular weight of the composition used to prepare the implant. The implant can be formed by 3D printing, including fused filament fabrication, molten pellet deposition, melt extrusion deposition, and selective laser melting, but can also be formed using other thermal processing techniques such as melt processing, melt extrusion, melt blowing, melt spinning, injection molding, compression molding, lamination, foaming, film extrusion, thermoforming, pultrusion, molding, tube extrusion, spunbonding, nonwoven fabric manufacturing. In one embodiment, an implant comprising PBS and its copolymers can be formed by melt processing, and its weight average molecular weight is 1% to 50% higher than the weight average molecular weight of the PBS and copolymer resin used to prepare the implant, more preferably 5% to 30%.

[0293] In one embodiment, implants comprising PBS and copolymers thereof that do not contain knots or interwoven fibers (including meshes and grids) can be prepared by 3D printing. In a particularly preferred embodiment, knotless meshes comprising PBS and copolymers thereof can be prepared by 3D printing. These knotless meshes can be used, for example, for hernia repair, breast reconstruction, plastic surgery, treatment of stress urinary incontinence, soft tissue reinforcement, and pelvic floor reconstruction including treatment of pelvic organ prolapse (including treatment of cystocele, urethrocele, uterine prolapse, vaginal fault prolapse, enterocele, and rectocele).

[0294] In other embodiments, completely non-oriented or only partially oriented implants comprising PBS and its copolymers can be prepared by 3D printing. In a particularly preferred embodiment, non-oriented meshes comprising PBS and its copolymers can be prepared by 3D printing. These non-oriented meshes can be used for example for hernia repair, breast reconstruction, plastic surgery, treatment of stress urinary incontinence, soft tissue reinforcement and pelvic floor reconstruction including the treatment of pelvic organ prolapse (including cystocele, urethrocele, uterine prolapse, vaginal misprolapse, enterocele and rectocele). In another embodiment, non-oriented knotless meshes comprising PBS or its copolymers can be prepared by 3D printing.

[0295] In a particularly preferred embodiment, implants for hernia repair, soft tissue augmentation, breast surgery including breast reconstruction and mastopexy, pelvic floor reconstruction including treatment of pelvic organ prolapse (including treatment of cystocele, urethrocele, uterine prolapse, vaginal misprolapse, enterocele, and rectocele), and treatment of stress urinary incontinence are prepared by 3D printing. These 3D printed products include 3D printed hernia repair grids, 3D printed breast implant grids, 3D printed mastopexy grids, 3D printed breast reconstruction grids, slings including 3D printed breast lift operation grids, 3D printed stress urinary incontinence treatment grids, and 3D printed pelvic floor reconstruction grids. Examples of 3D printed grids are given in Example 9 (3D printed implantable mesh). The gratings prepared using the method of Example 9 can be used for hernia repair, soft tissue augmentation, breast surgery including breast reconstruction and mastopexy, pelvic floor reconstruction including treatment of pelvic organ prolapse (including treatment of cystocele, urethrocele, uterine prolapse, vaginal prolapse, enterocele and rectocele), and treatment of stress urinary incontinence.

[0296] D. Methods of Making Membranes

[0297] In another preferred embodiment, the implant can be prepared by forming a film made from a polymer composition comprising 1,4-butanediol units and succinic acid units as described herein. Such a film itself may be suitable for use as an implant, or may be further modified to form an implant. Any suitable method of forming a film may be used, including, for example, by solvent casting or melt extrusion. Such a film is characterized in that it may be less than 100 μm, even less than 50 μm thinness.

[0298] (i) Method for producing films by solvent casting

[0299] In a preferred method, the film of PBS polymer or its copolymer can be prepared by following solution casting.Prepare a uniform solution of PBS polymer or copolymer in a suitable solvent.Make the polymer solution be pumped to a moving belt (moving web) of, for example, aluminum foil by a slot die with a suitable die gap.The belt speed (web speed) can be, for example, about 0.5m / minute and it can travel 5m before being collected on a collection roll.Regulate the speed to ensure the evaporation of the solvent.Adopt one or more independent air drying zones arranged at a suitable temperature to remove solvent from the polymer film before being collected on the final roll.Many parameters can be changed to control film thickness, including but not limited to pump speed, die gap and width, polymer concentration and belt speed.

[0300] A method for forming a PBS copolymer film by casting and melt pressing is given in Example 21, and the properties of the film are shown in Table 19. The cast film produced by this method had a tensile modulus of 487 MPa, a stress of 33 MPa, and an elongation at break of 51%.

[0301] Also shown in Example 21 and Table 19 is a film produced by casting a film of a PBS copolymer blended with poly-4-hydroxybutyrate (P4HB). It is apparent from Table 19 that the tensile modulus of the P4HB / PBS copolymer blend increases with the increase in the percentage of the PBS copolymer in the blend. The breaking strength of the blend generally decreases with the increase in the percentage of the PBS copolymer in the blend, although the change is small when a lower amount of PBS copolymer is present in the blend. The elongation at break of the film decreases with the increase in the percentage of the PBS copolymer in the blended film. In addition to the results shown in Table 19, the following results were observed: (i) a slight decrease in the melting temperature of the PBS copolymer and P4HB was observed in the blend when the PBS copolymer was added to P4HB, or vice versa, and (ii) when 10% PBS copolymer was added to P4HB, the crystallization of P4HB was faster and occurred at a higher temperature. The results show that the addition of PBS or its copolymer increases the crystallization rate of P4HB, which is useful in processing P4HB, for example, by film melt extrusion, melt spinning or injection molding.

[0302] Therefore, the present invention also provides the subject matter disclosed by the following numbered paragraphs:

[0303] Paragraph 1. A film comprising a blend of PBS or a copolymer thereof and poly-4-hydroxybutyrate (P4HB), wherein the weight percentage of P4HB present in the film is from 10 wt % to 90 wt %, and wherein the Young's modulus of the film is from 333 MPa to 287 MPa.

[0304] Paragraph 2. The film of Paragraph 1, wherein the film has a breaking stress of 36 MPa to 49 MPa.

[0305] Paragraph 3. The film of Paragraph 1, wherein the film has an elongation at break of 95% to 165%.

[0306] (ii) Method for producing a film by melt processing using melt extrusion

[0307] The film can also be prepared by melt extrusion. The preferred method is T-die extrusion or inflation.

[0308] When forming film by melt extrusion, select the temperature of suitable barrel and T-die for carrying out this formation to ensure the melting of PBS polymer or its copolymer, but not high enough to cause unacceptable thermal decomposition. However, the temperature of the position of the barrel just below the hopper can be lower than the melting temperature of PBS polymer or its copolymer. The molten film leaves the T-die and is cast on the cooling moving surface, and preferably, the surface temperature remains on one or more rotating cylindrical casting rollers of the temperature lower than the melting temperature of PBS polymer or its copolymer. This step is followed by a winding step to wind the film extruded. Film thickness can change by changing the gap, polymer flow rate and casting roller speed of the T-die seam.

[0309] In some embodiments, a film of PBS or its copolymer is extruded by a method comprising the steps of: (i) drying the PBS polymer or its copolymer to a water content of less than 0.01 wt % water; (ii) feeding the dried polymer or copolymer to an extruder barrel with a film extrusion die, wherein the heating zones of the extruder and the die are set at a temperature of 60° C. to 240° C., more preferably 70° C. to 220° C., and (iii) casting the extrudate on a cooling roll stack set at a temperature below the melting temperature of the PBS polymer or copolymer, more preferably at a temperature of 5° C. to 50° C. In some embodiments, a non-oriented extruded film of PBS or its copolymer has one or more of the following properties: (i) a tensile stress of 30 MPa to 60 MPa, an elongation at break of 40% to 200%, and (iii) a Young's modulus of 400 MPa to 1.5 GPa. In some embodiments, an oriented extruded film of PBS or its copolymer has a tensile stress of 61 MPa to 300 MPa.

[0310] Example 23 describes the melt extrusion of a PBS copolymer. The melt temperature of the PBS copolymer is 115°C. The copolymer is extruded with a temperature spectrum of 75°C to 180°C and a die temperature of 210°C. The extruded film is collected using three horizontal cooling rolls set at a temperature of 20°C. The extruded film has the following tensile properties: tensile stress 43MPa to 47MPa, elongation at break 86% to 146%, and Young's modulus of 949MPa to 989MPa.

[0311] When forming film by inflation method, use inflation molding circular die to replace T-die to extrude cylindrical film of PBS polymer or its copolymer.The molten cylindrical film is blown up by the cold air blown out from the center of the circular die and cooled and solidified, and the blown cylindrical film is collected by winder.Film thickness can be changed by changing the gap of inflation die slit, polymer flow rate, cooling air pressure and temperature and winding speed.

[0312] (iii) Film orientation

[0313] Films formed by PBS polymers or copolymers thereof, such as melt extruded films and solvent cast films, can exhibit improved mechanical properties when stretched. The melt extruded film can be stretched by several methods such as a roller stretching method and / or a stretching method using a tenter. The melt extruded film can be stretched with a stretch ratio of 0.25 to 15. The stretching can be a uniaxial stretching for forming a uniaxially oriented film, a continuous biaxial stretching for forming a biaxially oriented film, and a simultaneous biaxial stretching for forming a planar oriented film. When the melt extruded film is stretched, the physical properties in the direction in which the film is stretched can be changed, such as the tensile strength in the direction in which the film is stretched increases. Optionally, the film is stretched in one or more directions to provide a tensile strength of 400MPa to 1200MPa in each stretching direction; wherein the stretch ratio in each stretching direction can be the same or different, and then the tensile strength in each stretching direction obtained thereby can be the same or different. For example, the biaxially oriented film can be oriented with the same stretch ratio in each stretching direction and have the same tensile strength in each stretching direction. Alternatively, the biaxially oriented film can be oriented with different stretch ratios in each stretching direction and have different tensile strengths in each stretching direction.

[0314] Thus, in the case of a film, the invention also provides an implant comprising a polymer composition, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, wherein the implant comprises an oriented film of the polymer composition, and optionally, the polymer composition is isotopically enriched. Optionally, the oriented film is uniaxially or biaxially oriented.

[0315] E. Method for producing ultrafine fibers and three-dimensional structures of PBS and its copolymers

[0316] Provided are methods for manufacturing ultrafine fibers of PBS and copolymers by electrospinning, three-dimensional structures comprising the ultrafine fibers, and medical implants comprising the ultrafine fibers.

[0317] (i) Method for making PBS polymer or copolymer ultrafine fibers by electrospinning

[0318] In a preferred method, the ultrafine fiber of PBS polymer or its copolymer can be prepared as follows. PBS polymer or copolymer is dissolved in solvent to make polymer solution. Suitable electrostatic spinning device is composed of high voltage power supply with positive lead connected to copper wire. Copper wire is inserted into nozzle such as glass capillary, and polymer solution is electrostatically spun therefrom. Glass capillary is filled with polymer solution, or polymer solution can be pumped through capillary (such as with precision pump). Collector is positioned at the desired distance from nozzle or capillary, and collector is connected to the negative lead (i.e. ground wire) of power supply. Charged polymer jet is uniformly shot to collector due to applied potential. Due to the high surface area and volume ratio of strand plus humidity and temperature, solvent is evaporated during polymer jet impact collector.

[0319] Many parameters can be varied to control the size of the ultrafine fibers. These include, but are not limited to, solution flow rate (ml / min), distance between nozzle and collector, needle configuration (including needle diameter and needle extrusion distance), temperature, humidity, solvent selection, polymer molecular weight, collection time, electric potential, and use of compressed gas to thin the fibers.

[0320] The solvent that can be used is not particularly limited, but it must be able to dissolve the selected PBS or its copolymer, and evaporate in the spinning stage to allow the formation of electrostatic spinning ultrafine fibers. If necessary, if the solvent evaporation is insufficient, reduced pressure conditions can be used in the fiber drawing stage, and the temperature selected according to the evaporation behavior of the solvent and the stability of the polymer. It is particularly preferred to be a volatile solvent that is liquid at room temperature and has a boiling point not higher than 200 ° C. The example of volatile solvents includes dichloromethane, chloroform, dichloroethane, tetrachloroethane, trichloroethane, dibromomethane, bromoform, acetone, acetonitrile, tetrahydrofuran, 1,4-dioxane, 1,1,1,3,3,3-hexafluoroisopropanol, toluene, xylene, dimethylformamide (DMF) and dimethyl sulfoxide. These solvents can be used alone, or two or more solvents can be combined as a mixed solvent system. Particularly preferred solvents include dichloromethane, chloroform, dichloroethane, tetrachloroethane, trichloroethane, dibromomethane, bromoform, tetrahydrofuran, acetone, dimethylformamide and 1,4-dioxane.

[0321] Alternatively, PBS polymers can be electrospun without using solvents in a process called melt electrospinning or melt electrostatic writing. The method is similar to solution electrospinning, but the molecular weight and spinning temperature of the polymer are selected so that the melt viscosity of the polymer is low enough to flow under the electrostatic force of the electrospinning device. A voltage difference is maintained between the spinning nozzle and the collector, and the molten polymer can be pumped through the nozzle connected to the positive voltage. The collector is positioned at a desired distance from the spinning nozzle or capillary, and the collector is connected to the negative lead (i.e., ground wire) of the power supply. The charged polymer jet is uniformly directed to the collector due to the applied potential. The molten polymer jet impacts the collector and solidifies. The electric field can be modified to guide the charged molten polymer fiber to a specific position or a specific pattern on the collector. A computer controller can be used to move the nozzle or collector independently of each other to control the special pattern of the fiber on the collector.

[0322] (ii) Method for fabricating three-dimensional PBS polymer or copolymer structures by electrospinning

[0323] A particular advantage of the electrospinning method over the meltblown fiber spinning method is that ultrafine fibers can be spun directly onto the support structure. The method can also be used to make three-dimensional structures. This can be achieved by positioning the support on a fiber collection plate and rotating the support structure during fiber collection, or rotating the nozzle around the support. Alternatively, the electric field can be changed to change the deposition of the spun fibers.

[0324] In a preferred embodiment, the ultrafine fibers are electrospun onto a collector sprayed or coated with an antistatic agent such as an antistatic guard. The use of an antistatic (or conductive) coating can change the deposition of ultrafine fibers on a collector plate and improve the coating of collector materials by ultrafine fibers. In a particularly preferred embodiment, the ultrafine fibers are electrospun onto the following collector sprayed or coated with an antistatic (or conductive) coating: a monofilament mesh, a multifilament mesh, a nonwoven fabric, a woven fabric, a foam or a film, or any combination thereof. A special advantage of using an antistatic agent to coat these collector materials is that it allows the ultrafine fibers to be in close contact with these collector materials, such as invading the holes of meshes, fabrics, and foams. This results in a greater proportion of substrates being covered with ultrafine fibers, and is particularly useful in preparing a scaffold for tissue repair and regeneration. In a particularly preferred embodiment, the microfibers cover more than 25% of the surface area of ​​a collector material (eg, a monofilament web, a multifilament web, a nonwoven fabric, a woven fabric, a foam, or a film) that has been treated with an antistatic agent.

[0325] Therefore, the present application also provides a medical device or medical implant (e.g., an implant disclosed elsewhere in the present application) comprising a superfine fiber of a polymer composition, the polymer composition comprising 1,4-butanediol units and succinic acid units or copolymers thereof, wherein the superfine fibers are preferably produced by electrospinning or melt electrospinning, and preferably have an average diameter of 10 nm to 10 μm and more preferably 50 nm to 5 μm. For example, the average diameter may be greater than 10 nm, 50 nm, 100 nm, 200 nm, 300 nm, 400 nm, 500 nm, 600 nm, 700 nm, 800 nm, 900 nm, 1 μm, 2 μm, 3 μm or 4 μm but less than 10 μm, 9 μm, 8 μm, 7 μm, 6 μm or 5 μm. The average fiber diameter of the fiber can be measured by selecting random positions on the fiber (e.g., 100 to 120 random positions) using a scanning electron microscope to take a photograph of the surface of the fiber structure at high magnification and calculating the average value based on the number of measured positions. Optionally, the medical device or medical implant comprises ultrafine fibers having a fiber diameter of less than 900 nm. Optionally, the medical device or medical implant comprises ultrafine fibers having a fiber diameter of no more than 25 μm. In a preferred embodiment, the medical device or medical implant comprises ultrafine fibers that have been deposited on a monofilament web, a multifilament web, a nonwoven fabric, a woven fabric, a foam or a film.

[0326] F. Coating and Spinning Oil

[0327] Biocompatible coatings and spin finishes can be applied to PBS and its copolymers, and medical devices made from PBS and its copolymers.

[0328] Spin finishes can be applied to fibers formed from PBS and its copolymers to facilitate their manufacture and can also be used to convert them into other products, including medical textiles. Spin finishes protect the multifilament fiber bundles, keeping them intact after extrusion, and impart lubricity to the fiber bundles and monofilament fibers, preventing them from being damaged in subsequent processing steps, particularly in textile processing. In a preferred embodiment, the coating and spin finish are applied to PBS or its copolymers.

[0329] These coatings include waxes, natural and synthetic polymers (e.g., polyvinyl alcohol), and spin finishes including polyethylene glycol sorbitan monolaurate, and polymers or oligomers of ethylene oxide, propylene oxide, copolymers of ethylene oxide and propylene oxide, PEG400, PEG40 stearate, Dacospin, and Filapan. These coatings are preferably applied so that the coating weight of the coated article is less than 6 wt%, more preferably less than 3 wt%, and even more preferably less than 2 wt%. It is preferred that the coating easily leaves the surface of the coated article or fiber-based device in vivo, such as by degradation or dissolution (e.g., if the coating is water-soluble).

[0330] Spinning oil is preferably liquid under fiber processing temperature.For example, if PBS or its copolymer is processed at room temperature or near room temperature, then spinning oil is preferably liquid at room temperature.In other embodiments, polyalkylene oxide can be wetted with water or solvent to provide the liquid solution under processing temperature.A particularly preferred embodiment is that wherein spinning oil is the polyethylene glycol (PEG) of about 400 daltons (PEG 400) to 2000 daltons (PEG2000) that is applied to PBS polymer or its copolymer with mean molecular weight.Mean molecular weight is that PEG of about 400 daltons (PEG 400) to 1000 daltons (PEG 1000) is preferred for the polymer processed at room temperature or near room temperature.For the polymer processed at higher temperatures, higher molecular weight can be preferred.

[0331] In another preferred embodiment for processing monofilament fibers of PBS or its copolymers into textiles, the spinning finish is polyethylene glycol sorbitan monolaurate (e.g., sold under the trade name 20 available polysorbate detergent). A particularly preferred embodiment is one in which the spinning finish 20 Monofilament fibers of PBS or its copolymers are applied and knitted or woven into textile structures.

[0332] The preferred coating weight of the spin finish will depend on the fiber being processed. Monofilaments require less spin finish than multifilaments due to the smaller total surface area of ​​the monofilament fiber. Thus, the preferred coating weight on monofilaments may be less than 2 wt%, preferably less than 1 wt%, while for multifilaments it may be less than 10 wt%, preferably less than 8 wt%.

[0333] The spin finish can be removed by a scrubbing process to prevent cytotoxicity or poor biocompatibility. In a preferred embodiment, the spin finish (e.g. 20) is less than about 0.5 weight %, including less than about 0.4 weight %, 0.3 weight %, 0.2 weight %, 0.1 weight %, 0.09 weight %, 0.08 weight %, 0.07 weight %, 0.06 weight %, 0.05 weight %, 0.04 weight % or 0.03 weight %. In a preferred embodiment, the residual content of PEG400 after scrubbing is less than about 2 weight %, including less than about 1 weight %, 0.5 weight %, 0.4 weight %, 0.3 weight %, 0.2 weight % or 0.1 weight %.

[0334] Textile constructions produced from coated fibers of PBS or its copolymers may also be coated, impregnated, covered or encapsulated with or include collagen.Other coatings disclosed herein include waxes, and natural and synthetic polymers such as polyvinyl alcohol.

[0335] The coating preferably imparts good lubricity to PBS and / or its copolymers, particularly fibers and braids made from these materials, making the coating ideally suited for use in medical devices such as braided sutures. Braided monofilament fibers or multifilament yarns coated with polymers or oligomers of ethylene oxide, polymers or oligomers of propylene oxide, polyvinyl alcohol, or combinations thereof are provided.

[0336] In a preferred embodiment, the coating is polyethylene glycol (PEG) having an average molecular weight of about 1000 Daltons (PEG 1000) to 10,000 Daltons (PEG 10000) and is applied to a device derived from PBS or its copolymers, such as a braided suture.

[0337] In another embodiment, the coating is polyvinyl alcohol (PVOH).A particularly preferred embodiment is where the coating is polyvinyl alcohol applied to a PBS polymer or copolymer thereof or to a device derived from PBS or copolymer thereof, such as a braided suture.

[0338] In preferred embodiments, the biocompatible coating is present on a PBS polymer or copolymer or a medical device made of a PBS polymer or copolymer at a coating weight of about 0.1% to 10% (including about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, and 10%). For example, PEG 2000 is preferably present on a polymer or a medical device made of a polymer at a coating weight of less than 10%, more preferably less than 7%, and even more preferably less than 5%. For example, PVA is preferably present on a polymer or a medical device made of a polymer at a coating weight of less than 6%, more preferably less than 4%, and even more preferably less than 3%.

[0339] Also provided is a method of reducing tissue drag of a braided suture formed of filaments formed of PBS or a copolymer thereof. The method may involve coating the braided suture with a combination of a polymer or oligomer of ethylene oxide, a polymer or oligomer of propylene oxide, polyvinyl alcohol, or a copolymer thereof.

[0340] Therefore, the present invention also provides the subject matter disclosed by the following numbered paragraphs:

[0341] Paragraph 1. A monofilament fiber or a multifilament yarn comprising a polymer composition, wherein the polymer composition is coated with a spin finish comprising a coating material as described herein,

[0342] Wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, and is optionally isotopically enriched, and preferably the polymer composition comprising 1,4-butanediol units and succinic acid units therein is a composition as defined in any one of the claims of the present application.

[0343] Paragraph 2. The monofilament fiber or multifilament yarn of Paragraph 1, wherein the polymer composition comprises PBS.

[0344] Paragraph 3. The monofilament fiber or multifilament yarn of Paragraph 1, wherein the coating material is selected from polyethylene glycol sorbitan monolaurate, polymers or oligomers of ethylene oxide and propylene oxide, copolymers of ethylene and propylene oxide, PEG400, PEG40 stearate, Dacospin, Filapan and combinations thereof.

[0345] Paragraph 4. The monofilament fiber or multifilament yarn of Paragraph 3, wherein the polymer is polyethylene glycol having an average molecular weight of 100 to 1000 Daltons in the spin finish or polyethylene glycol having an average molecular weight of 1000 to 10,000 in the coating.

[0346] Paragraph 5. The monofilament fiber or multifilament yarn of Paragraph 1, wherein the coating material is polyethylene glycol sorbitan monolaurate.

[0347] Paragraph 6. A medical device formed from the monofilament fiber or multifilament yarn of any of Paragraphs 1 to 5.

[0348] Paragraph 7. The apparatus of Paragraph 6 which has been scrubbed to remove substantially all of the spin finish.

[0349] Paragraph 8. The device of Paragraph 7, wherein the device is selected from the group consisting of barbed sutures, braided sutures, monofilament sutures, ligature filaments, hybrid sutures of monofilament and multifilament fibers, braids, knitted or woven meshes, monofilament meshes, multifilament meshes, knitted tubes, stents, stent grafts, drug delivery devices, devices for temporary wound or tissue support, devices for soft tissue repair, devices for replacement or regeneration, repair patches, tissue engineering scaffolds, retention membranes, anti-adhesion membranes, tissue separation membranes, hernia repair devices, breast reconstruction devices, devices for blepharoplasty, devices for facial scar repair, devices for forehead lift, devices for genioplasty, devices for zygomatic bone augmentation, devices for otoplasty, devices for rhinoplasty, devices for neck lift surgery , devices for rhytidectomy, thread lift devices for lifting and supporting sagging areas of the face, brow and neck, fixation devices, cardiovascular patches, vascular closure devices, vascular grafts, slings, biocompatible coatings, rotator cuff repair devices, meniscus repair devices, adhesion barriers, guided tissue repair / regeneration devices, articular cartilage repair devices, nerve guides, tendon repair devices, ligament repair devices, intracardiac septal defect repair devices, left atrial appendage (LAA) closure devices, pericardial patches, expanders or fillers, venous valves, heart valves, bone marrow scaffolds, meniscus regeneration devices, ligament and tendon grafts, ocular cell implants, spinal fusion devices, imaging devices, skin substitutes, dura mater substitutes, bone graft substitutes, wound dressings and hemostats, or any other device disclosed in this application.

[0350] Paragraph 9. The device of Paragraph 8, wherein the breast reconstruction device is selected from a device for augmentation mammoplasty, a device for mastopexy, a device for breast reduction, a device for breast positioning and shaping, and a device for breast reconstruction following mastectomy.

[0351] Paragraph 10. The device of Paragraph 8, comprising a braided suture, wherein the suture comprises an outer multifilament sheath optionally formed of PBS or a copolymer thereof and an inner monofilament core optionally formed of PBS or a copolymer thereof.

[0352] Paragraph 11. The device of Paragraph 10, comprising a suture, wherein the suture comprises an outer multifilament and monofilament sheath comprising a PBS polymer or copolymer, and an inner monofilament core comprising a PBS polymer or copolymer.

[0353] Paragraph 12. The device of Paragraph 10, wherein the inner monofilament core is barbed or made of a non-degradable polymer.

[0354] Paragraph 13. The device of any of Paragraphs 6 to 12, wherein the device comprises one or more additional components selected from the group consisting of a plasticizer, a nucleating agent, collagen, cross-linked collagen, hyaluronic acid or a derivative thereof, a ceramic, a medical glass, a bioactive glass, a polyhydroxyalkanoate, a poly-4-hydroxybutyrate, a polymer or copolymer of lactic acid, glycolic acid, caprolactone, p-dioxanone or trimethylene carbonate, a polymer additive, a dye, a volume extender, a filler, a therapeutic agent, an antimicrobial agent, a diagnostic agent and a prophylactic agent.

[0355] Paragraph 14. The device of Paragraph 6, wherein the device is a suture and comprises at least one or more fibers having a contrasting dye to provide a recognizable color mark in the suture strand.

[0356] Paragraph 15. The device of Paragraph 6, wherein the device is a suture for ligament and tendon repair.

[0357] Paragraph 16. The device of Paragraph 6, wherein the device is a surgical mesh.

[0358] Paragraph 17. The device of Paragraph 16, wherein the surgical mesh comprises fibers formed from PBS or a copolymer thereof and permanent fibers.

[0359] Paragraph 18. The device of Paragraph 17, wherein the permanent fiber is polypropylene, polyester, or a combination thereof.

[0360] Paragraph 19. The device of Paragraph 16, wherein the surgical mesh comprises monofilament fibers.

[0361] Paragraph 20. The device of Paragraph 16, wherein the surgical mesh has been coated or encapsulated with collagen.

[0362] Paragraph 21. The device of Paragraph 20, wherein the porosity of the collagen has a diameter of at least 5 μm.

[0363] Paragraph 22. A method of producing the device of Paragraph 20 or 21, wherein the PBS or copolymer component is optionally treated with plasma gas, coated or encapsulated with collagen, the collagen is cross-linked, and the device is sterilized with ethylene oxide or by irradiation.

[0364] Paragraph 23. A method of using the device of Paragraph 8 comprising implanting or administering the device at a site in or on a patient in need thereof.

[0365] Paragraph 24. The device of Paragraph 7 or any of its dependencies, which is tested for cytotoxicity using the ISO Elution Method (1×MEM extract).

[0366] Paragraph 25. A method for producing a monofilament fiber or a multifilament yarn comprising a PBS polymer or a copolymer, wherein the PBS polymer or copolymer is coated with a coating material selected from the group consisting of polyethylene glycol sorbitan monolaurate, polymers or oligomers of ethylene oxide, propylene oxide, PEG400, PEG40 stearate, Dacospin, Filapan, and combinations thereof, the method comprising obtaining a monofilament fiber or a multifilament yarn by melt extrusion processing of the PBS polymer or copolymer, cooling and solidifying the PBS polymer or copolymer, and applying the coating material to the fiber or yarn by an online or offline spin finish applicator.

[0367] Paragraph 26. A braided monofilament fiber or multifilament yarn comprising filaments formed from a PBS polymer or copolymer and coated with a coating material selected from the group consisting of polyethylene glycol sorbitan monolaurate, polymers or oligomers of ethylene oxide, propylene oxide, PEG400, PEG40 stearate, Dacospin, Filapan, and combinations thereof.

[0368] Paragraph 27. The braided monofilament fiber or multifilament yarn of Paragraph 26, wherein the coating material is polyethylene glycol, wherein the average molecular weight of the polyethylene glycol is from 1000 Daltons to 10,000 Daltons.

[0369] Paragraph 28. The braided monofilament fiber or multifilament yarn of Paragraph 26 or 27, wherein the average tissue drag of the coated braid is reduced by at least 10% relative to the uncoated braid.

[0370] G. Other Methods of Making Implants

[0371] Implants comprising poly(butylene succinate) and copolymers thereof can also be prepared by casting, solvent casting, solution spinning, solution bonding of fibers, melt processing, extrusion, melt extrusion, melt spinning, fiber spinning, orientation, relaxation, annealing, injection molding, compression molding, machining, machining of extrudates, lamination, particle formation, microparticle, macroparticle and nanoparticle formation, foaming, dry spinning, knitting, weaving, crocheting, melt blowing, film formation, film blowing, film casting, membrane forming, forming), electrospinning, thermoforming, pultrusion, centrifugal spinning, molding, tube extrusion, spunbonding, spunlaiding, nonwoven manufacturing, entanglement of staple fibers, fiber knitting, weaving and crocheting, mesh manufacturing, coating, dip coating, laser cutting, barb formation, fiber barb formation, stamping, punching, hole formation, freeze drying, stitching, calendaring, freeze drying, phase separation, particle leaching, thermal phase separation, leaching, latex processing, gas plasma processing, emulsion processing, 3D printing, fused filament fabrication, molten pellet deposition, melt extrusion deposition, selective laser melting, printing of slurries and solutions using a coagulation bath, and printing using adhesive solutions and powder particles.

[0372] In one embodiment, implants comprising PBS and its copolymers can be prepared by solution processing (including the methods disclosed herein) using solvents such as dichloromethane, chloroform, dichloroethane, tetrachloroethane, trichloroethane, dibromomethane, bromoform, tetrahydrofuran, acetone, THF, ethyl acetate, dimethylformamide, 1,4-dioxane, DMF and DMSO, and combinations thereof.

[0373] In some embodiments, the implant comprising PBS and its copolymer is a sponge or foam, and is preferably highly porous. The highly porous sponge or foam comprising PBS and its copolymer is particularly ideally used in tissue engineering applications. For example, in the application of expecting cells to invade implants to form new tissues. In some embodiments, PBS and its copolymer can be used as the coating on other polymers and materials to form coated sponges and foams. For example, other polymers as herein described can be formed as sponges or foams, and are coated with PBS and its copolymer.

[0374] As mentioned above, in a selection, the implant comprising poly-(butylene succinate) and / or its copolymer can also be prepared by pultrusion.Compare with melt extrusion processing (wherein polymer powder or pellet is melt extruded and oriented to form crystalline structure by stretching extrudate), pultrusion is such process, wherein non-oriented polymer rod is pulled through a series of profile dies to provide the profile with the reduction of high modulus and tensile strength.Pultrusion can be used to significantly increase the orientation of the goods formed by PBS or its copolymer, causing the same polymer before orientation to compare, the modulus and tensile strength of polymer improve, and processed polymer and the elongation at break of the device made of processed polymer reduce.Pultrusion is completely different from the melt extrusion and orientation of polymer fiber.

[0375] The present application also discloses a microfiber web comprising fibers of poly(butylene succinate) and / or its copolymers, and a method for producing the same. The average diameter of the microfibers ranges from 0.01 μm to 100 μm. The microfiber web having a higher elongation at break value can be manufactured by centrifugal spinning. Unlike the fibers typically obtained by meltblown extrusion, dry spinning, and electrospinning, the microfiber web may contain curled fibers. The microfiber web also has a higher elongation at break value than nonwovens produced by meltblown extrusion, dry spinning, and electrospinning.

[0376] Also disclosed is a method for making a microfiber web from PBS and its copolymers. The method allows the production of a microfiber web without significantly losing the weight average molecular weight of the polymer. The microfiber web containing / comprising the microfibers of PBS or its copolymers is preferably obtained by centrifugal spinning. In one embodiment, the PBS polymer or copolymer is dissolved in a solvent, the polymer solution is pumped through a rotating spinneret, and the fibers are collected into a web. The equipment for centrifugal spinning generally includes one or more spinnerets fed by a polymer melt or a solution of PBS or its copolymers, which are combined with one or more orifices, and can be rotated at high speed. The high-speed rotation of the spinneret applies centrifugal force to the polymer solution, causing it to be pulled out of the orifice of the spinneret and released as a polymer jet. The evaporation of the solvent in the polymer jet causes the formation of fibers, and the fibers are collected to form a microfiber web. The average diameter range of the fibers in the microfiber web is 0.01 microns to 100 microns.

[0377] Medical implants and other medical devices and articles as described herein can be coated with compositions of poly(butylene succinate) or its copolymers as described herein. Optionally, poly(butylene succinate) or its copolymers can be formed into latex or emulsions and used to coat medical implants and other medical devices and articles. For example, emulsions can be prepared by water-in-oil or oil-in-water methods. In an exemplary embodiment, PBS: solvent: oleic acid: triethanolamine: water (10 g: 40 g: 4 g: 6 g: 30 g) emulsions can be used.

[0378] Also disclosed is a method for forming a perforated implant, the method comprising the steps of positioning a needle through a hole of a surgical mesh formed from a polymer composition, coating the surgical mesh with a collagen solution, freezing the coated mesh, removing the needle from the hole of the frozen coated mesh, and drying the coated mesh, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, and is optionally isotopically enriched, and preferably the polymer composition comprising 1,4-butanediol units and succinic acid units is a composition as defined in any one of the claims of the present application.

[0379] Thus described herein are perforated collagen coated meshes that can be used in vivo for soft or hard tissue repair, regeneration or remodeling. At least as a result of the method used to make the mesh, the perforated collagen coated meshes do not have a significant percentage of partially closed or occluded perforations.

[0380] As used herein, "perforations" in connection with the disclosed perforated collagen mesh are distinct from "holes" that may otherwise be present in the disclosed perforated mesh. "Perforations" are used to refer to holes that span the thickness of the collagen-coated mesh, which are distinct from holes that may be present in the collagen-coated mesh, but do not span the thickness of the mesh and do not form an open passage from one side of the implant to the other side of the implant (e.g., obtained by applying only a collagen coating to, for example, a polymer mesh). The perforated collagen mesh disclosed herein includes holes that are perforations and holes that are not perforations.

[0381] In one embodiment, at least 70% of the perforations through the implant are not occluded by any mesh fibers or collagen, and more preferably, greater than 75%, 80%, 85%, 90%, 95% or 100% of the perforations are not partially occluded by collagen or mesh fibers.

[0382] The method provides a method for making a perforated collagen coated mesh without damaging the surface of the mesh. The method also allows the production of perforated collagen coated meshes with a wide range of thicknesses that are difficult to produce by standard coating techniques. The ability to produce these perforated collagen coated meshes has been made possible by a method in which a needle is inserted into the hole of the mesh before the mesh is coated with collagen. In this process, the needle blocks the collagen from entering the hole, and the needle can also produce long perforations of a selected diameter through a thick collagen coating that has been applied to the mesh. Importantly, the method produces a perforated collagen coated mesh in which the perforations are not occluded with collagen and the surface of the mesh is not damaged.

[0383] The collagen used to coat the mesh can be derived from a natural source, or it can be produced using recombinant DNA technology. In one embodiment, the collagen can be derived from a horse source, a pig source, an ovine source, a bovine source, an ovine source, a marine source, or a human source. In a preferred embodiment, the collagen is derived from a bovine source, more preferably a bovine source that is proven to be free of bovine spongiform encephalopathy (BSE).

[0384] The collagen may be of the same fibril type, or a mixture of fibril types including any one of types I to XIII. In a preferred embodiment, it may be a mixture of types I to III. In a particularly preferred embodiment, the collagen is predominantly type I, or only type I.

[0385] The collagen used to coat the mesh is preferably in the form of a solution, slurry or gel. For example, the collagen can be in a neutral salt solution or a dilute acid solution. In a preferred embodiment, the collagen is in a dilute acid solution. Examples of suitable solutions include collagen in acetic acid, citrate buffer or hydrochloric acid. Generally preferred dilute solutions, such as acetic acid (0.5M) or hydrochloric acid pH 2 to 3.5. A particularly preferred solution is a 1% acid-swollen bovine collagen gel produced by Devro Pty Ltd (Kelso, NSW, Australia). The solution has a pH of 2.9 to 3.1, a fat content of ≤7%, an ash content of ≤1%, and an endotoxin content of ≤10EU / mL.

[0386] Collagen can be processed by treatment with alkali or enzymes. These agents can be used to cleave crosslinks and suspend or dissolve acid-insoluble collagen structures. For example, collagen can be processed using about 10% sodium hydroxide and 10% sodium sulfate. Alternatively, collagen can be treated with pepsin to provide collagen that can be swollen and dissolved. Collagen can also be subjected to treatment with denaturants and mechanical disruption, or chemical modification and derivatization, such as by succinylation, acetylation, methylation, or attachment of other polymers or chemical entities.

[0387] Other proteins, including fibrous and globular proteins, may be added to the collagen solution. In a preferred embodiment, gelatin may be added to the collagen solution.

[0388] The perforated collagen coated mesh may contain bioactive agents. These agents may be present in the mesh or the collagen, or in both the mesh and the collagen, or may be present on the surface of the mesh or the collagen, or on the surface of both.

[0389] Bioactive agents can be used to, for example, improve the wettability, water contact angle, cell attachment, tissue ingrowth or tissue maturation of the perforated collagen coated mesh. Bioactive agents can also be incorporated for the purpose of delivering the bioactive agent in vivo. In a particularly preferred embodiment, the bioactive agent is delivered near the perforated collagen coated mesh.

[0390] Optionally, in a method of forming the above-described perforated implant, a surgical mesh having needles passing through holes in the mesh can be contacted with a collagen solution on one side of the surgical mesh to coat that side of the mesh with collagen, and optionally, additional collagen solution is added to the other side of the mesh to completely coat the mesh with collagen.

[0391] The method may also include heating the needle prior to removing the needle from the hole of the coated mesh. Optionally, the coated mesh is dried by freeze drying. Optionally, the method also includes heat setting the mesh after positioning the needle through the hole of the surgical mesh, and for example, the heat set mesh can be removed from the needle and subsequently repositioned on the needle at the same location. Optionally, the method also includes cross-linking the collagen.

[0392] The perforated implants produced by this process may optionally have one or more of the following properties: an average thickness of 0.1 mm to 25 mm, perforations having a diameter of 0.1 mm to 10 mm, a perforation density of 1 to 50 per square centimeter, and a burst strength of 1 kgf to 100 kgf.

[0393] Optionally, the needle is tapered. Optionally, the perforations in the implant are positioned in a random, orderly or patterned manner. Optionally, the shape of the perforations in the implant can be defined by curved or straight boundaries or a combination thereof, for example, the shape of the perforations in the implant can be circular, oval, triangular, square and polygonal.

[0394] Optionally, the perforated implant is formed using an assembly comprising a needle plate consisting of: a pattern of needles mounted on a backing plate, a base plate with holes matching the needle pattern on the needle plate, a frame plate connected to the base plate to form a container for the collagen solution, a spacer edge plate for adjusting the thickness of the implant, and a perforated separator plate with holes matching the needle pattern on the needle base plate. In a preferred option, (i) the needles of the needle plate are positioned through the holes of the surgical mesh and the mesh is optionally heat set on the needle plate, (ii) the mesh is removed from the needle plate and the needle plate is inserted into the base plate until it is flush with one side of the base plate and the needles protrude from the other side of the base plate, (iii) the frame plate is connected to each side of the base plate to form a container, (iv) the spacer edge plate is placed on top of the base plate and within the container formed by the frame plate so that it is located between the needles and the inner wall of the frame plate, (v) the collagen solution is poured to cover the base plate to the desired depth, (vi) the mesh is placed in the same manner as previously used for heat setting. The same orientation of the mesh is placed back on the needles and the mesh is moved on the needles until it contacts the collagen solution, (vii) optionally, the collagen solution is poured on top of the surgical mesh so that it covers the mesh and the mesh is completely encapsulated by collagen, (viii) the perforated separator plate is slid down the needles of the needle plate until it contacts the separator edge plate, (ix) the entire assembly containing the collagen-coated mesh is frozen, (x) the needles of the needle plate are heated, the assembly is disassembled to release the perforated frozen collagen-coated mesh, and (xi) the perforated collagen-coated mesh is freeze-dried. For example, the method may also include cross-linking the perforated collagen coated mesh with formaldehyde, glutaraldehyde, grape seed extract, genepin or other suitable cross-linking agents, and / or may also include one or more of the following steps: adding graduated markings to the perforated collagen coated mesh, cutting the perforated collagen coated mesh; packaging the perforated collagen coated mesh and sterilizing the perforated collagen coated mesh. Optionally, the mesh is sterilized with ethylene oxide. The method may also include keeping the perforated collagen mesh flat while freeze drying it. The perforated collagen coated mesh can be frozen to a temperature of -40°C ± 10°C and freeze dried using a freeze dryer for a period of 5 to 20 hours.

[0395] Optionally, the mesh can be made of monofilament or multifilament or a combination thereof. Optionally, the implant is sized to be used as an implant, and / or the implant can be trimmed to a predetermined shape. The implant can optionally have one or more of the following properties within 20% of the value of the uncoated mesh: (i) burst strength, (ii) suture pull-out strength, and (iii) tensile strength.

[0396] The present application also discloses a perforated implant comprising a perforated collagen-coated mesh obtainable by the aforementioned method having one or more of the following properties: an average thickness of 0.1 mm to 25 mm, perforations having a diameter of 0.01 mm to 10 mm, a perforation density of 1 to 50 per square centimeter, and a burst strength of 1 kgf to 100 kgf, wherein the mesh is formed by a polymer composition comprising 1,4-butanediol units and succinic acid units and optionally isotopically enriched, and preferably the polymer composition comprising 1,4-butanediol units and succinic acid units is a composition as defined in any one of the claims of the present application.

[0397] The implant may have a burst strength of at least 65% of a non-collagen coated mesh. The mesh may be made of monofilament fibers formed from a polymer composition having an average diameter of 0.001 mm to 1.0 mm. The implant may be made of a knitted monofilament mesh. The collagen may be cross-linked.

[0398] The present application also discloses a perforated implant comprising a perforated collagen coated mesh, wherein the perforations are aligned with the pores of the mesh so that the perforations in the implant are formed through the pores of the mesh, wherein the mesh is formed by a polymer composition comprising 1,4-butanediol units and succinic acid units and optionally isotopically enriched, and preferably the polymer composition comprising 1,4-butanediol units and succinic acid units is a composition as defined in any one of the claims of the present application. The mesh may be a monofilament knitted mesh.

[0399] Also disclosed are methods of using the perforated implants as disclosed above, wherein the implants are implanted into the body or applied to the surface of the body. For example, the implants can be used for soft tissue or hard tissue repair. Optionally, the implants are used for plastic surgery, mastopexy, breast reconstruction, hernia repair, treatment of urinary incontinence, pelvic floor reconstruction, ligament and tendon repair, or lifting procedures including face lifts, neck lifts, brow lifts, and breast lifts.

[0400] H. Orientation

[0401] The present application provides an implant comprising a polymer composition, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, wherein the implant comprises an oriented form of the polymer composition, and optionally, the polymer composition is isotopically enriched.

[0402] Orientation can be used to modify many physical properties of such polymer compositions and implants made therefrom, including but not limited to crystallinity, tensile strength, Young's modulus, elongation at break and toughness, as well as degradation properties, for example, retention of tensile strength, retention of mass and / or retention of weight average molecular weight over a measured time period of, for example, 4 weeks, 8 weeks, 12 weeks, 24 weeks or longer after implantation in vivo and / or under physiological conditions in vitro (e.g., in phosphate buffered saline at 37°C); wherein the point of comparison is a non-oriented form of the same polymer composition or implant made therefrom, which differs from the oriented form only in that no orientation was used in its production.

[0403] Any form of the polymer composition can be selected for orientation, and / or includes an oriented form of the PBS polymer composition. For example, the form can be a form of a polymer composition prepared by casting, solvent casting, solution spinning, solution bonding of fibers, melt processing, extrusion, melt extrusion, melt spinning, fiber spinning, injection molding, compression molding, machining, machining of extrudates, lamination, foaming, dry spinning, wet spinning, knitting, weaving, crocheting, melt blowing, film formation, film blowing, film casting, film forming, electrospinning, melt electrospinning, melt electrospinning, thermoforming, pultrusion, centrifugal spinning, molding, tube extrusion, spunbonding, spun-web , nonwoven fabric manufacturing, entanglement of staple fibers, fiber knitting, weaving and crocheting, mesh manufacturing, coating, dip coating, laser cutting, barb formation, fiber barb formation, stamping, punching, hole formation, freeze drying, stitching, calendaring, freeze drying, phase separation, particle leaching, thermal phase separation, leaching, latex processing, gas plasma processing, emulsion processing, 3D printing, fused filament manufacturing, melt pellet deposition, melt extrusion deposition, selective laser melting, printing of slurries and solutions using a coagulation bath, and printing using adhesive solutions and powder particles. In addition, or alternatively, the oriented form of the polymer composition can be used in any of the aforementioned methods for preparing a polymer article.

[0404] Optionally, the oriented form comprises a fiber, a web, a woven fabric, a nonwoven fabric, a film, a molded article, a patch, a tube, a laminate or a pultruded profile. In a particularly preferred embodiment, the oriented form is a fiber selected from a monofilament, a multifilament, a braided fiber or a barbed fiber. In another particularly preferred embodiment, the oriented form is a web that can be selected from woven and nonwoven forms, including a knitted web, a woven web, a monofilament web or a multifilament web.

[0405] For example, the oriented form may have been uniaxially oriented or biaxially oriented.

[0406] The orientation process used to produce the oriented form may additionally include either or both of relaxation and annealing steps.

[0407] The properties of the oriented form can be modified by adding a relaxation step after the orientation and / or annealing step. The relaxation step can be carried out at a temperature suitable for relaxation of the selected PBS polymer or copolymer, such as 30°C to 150°C, and / or the annealing step can be carried out at a temperature suitable for annealing of the selected PBS polymer or copolymer, such as 80°C to 120°C, more preferably 105°C ± 10°C.

[0408] For example, introducing an annealing process and a relaxation step during the fiber orientation process can further improve the handling characteristics of the resulting fiber. The relaxation step allows the oriented form to shrink and allows the elongation to increase by up to 25%, followed by an online or offline annealing step to further control and fine-tune the elongation, modulus and strength.

[0409] The PBS or its copolymers may additionally be combined with absorbable additives and then processed by relaxation and / or annealing to further enhance the properties of the oriented form.

[0410] As discussed elsewhere in this application, a spin finish may be applied to the polymer composition and present for the duration of the orientation, relaxation, and / or annealing steps, and optionally removed by subsequent scrubbing.

[0411] Orienting the article to produce an oriented form of the article formed from the polymer composition may include one or more stages of drawing the article. Preferably, the monofilament fibers are oriented with 2 to 6 orientation stages, more preferably 3, 4 or 5 orientation stages. A suitable sum of orientation ratios within one or more drawing stages may be, but is not limited to, about or at least 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0 or more.

[0412] One example of a multi-stage drawing process may include the steps of: (a) drawing the article at an orientation ratio of at least 3.5 at a temperature of 50° C. to 70° C., (b) one or more stages of drawing the article at an orientation ratio of at least 2.0 at a temperature of 65° C. to 75° C., and (c) drawing the article at an orientation ratio greater than 1.0 at a temperature of 70° C. to 75° C. Preferably, the sum of the orientation ratios within the multi-stage drawing process is greater than 6.0, 6.5, 7.0, 7.5 or 8.0.

[0413] In another option, the article formed from the polymer composition can be drawn in a conductive liquid chamber. Before drawing the article, the melt-extruded polymer is preferably quenched in a conductive liquid bath. The temperature of the bath is preferably 50°C to 70°C. Further cooling of the article after its quenching may be desirable and may be achieved (for example, by passing the article between two godet rollers). In one embodiment, the temperature range for extruding PBS or its copolymers to form high-strength articles is 60°C to 230°C, or 75°C to 220°C, but more preferably 75°C to 200°C, 80°C to 180°C, 80°C to 175°C, or 80°C to 170°C. Example 3 discloses a specific example of a method for preparing multifilament fibers of PBS and its copolymers using multi-stage incremental orientation and using a conductive chamber. Examples of multifilament fibers with a tenacity of 8.3g / d to 12.5g / d are shown.

[0414] Also disclosed herein is a method for further improving the production of monofilament fibers of a polymer composition comprising PBS or its copolymers, wherein the monofilament fibers are cold drawn and then hot drawn at a temperature higher than the melting temperature of the polymer composition. This process can provide even higher breaking strength. According to this embodiment, the polymer composition should not be drawn immediately after it leaves the molten state. In addition, the fiber extrudate is preferably not drawn under the tension of the extruder.

[0415] The process generally comprises the steps of: (i) spinning the polymer composition into fibers (multifilament or monofilament), (ii) allowing time for the fibers to crystallize, (iii) cold drawing, and (iv) one or more orientation steps of hot drawing.

[0416] In some embodiments, the final hot-draw orientation step is followed by a relaxation step (also sometimes referred to as "hot-stretching").

[0417] In one embodiment, articles formed from PBS and copolymers thereof that have been oriented and optionally relaxed and / or annealed have a tensile strength of 400 MPa to 2,000 MPa, more preferably greater than 500 MPa, 600 MPa, 700 MPa or 800 MPa, but less than 1,200 MPa.

[0418] In another embodiment, an article formed from PBS and its copolymers that has been oriented and optionally relaxed and / or annealed has a Young's modulus of at least 400 MPa and less than 5 GPa, but more preferably greater than 600 MPa, 800 MPa, 1 GPa, 1.5 GPa and 2 GPa.

[0419] In another embodiment, an article formed from PBS and its copolymers that has been oriented and optionally relaxed and / or annealed has an elongation at break of 10% to 150%, more preferably, 10% to 50%, such as 15% to 50%.

[0420] In yet another embodiment, articles formed from PBS and copolymers thereof that have been oriented and optionally relaxed and / or annealed have a tenacity greater than 4 g / denier but less than 14 g / denier.Preferably, the elongation at break of the multifilament fibers is from 15% to 50%.

[0421] The present application also discloses subject matter as described in the following numbered paragraphs:

[0422] Paragraph 1. A polymer composition in the form of an implantable medical device or a component thereof, the polymer composition comprising PBS or a copolymer thereof having:

[0423] (i) having a tensile strength of 400 MPa to 2,000 MPa,

[0424] (ii) an elongation at break of 10% to 150%, and / or

[0425] (iii) a Young's modulus of at least 400 MPa and less than 5 GPa,

[0426] The polymer composition can be produced by extrusion and orientation and optionally further by relaxation and / or annealing.

[0427] Paragraph 2. A polymer composition according to Paragraph 1 in the form of an implantable medical device or a component thereof, wherein the filament has:

[0428] (i) Elongation at break of 10% to 50%, for example 15% to 50%.

[0429] (ii) a Young's modulus greater than 600 MPa, 800 MPa, 1 GPa, 1.5 GPa or 2 GPa, and less than 5 GPa; and / or

[0430] (iii) A tensile strength greater than 500 MPa, 600 MPa, 700 MPa or 800 MPa but less than 1,200 MPa

[0431] The polymer composition can be produced by extrusion and orientation and optionally further by relaxation and / or annealing.

[0432] Paragraph 3. A polymer composition in the form of an implantable medical device or a component thereof according to Paragraph 2, wherein it is produced by extrusion, orientation by drawing the extruded polymer composition to six to eleven times its original length, contraction and elongation of the filaments, and annealing.

[0433] Paragraph 4. A polymer composition according to any one of Paragraphs 1 to 3 in the form of an implantable medical device or component thereof in the form of a suture, a monofilament fiber, or a multifilament fiber or yarn.

[0434] Paragraph 5. A polymer composition in the form of an implantable medical device or a component thereof according to any one of Paragraphs 1 to 3, which is in the form of a mesh.

[0435] Paragraph 6. A polymer composition according to any one of Paragraphs 1 to 3 in the form of an implantable medical device or a component thereof, which is in the form of a device for repairing tendons or ligaments or any other medical device as disclosed in the present application or claims.

[0436] I. Antimicrobial Coating

[0437] In one embodiment, implants comprising poly(butylene succinate) and copolymers thereof can be coated with a solution of an antimicrobial agent dissolved in a poor solvent for poly(butylene succinate) and copolymers thereof. These poor solvents do not result in significant loss of orientation (if any) of the poly(butylene succinate) or copolymers thereof. However, these poor solvents slightly soften the antimicrobial agent and penetrate into the surface of the implant. This has two major advantages. First, it allows the implant to be coated with a higher concentration of antimicrobial agent, and secondly it allows the antimicrobial agent to diffuse into the implant. The diffusion of the antimicrobial agent into the implant results in a more extended release spectrum, as well as the ability of the enhanced implant to prevent implant colonization, and to reduce or prevent infection after implantation in the patient. Suitable poor solvents that can dissolve the antimicrobial agent but do not result in loss of implant orientation are aqueous or alcoholic solutions of tetrahydrofuran (THF). Alcohols that can be combined with this solvent include methanol and ethanol. The concentration of the antimicrobial agent in the poor solvent can range from about 0.1 mg / mL to about 100 mg / mL, preferably from about 1 mg / mL to about 30 mg / mL. The amount of each antimicrobial agent coated on the implant (coverage density) can range from about 1 μg / cm 2 to about 1000 μg / cm 2 , or preferably about 50 μg / cm 2 About 200 μg / cm 2 In various embodiments, this amount ranges from about 10 μg / cm 2 About 175 μg / cm 2 , or about 10 μg / cm 2 About 150 μg / cm 2 , or about 10 μg / cm 2 About 100 μg / cm 2 , or about 10 μg / cm 2 To about 75mg / cm2 , or about 20 μg / cm 2 About 200 μg / cm 2 or about 50 μg / cm 2 About 200 μg / cm 2 , or about 75 μg / cm 2 About 200 μg / cm 2 or about 100 μg / cm 2 About 200 μg / cm 2 , or about 150 μg / cm 2 About 200 μg / cm 2 .

[0438] In a preferred embodiment of the present invention, implants of poly(butylene succinate) and copolymers thereof are coated with rifampicin and minocycline (including its hydrochloride, sulfate or phosphate) dissolved in a poor solvent for poly(butylene succinate) and copolymers thereof. The antimicrobial agents can be applied to the oriented implant using the same or different poor solvents, or a single solution of the two antimicrobial agents contained in a poor solvent. In one embodiment, rifampicin can be applied to the implant of poly(butylene succinate) and copolymers thereof from solutions of the following poor solvents (i) THF, (ii) DMSO, (iii) DMF and (iv) DMA, each mixed with one or more of the following, i.e., water, methanol and / or ethanol. In another embodiment, minocycline can be applied to the oriented implant of poly(butylene succinate) and copolymers thereof from solutions of the following poor solvents, i.e., THF / water, THF / methanol and THF / ethanol. In a preferred embodiment, rifampicin and minocycline (including their hydrochloride, sulfate or phosphate forms) are dissolved in a solution of THF / water, THF / ethanol or THF / ethanol and applied to the implant.

[0439] J. Sterilization of Implants

[0440] Implants made of high tenacity yarns and monofilament fibers of poly(butylene succinate) and copolymers thereof, or other implants made of poly(butylene succinate) and copolymers thereof, can be sterilized using ethylene oxide gas, even more preferably using ethylene oxide cold cycles. In another preferred embodiment, the implants can be sterilized using electron beam irradiation or gamma irradiation. In another embodiment, the implants can be sterilized using ethanol, hypochlorous acid or gaseous hydrogen peroxide, nitrogen dioxide, chlorine dioxide or peracetic acid.

[0441] The sterility of the device can be maintained by packaging the device in a package designed to protect the device from contamination and maintain sterility. In a preferred embodiment, the implant comprising poly (butylene succinate) or its copolymer is sterilized using ethylene oxide. Preferably ethylene oxide is used because it has been found that the implant can be sterilized without significant weight average molecular weight loss. In a particularly preferred embodiment, the implant sterilized through ethylene oxide maintains at least 80%, more preferably at least 90%, even more preferably at least 95% of its weight average molecular weight during sterilization.

[0442] K. Microparticle Composition

[0443] In some embodiments, poly(butylene succinate) and copolymers thereof can be formed into microparticle compositions.The microparticle compositions can be delivered for a variety of purposes ranging from medical device applications to drug delivery or pharmaceutical purposes.

[0444] In some embodiments, the microparticle composition comprises particles having a diameter of about 1 nanometer (nm) to about 1000 microns (μm), or 10nm to 1,000 μm. In general, microparticle compositions with suitable sizes or size ranges for various medical, surgical, clinical, cosmetic, medical device, drug and / or drug delivery applications can be prepared within this size range. In some embodiments, the size of the microparticle is about 250 microns to about 1000 microns. In another embodiment, the size of the microparticle is about 100 microns to about 250 microns. In another embodiment, as is the case with microparticle compositions commonly used for subcutaneous (SC) or intramuscular (IM) administration, the diameter of the microparticle is about 20 microns to about 150 microns. In some embodiments, the diameter of the microparticle is about 20 microns to about 50 microns, preferably about 20 microns to about 40 microns. In other embodiments, the diameter of the microparticle is about 1 micron to about 30 microns, preferably about 1 micron to about 20 microns, more preferably about 1 micron to about 10 microns. In one embodiment, the size of the microparticle is less than 10 microns. In yet another embodiment, the size of the microparticle is less than 1 micron. Other embodiments include microparticles between about 500 nm to 1000 nm or 200 nm to 500 nm. Still other embodiments may include particles with sizes primarily in the range of 100 nm to 200 nm and particles with sizes ranging from 10 nm to 100 nm or 1 nm to 100 nm.

[0445] The microparticle compositions described herein can be prepared by a variety of methods, including spray drying; fluidized bed technology; technology that utilizes spraying a solution into air or liquid through a nozzle (or injector) to prepare microparticles; cryogenic spray technology; ultrasonic spraying (e.g., electrostatic spraying) through a nozzle (or injector) in the absence or presence of an applied electric potential; supercritical fluid technology for preparing microparticle compositions; or any general technology involving polymer precipitation or phase separation or coacervation; and any combination thereof.

[0446] The following is a representative method for forming microparticles comprising poly(butylene succinate) or a copolymer thereof and a core material to be encapsulated. The core material may be omitted if no core material is to be encapsulated in the microparticle. The core material may be a bioactive agent, or other additive or polymer including a diagnostic agent or an imaging agent. As used herein, "core material" means a material incorporated into a microparticle, and includes material incorporated anywhere in the microparticle, and is not limited to the core or center of the microparticle.

[0447] Spray drying

[0448] In spray drying, the core material to be encapsulated can be dispersed or dissolved in a solution comprising poly(butylene succinate) or its copolymer. The solution or dispersion can then be pumped through a micronizing nozzle driven by a compressed gas stream, and the resulting aerosol is suspended in a heated air cyclone, thereby evaporating the solvent from the droplets. The solidified microparticles comprising poly(butylene succinate) or its copolymer enter the second chamber and are captured in a collection bottle.

[0449] Hot melt encapsulation

[0450] In hot melt microencapsulation, the core material to be encapsulated can be added to molten poly(butylene succinate) or its copolymer. The mixture can then be suspended as molten droplets in a non-solvent for the polymer that has been heated to about 10°C above the melting point of the polymer. The emulsion is maintained under vigorous stirring while the non-solvent is rapidly cooled to below the glass transition of the polymer, causing the molten droplets to solidify and capture the core material.

[0451] Solvent Evaporation Microencapsulation

[0452] In solvent evaporation microencapsulation, poly (butylene succinate) or its copolymer can be dissolved in an organic solvent immiscible with water, and the core material to be encapsulated is added to the polymer solution as a suspension or solution in an organic solvent. An emulsion can be formed by adding the suspension or solution to a beaker of vigorously stirred water (which can contain a surfactant, for example, polyethylene glycol or polyvinyl alcohol, so that the emulsion is stable). The organic solvent is then evaporated while continuing to stir. Evaporation causes polymer precipitation to form a solid microcapsule comprising the core material.

[0453] The solvent evaporation process can be used to capture the liquid core material in the microcapsule of poly (butylene succinate) or its copolymer. The polymer can be dissolved in a miscible mixture of a solvent and a non-solvent, and the non-solvent concentration is just below the concentration (i.e., cloud point) at which phase separation will occur. The liquid core material can be added to the solution while stirring to form an emulsion and the material is dispersed as droplets. The solvent and non-solvent are evaporated, wherein the solvent evaporates at a faster rate, causing the polymer or copolymer to phase separate and migrate toward the surface of the core material droplets. The phase-separated solution can then be transferred to a certain volume of non-solvent stirred, causing any remaining dissolved polymer to precipitate and extract any residual solvent from the formed film. The process can be used to form a microcapsule consisting of a polymer shell of poly (butylene succinate) or its copolymer and a core of a liquid material.

[0454] In some embodiments, microparticles comprising poly(butylene succinate) or its copolymer are prepared using an emulsion-based method. These methods may include an emulsion-solvent extraction method, an emulsion-solvent evaporation method, or a combination of extraction and evaporation techniques. In these methods for preparing microparticle compositions, a polymer solution is typically prepared by dissolving poly(butylene succinate) or its copolymer in a suitable solvent. The solvent may be a single solvent or a co-solvent. A single solvent or a mixture of two or more solvents may be referred to as a "solvent system". The core material may typically be added to the polymer solution as a solid or as a solution or suspension. The core material may be soluble or insoluble in the polymer solution. In some embodiments, the core material may be added after first dissolving or suspending the core material in a solvent system ("first solvent") and then adding the solution or suspension to a polymer solution comprising poly(butylene succinate) or its copolymer. The core material may be dissolved in the first solvent, and when the solution is added to the polymer solution comprising poly(butylene succinate) or its copolymer, the core material may remain dissolved in the resulting polymer solution. Alternatively, adding a solution comprising the core material to the polymer solution can cause the core material to precipitate from the solution to a greater or lesser extent, depending on the overall solubility of the core material in the resulting solution. The first solvent (i.e., a solvent system for dissolving or suspending the core material) can be completely soluble in a polymer solution comprising poly(butylene succinate) or its copolymer. In another embodiment, the first solvent may be only partially soluble (or miscible) in the resulting polymer solution, and a liquid-liquid emulsion may be formed. In another embodiment, the first solvent may be only slightly soluble in the polymer solution; or, the solvent may be almost or virtually insoluble in the polymer solution. In the case where the first solvent is not completely soluble in a polymer solution comprising poly(butylene succinate) or its copolymer, a liquid-liquid emulsion will then be formed. Depending on the specific solvent system used to prepare the polymer and core material solution, the emulsion may be an oil-in-water emulsion or an oil-in-water emulsion. Preparing a polymer solution in the form of an emulsion is generally described as a "double emulsion" technique for preparing a microparticle composition.

[0455] The core material may be uniformly distributed throughout the microparticle. Alternatively, the core material may be non-uniformly distributed in the microparticle matrix, ie, encapsulated within the microparticle (eg, in its interior) or in an outer region of the microparticle.

[0456] Solvent Removal Microencapsulation

[0457] In the solvent removal microencapsulation, poly (butylene succinate) or its copolymer can be dissolved in the miscible organic solvent of oil, and the core material to be encapsulated is added to the polymer solution as a suspension dissolved in water or as a solution in an organic solvent. Surfactant can be added to improve the dispersion of the core material to be encapsulated. An emulsion can be formed by adding a suspension or solution to oil under agitation, wherein oil is a non-solvent for polymer and polymer / solvent solution is immiscible in oil. Organic solvent can be removed by being diffused into the oil phase while continuing to stir. Solvent removal causes polymer precipitation, forms a solid microcapsule / microparticle comprising the core material.

[0458] Phase separation microencapsulation

[0459] In phase separation microencapsulation, the core material to be encapsulated can be dispersed in a polymer solution comprising poly(butylene succinate) or its copolymer under stirring. While constantly stirring to evenly suspend the core material, a non-solvent for the polymer is slowly added to the solution to reduce the solubility of the polymer. Depending on the solubility of the polymer in the solvent and the non-solvent, the polymer can be precipitated or phase-separated into a polymer-rich phase and a polymer-poor phase. In some embodiments, the polymer in the polymer-rich phase will migrate to the interface with the continuous phase, and the core material is encapsulated in a droplet with an outer polymer shell comprising poly(butylene succinate) or its copolymer.

[0460] Spontaneous emulsification

[0461] In spontaneous emulsification, emulsified liquid polymer droplets comprising poly(butylene succinate) or its copolymers are solidified by changing the temperature, evaporating the solvent, or adding a chemical cross-linking agent.

[0462] Cohesion

[0463] In coacervation, poly(butylene succinate) or its copolymers can be used to encapsulate the core material. Coacervation is a process involving the separation of a colloidal solution into two or more immiscible liquid layers. Through the coacervation process, a composition called a coacervate composed of two or more phases can be produced. The components that make up the two-phase coacervate system are present in both phases; however, the colloid-rich phase has a higher concentration of the component than the colloid-poor phase.

[0464] Phase Inversion Nanoencapsulation ("PIN")

[0465] In some embodiments, microparticles comprising poly(butylene succinate) or its copolymer are formed by PIN. In PIN, poly(butylene succinate) or its copolymer can be dissolved in an effective amount of solvent. The core material to be encapsulated can also be dissolved or dispersed in an effective amount of solvent. The polymer, core material and solvent together form a mixture with a continuous phase, wherein the solvent is the continuous phase. The mixture can then be introduced into an effective amount of non-solvent to cause spontaneous formation of microencapsulated core material, wherein the solvent and non-solvent are miscible. In some embodiments, the hydrophobic core material is dissolved in an effective amount of a first solvent that does not contain a polymer. The hydrophobic agent and the solvent form a mixture with a continuous phase. Then a second solvent comprising poly(butylene succinate) or its copolymer is also introduced into the mixture with an aqueous solution. The introduction of the aqueous solution causes the hydrophobic core material to precipitate and produce a composition of a micronized hydrophobic core material having an average particle size of 1 micron or less.

[0466] Melt-Solvent Evaporation Method

[0467] In the melt-solvent evaporation method, poly (butylene succinate) or its copolymer is heated above its melting point to a point with sufficient fluidity to allow easy operation (e.g., stirring with a spatula). The core material is then added to the molten polymer and physically mixed while maintaining the temperature. This preferably results in the melting of the core material in the polymer and / or the dispersion of the core material in the polymer. The mixture is then cooled to room temperature and hardened. The mixture can then be used to form microparticles using a solvent-based method as described herein, such as a double emulsion technique. In some embodiments, the core material dispersed in poly (butylene succinate) or its copolymer prepared, for example, as described above, is dissolved or dispersed in an organic solvent composition with or without a nonionic surfactant of a plurality of hydrophilic-lipophilic ratios. The composition is then introduced into an aqueous solution containing a surfactant such as PVA (polyvinyl alcohol). The water-insoluble solvent forms an oil phase (internal phase) and can be stirred into an aqueous solution or an aqueous phase (external phase). The O / W (oil / water) emulsion is then combined with fresh water containing PVA and stirred to help promote solvent evaporation and the formation of microparticles.

[0468] In the above methods for forming microparticles, one or more other polymers described herein can be used to form microparticles comprising a blend of poly(butylene succinate) or a copolymer thereof and one or more other polymers disclosed herein.

[0469] Injectable carriers for microparticle compositions

[0470] In some embodiments, the microparticle composition is incorporated into an injection vehicle or liquid phase. The injection vehicle or liquid phase can be aqueous or non-aqueous. Preferably, an injection vehicle with a certain viscosity and density is selected so that the resulting suspension formed by the microparticle composition is stable in the suspension and has a suitable viscosity to pass through a needle for administering the microparticles to a human or animal. Suitable aqueous injection vehicles include, but are not limited to, saline solutions and contrast medium solutions suitable for injection. Suitable non-aqueous injection vehicles include, but are not limited to, fluorinated liquid vehicles, such as polyfluoroalkylmethylsiloxanes, Miglyol or other pharmaceutically acceptable oils and oil-based vehicles.

[0471] The injection vehicle may contain one or more viscosity modifiers and / or surfactants. Other suitable additives include, but are not limited to, buffers, osmotic agents, and preservatives. Examples of viscosity modifiers include, but are not limited to, synthetic polymers such as poloxamers, pluronics, or polyvinyl pyrrolidone; polysaccharides such as sodium carboxymethylcellulose (CMC); natural polymers such as gelatin, hyaluronic acid, or collagen. Viscosity modifiers may be used in any concentration range that provides sufficient fluidity for administration through a needle. Thus, the injection vehicle may be a low viscosity solution with or without a surfactant; in addition, the injection vehicle may be a medium or high viscosity solution. Suitable surfactants include anionic surfactants, cationic surfactants, amphiphilic surfactants, or nonionic surfactants. Examples of surfactants that may be included in the injection vehicle include, but are not limited to, Tween 20, Tween 80, sodium dodecyl sulfate, or sodium lauryl sulfate.

[0472] Since the density of poly (butylene succinate) or copolymer may be greater than the density of injection saline, it may be necessary to optimize the injection vehicle to match the density of the microparticles and may include one or more density modifiers and / or surfactants. The example of density modifier includes, but is not limited to, synthetic polymers, contrast agents for imaging, or iodine-containing compounds such as iopamidol (Isovue), iohexol (Omnipaque), iopromide (Ultravist), iofosmol (Optiray) and / or iodine blue (Oxilan). For example, the density of the aqueous solution for injection of iopamidol increases with its concentration, so that the density (specific gravity) of 41 wt %, 51 wt %, 61 wt % and 76 wt % solutions at 37° C. is 1.23 g / ml, 1.28 g / ml, 1.34 g / ml and 1.41 g / ml. Thus, such contrast agents may be added to an aqueous suspension of microparticles to change the density of the solution to match the density of the microparticles to prevent the microparticles from floating or settling out of the suspension.

[0473] Specific examples of injection vehicles include, but are not limited to, those vehicles used in commercial pharmaceutical preparations or those that are identical or similar to the contrast agents used in imaging. In some embodiments, the injection vehicle comprises carboxymethyl cellulose (CMC) in a concentration range of about 0.05% by weight to about 25% by weight, preferably 0.05% by weight to 3% by weight, more preferably 3% by weight to 6% by weight, even more preferably 6% by weight to 10% by weight, and most preferably 10% by weight to 25% by weight as a viscosity modifier. In some embodiments, the injection vehicle may include a surfactant in a concentration range of about 0.05% by weight to 0.5% by weight, such as Tween 20 or Tween 80. In other embodiments, the injection vehicle may be prepared using a viscosity modifier poloxamer (or pluronic) in a concentration range of 0.5% by weight to 50% by weight; 0.05% by weight to 5% by weight, 5% by weight to 20% by weight; or 20% by weight to 50% by weight. In one embodiment, the injection vehicle requires little or no surfactant. In some embodiments, the injection vehicle may also include polyvinylpyrrolidone (PVP) in the range of 0.1 wt % to 10 wt % as a viscosity modifier. In some embodiments, the injection vehicle may include other additives such as osmotic agents, for example, to make the osmotic pressure of the microparticle formulation close to the osmotic pressure of the physiological environment. In some embodiments, the injection vehicle may include mannitol; for example, the injection vehicle may include mannitol in the range of about 0.5 wt % to 15 wt %, 0.5 wt % to 5 wt %, or 5 wt % to 15 wt %. In other embodiments, a density modifier such as a contrast agent may be added to the injection vehicle in the range of about 5 wt % to 70 wt %, 20 wt % to 60 wt %, or 30 wt % to 50 wt %.

[0474] In some embodiments, the microparticle composition can be dispersed into or suspended in an injection vehicle. The concentration range of the microparticle composition solid added to and dispersed in or suspended in the injection vehicle of a specific volume can be from dilute to dense. As used herein, the concentration of microparticles refers to the solid load of microparticles comprising poly (butylene succinate) or its copolymer in a liquid injection vehicle. The solid concentration required in the suspension can be determined by application or by the intensity or activity of the bioactivator or both. In one embodiment, the solid concentration in the suspension is about 0.1 wt % to about 75 wt %. The preferred solid content of the microparticle composition dispersed or suspended in the injection vehicle includes about 0.1 wt % to about 1 wt %, about 1 wt % to about 10 wt %, about 5 wt % to about 50 wt % or about 50 wt % to about 75 wt %.

[0475] In some embodiments, the microparticle composition can be suspended in a water-based carrier. In some embodiments, the aqueous carrier can contain a viscosity modifier, a density modifier, and / or a surfactant. In some embodiments, the concentration level of the suspension of the microparticle composition in the aqueous carrier can be about 10% to 40% by weight (percent solids).

[0476] Microparticles comprising core material

[0477] In some embodiments, microparticles can be used to deliver one or more core materials, which are bioactive agents, additives, or therapeutic agents, diagnostic agents, or preventive agents. The core material can be associated, fixed, adhered, or otherwise physically or chemically bound to the surface of the microparticle. The core material can be a small molecule (e.g., less than 1000 Daltons) or a macromolecule (e.g., equal to or greater than 1000 Daltons); and the core material can be from a biological source or can be prepared synthetically, or optionally, the core material can be from a biological source that is subsequently modified synthetically. Microparticles can be prepared with core materials such as bioactive agents, encapsulated in the microparticles in some way, associated with the surface of the microparticles, or otherwise connected to the surface of the microparticles (e.g., covalently, non-covalently, ionically). In some embodiments, the microparticle composition may not include a core material.

[0478] The core material can be a liquid or solid bioactive agent that can be incorporated into the delivery system described herein. In some embodiments, the core material can be at least slightly soluble in water or moderately soluble in water. In some embodiments, the core material can diffuse through the polymer composition. In some embodiments, the core material can be an acid salt, a basic salt, or an amphoteric salt. In some embodiments, the core material can be used as a free acid or base or as a pharmaceutically acceptable salt. In some embodiments, the core material can be included in the microparticle in the form of, for example, uncharged molecules, molecular complexes, salts, ethers, esters, amides, polymer-drug conjugates, prodrugs, or other forms to provide the desired effective biological or physiological activity.

[0479] Examples of bioactive agents that can be incorporated into the microparticles as core materials include those described in Section II.C, and also include, but are not limited to, peptides, proteins such as hormones, enzymes, antibodies, etc., nucleic acids such as aptamers, iRNA, siRNA, DNA, RNA, antisense nucleic acids, etc., antisense nucleic acid analogs, etc., low molecular weight compounds, or high molecular weight compounds. Bioactive agents contemplated for use in microparticle compositions also include anabolic agents, antacids, antiasthmatic agents, stimulants, anticholesterol and antilipidemic and antihyperlipidemic agents, anticholinergic agents, anticoagulants, anticonvulsants, antidiabetic agents; antidiarrheal agents, antiedema agents; antiemetics, anthelmintics; anti-infective agents, including antibacterial and antimicrobial agents, anti-inflammatory agents, antimanic agents, antimetabolites, antimigraine agents; antinausea agents, antitumor agents, antiobesity agents and anorexia agents; antipruritic agents; antipyretic analgesics, antismoking (quit smoking) agents and antialcohol agents; antispasmodics, antithrombotic agents, antituberculosis agents; antitussives, antiuric acid agents, antianginal agents, antihistamines, antianxiety agents; appetite suppressants and anorexia agents; injections drugs for attention deficit hyperactivity disorder; biologics, cerebral dilators, coronary artery dilators, bronchodilators, cytotoxic agents, decongestants, diuretics, diagnostic agents, erythropoietic agents, expectorants, gastrointestinal sedatives, central nervous system ("CNS") agents, CNS stimulants, hyperglycemic agents, hypnotics, hypoglycemic agents, immunomodulators, immunosuppressants, muscle relaxants, nicotine, parasympatholytics; sialagogues, ion exchange resins, laxatives, mineral supplements, mucolytics, neuromuscular agents, vasodilators, peripheral vasodilators, beta-agonists; tocolytic agents; psychotropics, psychostimulants, sedatives, stimulants, thyroid and antithyroid agents, tissue growth agents, uterine relaxants, vitamins, or antigenic materials. Representative classes of drugs or bioactive agents that can be incorporated as core materials into microparticle compositions include, but are not limited to, peptide drugs, protein drugs, desensitizing materials, antigens, anti-infective agents such as antibiotics, antimicrobials, antivirals, antibacterials, antiparasitics, antifungal substances and combinations thereof, antiallergics, steroids, androgenic steroids, decongestants, hypnotics, steroidal anti-inflammatory agents, anticholinergics, sympathomimetics, sedatives, miotics, psychoenergetic agents, tranquilizers, vaccines, estrogens, progestational agents, humoral agents, prostaglandins, analgesics, antispasmodics, antimalarials, antihistamines, cardioactive agents, nonsteroidal anti-inflammatory agents, anti-Parkinson's disease agents, anti-Alzheimer's disease agents, antihypertensive agents, beta-adrenergic blocking agents, alpha-adrenergic blocking agents, nutritional agents, and benzophenanthridine alkaloids. The bioactive agent may also be a substance that can act as a stimulant, sedative, hypnotic, analgesic, anticonvulsant.

[0480] Suitable diagnostic agents that can be incorporated into the microparticles as core materials include medical imaging agents and diagnostic agents, such as MRI-based imaging, including, for example, iron oxide particles (including, for example, superparamagnetic iron oxide or SPIO particles) and gadolinium-containing agents. Microparticle core materials may also include dyes, contrast agents, fluorescent markers, imaging agents, radiopaque agents, and radiological agents used in medical diagnostic and imaging techniques.

[0481] In some embodiments, the microparticle composition may include one or more core materials having a concentration of about 0 weight percent to 99.9 weight percent (wt%) of the microparticle composition. In one embodiment, the microparticle is a placebo with a zero weight percent core material. In another embodiment, the microparticle composition intended for delivery of a vaccine antigen may only need to deliver a very small amount or trace of core material, in this case a vaccine antigen. In such a case, the load level of the antigen in the microparticle may be less than 1 weight percent, or may be less than 0.1 weight percent. In other embodiments, the load of the core material may be greater, for example, from about 1 weight percent to about 90 weight percent, preferably from about 1 weight percent to about 50 weight percent, more preferably from about 1% to about 10%. In order to incorporate one or more bioactive peptides into microparticles as core materials, the bioactive peptides may be present in the microparticle composition at a level of about 1 weight percent to about 10 weight percent. In other embodiments, the bioactive peptides and all their associated soluble salts may be present in the microparticle composition at a load level of about 40 weight percent or more. The load percentage depends on many factors, including but not limited to the specific application, the selection and properties of the core material itself, and the size and structure of the microparticle composition.

[0482] In some embodiments, the microparticle composition may include one or more pharmaceutically acceptable excipients, carriers and additives. As used herein, "carrier" is all components present in a pharmaceutical formulation except one or more active ingredients. The term "carrier" includes, but is not limited to, solvents, suspending agents, stabilizers, colorants, antioxidants, dispersants, buffers, pH regulators, isotonicity regulators, preservatives, antimicrobial agents and combinations thereof. Other additives that may be included in the microparticles include those additives that can be used for processing or preparing microparticles, those additives that can contribute to the incorporation or stability of microparticle bioactive agents, or those additives that can be used to change the performance of the microparticle composition (including, for example, changing the drug release rate, drug stability, water absorption or polymer degradation).

[0483] The microparticle composition may contain other excipients, including any number of other medically acceptable or pharmaceutically acceptable agents, such as preservatives, lipids, fatty acids, waxes, surfactants, plasticizers, pore-forming agents, antioxidants, swelling agents, buffers, chelating agents, cosolvents, water-soluble agents, insoluble agents, metal cations, anions, salts, osmotic agents, synthetic polymers, biopolymers, hydrophilic polymers, polysaccharides, sugars, hydrophobic polymers, hydrophilic block copolymers, hydrophobic block copolymers, block copolymers comprising hydrophilic and hydrophobic blocks. When preparing microparticles, such excipients may be used alone or in combination of two or more excipients. Excipients may be used to alter or affect drug release, water absorption, polymer degradation, or stability of the bioactive agent.

[0484] In some embodiments, one or more excipients can be incorporated into microparticles by first mixing with poly (butylene succinate) or its copolymer. In other embodiments, excipients can be added to a solution of poly (butylene succinate) or its copolymer separately. In other embodiments, excipients can be incorporated into a first solution composed of a core material such as a bioactive agent dissolved or dispersed in a first solvent. In some embodiments, excipients can be added to a solution of poly (butylene succinate) or its copolymer before, during or after core biomaterials such as bioactive agents are added to a polymer solution. In some embodiments, such excipients can be used to prepare microparticles that do not include core materials such as bioactive agents. In some embodiments, excipients can be directly added to a polymer solution of poly (butylene succinate) or a copolymer, or excipients can be first dissolved or dispersed in a solvent and then added to the polymer solution. Examples of water-soluble and hydrophilic excipients include poly(vinyl pyrrolidone) or PVP and copolymers comprising one or more blocks of PVP with blocks of other biocompatible polymers (e.g., poly(lactide) or poly(lactide-co-glycolide) or polycaprolactone); poly(ethylene glycol) or PEG and copolymers comprising blocks of PEG with blocks of other biocompatible polymers (e.g., poly(lactide) or poly(lactide-co-glycolide) or polycaprolactone); poly(ethylene oxide) or PEO and copolymers comprising one or more blocks of PEO with blocks of other biocompatible polymers (e.g., poly(lactide) or poly(lactide-co-glycolide) or polycaprolactone), and block copolymers comprising PEO and poly(propylene oxide) or PPO, such as triblock copolymers of PEO-PPO-PEO (e.g., Poloxamer). TM 、Pluronics TM ); and modified copolymers of PPO and PEO containing ethylenediamine (Poloxamines TM and TetronicsTM In some embodiments, microparticles may be prepared that include one or more bioactive agents or one or more excipients or a combination thereof.

[0485] In some embodiments, one or more excipients can be incorporated into the microparticles at a concentration of about 1% to about 90% by weight of the microparticle composition. In some embodiments, the microparticle composition can contain greater than 80%, 90%, or 99% excipients, and accordingly, the microparticles contain very little poly(butylene succinate) or a copolymer thereof.

[0486] IV. Implants of poly(butylene succinate) and its copolymers

[0487] The compositions of poly(butylene succinate) and copolymers thereof described herein are suitable for preparing implants for soft and hard tissue repair, regeneration and replacement.

[0488] Implants of poly(butylene succinate) and copolymers thereof in oriented form are particularly useful in applications requiring extended strength retention. Multifilament yarns and monofilament fibers disclosed herein have extended in vivo strength, making them useful in soft tissue repairs requiring high strength and requiring long-term strength retention. Other application examples for high-strength yarns and monofilament fibers include soft and hard tissue repair, replacement, remodeling and regeneration, including wound closure, breast reconstruction and breast lifting (including mastopexy operations), lifting operations performed on the face such as face lifting, neck lifting and eyebrow lifting, ligament and other tendon repair operations, abdominal closure, hernia repair, anastomosis, slings for lifting tissue, slings for the treatment of stress urinary incontinence, and pelvic floor reconstruction including the treatment of pelvic organ prolapse (including the treatment of cystocele, urethrocele, uterine prolapse, vaginal misprolapse, enterocele and rectocele).

[0489] A. Sutures and Braids

[0490] As shown in Examples 16 and 15, oriented fibers of PBS and its copolymers have been found to have extended retention of tensile strength when implanted in vivo. Figure 5is a SEM of oriented fibers removed after 4 weeks. Unexpectedly, at 400× magnification, the surface of the fibers showed almost no noticeable surface pitting or localized surface erosion. This result was unexpected in view of the known surface erosion and pitting of fibers derived from other resorbable fibers. This discovery allows the use of the fibers in applications where extended strength retention is required. The lack of surface erosion is particularly important for strength retention of small diameter fibers where pitting on the fiber surface can quickly reduce strength retention. The fibers can also be used in applications requiring high initial tensile strength. Example 16 clearly shows that when implanted in vivo, the oriented fibers do not lose a significant amount of tensile strength within the first 4 weeks. The studies described in Example 15 further demonstrated that a mesh made of oriented fibers of PBS or its copolymers retained 74.1% of its strength after 12 weeks, indicating that the strength retention of the fibers was extended. In these studies, analysis of the weight average molecular weight of the implanted fibers after 4 and 12 weeks indicated that the fibers were degrading. The weight average molecular weight of the suture fibers in Example 16 decreased from 7.3% to 92.7% of the initial value at 4 weeks, and the weight average molecular weight of the fibers in the mesh decreased from 25.9% to 74.1% of the initial value at 12 weeks. It is also clear that there is a good correlation between the weight average molecular weight loss of the oriented fibers of PBS and its copolymers in vitro shown in Example 12 and the in vivo data shown in Examples 15 and 16. This good correlation further demonstrates that the oriented fibers resist surface denting or surface erosion.

[0491] In a preferred embodiment, under physiological conditions, in vivo, the weight average molecular weight of the fiber of PBS or its copolymer decreases by 3% to 15% within a 4-week period in vivo, by 5% to 15% within an 8-week period, or by 10% to 35%, more preferably by 10% to 30% within a 12-week period. Under physiological conditions, in vivo, the percent mass loss of the fiber is preferably 0% to 5% within a 4-week period.

[0492] In one embodiment, the tensile strength of the monofilament fibers used to make sutures, suture meshes, braids and tapes is 400 MPa to 2,000 MPa, more preferably greater than 500 MPa, 600 MPa, 700 MPa or 800 MPa, and less than 1,200 MPa. Preferably, the Young's modulus of the monofilament fibers used to make sutures, suture meshes and tapes is 600 MPa to 5 GPa, but preferably at least 800 MPa, 1 GPa or 2 GPa. It has been found that the high Young's modulus of the fiber can prevent the suture from forming pigtails or curling during suturing. In another preferred embodiment, the melting temperature of the monofilament fibers used to make sutures, suture meshes, braids and tapes exceeds 100°C, preferably 105°C to 120°C.

[0493] In one embodiment, the suture made from the monofilament fiber of PBS or its copolymer has a knot pull tensile strength of 200MPa to 1,000MPa, more preferably greater than 300MPa, 400MPa and 500MPa, but less than 800MPa. In an even more preferred embodiment, the knot pull tensile strength of the suture is 300MPa to 600MPa.

[0494] The monofilament fiber of poly (butylene succinate) and copolymer thereof can also be used to prepare such high-strength monofilament suture, the hybrid suture of monofilament and multifilament fiber: it has good flexibility, high knot strength, and can be firmly knotted with low profile end (low profile knot bundle) (i.e. twist several times and tighten). In one embodiment, the monofilament fiber can be processed into resorbable high-strength suture and suture anchor that can be used for example in rotator cuff repair surgery. These sutures and anchors can be used for shoulder, elbow, wrist, hand hip, knee, ankle and foot repair (comprising tendon and ligament repair) especially, and for soft tissue approach (approximation), ligation of soft tissue, abdominal closure, and plastic surgery operation such as lifting and suspension operation (comprising face and breast lifting operation and breast reconstruction). Monofilament suture and suture anchor (comprising soft suture anchor) can be combined with one or more needles, can be transparent or dyed, and if necessary, can be woven into a part of suture or suture anchor, or woven into flat belt.

[0495] Thus, in the context of sutures, the present invention also provides the subject matter defined by the following numbered paragraphs:

[0496] Paragraph 1. An absorbable suture, wherein the diameter of the suture is 0.02 mm to 0.9 mm, and wherein the suture is formed of a polymer composition comprising 1,4-butanediol units and succinic acid units and is optionally isotopically enriched, and preferably the polymer composition comprising 1,4-butanediol units and succinic acid units is a composition as defined in any one of the claims of the present application.

[0497] Paragraph 2. The suture of Paragraph 1, wherein the suture is a monofilament suture, and wherein the tensile strength of the suture is from 400 MPa to 2,000 MPa.

[0498] Paragraph 3. The suture of Paragraph 2, wherein the suture has a tensile strength greater than 500 MPa, 600 MPa, 700 MPa, or 800 MPa.

[0499] Paragraph 4. The suture of Paragraphs 1 to 3, wherein the suture has a knot pull tensile strength of 200 MPa to 1,000 MPa.

[0500] Paragraph 5. The suture of Paragraph 4, wherein the knot pull tensile strength of the suture is greater than 300 MPa, 400 MPa, or 500 MPa.

[0501] Paragraph 6. The suture of Paragraphs 1 to 5, wherein the suture has an elongation at break of 15% to 50%.

[0502] Paragraph 7. The suture of Paragraphs 1 to 6, wherein the Young's modulus of the suture is from 600 MPa to 5 GPa.

[0503] Paragraph 8. The suture of Paragraph 7, wherein the Young's modulus of the suture is from 1 GPa to 3 GPa.

[0504] Monofilament fibers of poly(butylene succinate) and its copolymers can also be used to prepare barbed sutures. Barbs can be incorporated into sutures to physically engage tissue and allow the suture to pass through the tissue in one direction while preventing passage in the opposite direction.

[0505] It has been found that multifilament fibers of poly(butylene succinate) and copolymers thereof can be used to prepare high strength multifilament sutures, hybrid sutures of monofilament and multifilament fibers, which have excellent flexibility, extended strength retention, high knot strength, good drape, and can be securely knotted to form a soft end with a low profile. Example 3 discloses a method that can be used to produce high strength multifilaments of PBS or its copolymers suitable for these applications.

[0506] The multifilament yarn of PBS and its copolymer can be processed into resorbable high-strength suture and suture anchor that can be used for rotator cuff repair operation.At present, because existing resorbable suture degrades too fast, these operations are repaired with permanent suture.Compared with existing resorbable suture, the suture prepared with the high tenacity yarn of the present invention not only provides high initial strength to stabilize the repair under significant load, but also slowly loses strength to allow the repair of soft tissue.High-strength suture can also be used for bone anchor, suture anchor and soft suture anchor.These sutures and anchors can be used for shoulder, elbow, wrist, hand hip, knee, ankle and foot repair (including tendon and ligament repair), and for lifting and suspension operation.Bone anchor, suture anchor and soft suture anchor can be combined with one or more needles, yarns of different colors, and if necessary, can be combined with flat braided parts.The ability of using resorbable high-tenacity suture, suture anchor, bone anchor and soft suture anchor in the operation for such as rotator cuff repair eliminates the long-term complications that may be caused by foreign bodies such as permanent suture. These sutures may be used, for example, in soft tissue approximations, anastomosis, suspension and lift procedures, and for other applications in plastic surgery.

[0507] In a preferred embodiment, yarns of poly(butylene succinate) and copolymers thereof can be used to prepare high-strength braided sutures, wherein the breaking load of the suture is from 1 N to 270 N, or from 40 N to 270 N. In a particularly preferred embodiment, the high tensile strength braided suture comprising poly(butylene succinate) and copolymers thereof has an in vivo tensile strength retention rate of at least 40% under physiological conditions after implantation for 4 to 6 months.

[0508] Suture braids can be produced from yarns with USP suture sizes of 12-0, 11-0, 10-0, 9-0, 8-0, 7-0, 6-0, 5-0, 4-0, 3-0, 2-0, 0, 1, 2, 3, 4, and 5, and meet the USP knot pull tensile strength or breaking load of these sizes. In another embodiment, the diameter of the suture braid can be too large to meet the USP knot pull tensile strength or breaking load. For example, the diameter of the suture braid can be too large, up to 0.3 mm, preferably 0.2 mm, more preferably 0.1 mm, even more preferably 0.05 mm. The suture can be stitched with a needle and / or contain a loop at either end.

[0509] In another embodiment, yarns of poly(butylene succinate) and copolymers thereof and monofilaments of poly(butylene succinate) and copolymers thereof can be used to prepare flat suture bands (including flat braided suture bands). These suture bands can be used for the approach and / or ligation of soft tissues, and are particularly useful for operations requiring wide compression and increased cut-through resistance. For example, the suture band can be used for shoulder and rotator cuff repair operations such as acromioclavicular repair, and restoration of labrum height in unstable repairs, as well as for ACL and PCL repair operations. The suture band can have a flat end, a tapered end, a needle at one or both ends of the suture band, and include yarns with one or more different dyes.

[0510] The suture tapes disclosed herein may also be used as slings for tissue support, including slings for the treatment of stress urinary incontinence.

[0511] In another embodiment, coatings can be applied to increase the lubricity of braided sutures and other fiber-based implants. These coatings include waxes, natural and synthetic polymers such as polyvinyl alcohol, and spinning finishes including polyethylene glycol sorbitan monolaurate, and polymers or oligomers of ethylene oxide, propylene oxide, PEG400, PEG40 stearate, Dacospin and Filapan. Preferably, these coatings are applied so that the coating weight of the braided suture is less than 6 wt %, more preferably less than 3 wt %, even more preferably less than 2 wt %. Preferably, the coating easily leaves the surface of the braided suture or fiber-based device in vivo, such as by degradation or dissolution (e.g., if the coating is water-soluble).

[0512] In another embodiment, a coating can be applied to the surface of the suture to slow degradation and increase in vivo strength retention. For example, the suture can be coated with another polymer, preferably a slowly degrading polymer or composition, or coated with a wax. For example, the suture can be coated with polycaprolactone to slow degradation and further extend strength retention.

[0513] Braids (including suture tapes and suture braids) made of high tenacity yarns of poly(butylene succinate) and copolymers thereof are preferably prepared by coating the yarn with a spinning finish, twisting or plying the yarn and winding it onto a bobbin. Preferred spinning finishes are polyethylene glycol sorbitan monolaurate and polyethylene glycol. The bobbin is then placed on a braiding machine. The number of wefts per inch can be increased as needed to improve the fineness of the braid. The number of wefts per inch can be between 5 and 100, and preferably between 30 and 60. In some embodiments, the core of a monofilament, yarn or multi-strand yarn strand can be bonded to the center of the braid. Alternatively, a braid without a core can be prepared. For example, a hollow braid is produced.

[0514] In one embodiment, yarns and monofilament fibers of poly(butylene succinate) and copolymers thereof can be used to prepare mesh sutures, which can distribute the load applied to the reattached tissue, thereby reducing suture pull-through (cheese wiring effect) and wound dehiscence. The mesh suture can be threaded through the tissue, the mesh anchored in the tissue under tension to reattach the soft tissue, and then the needle is removed. Using a mesh rather than suture fibers to reattach the tissue increases the strength of the repair. The porosity of the mesh is designed to allow tissue to grow inward into the mesh.

[0515] The mesh suture comprises a suture needle and a mesh component. The mesh component comprises the fiber of poly (butylene succinate) and copolymer as described herein, preferably the monofilament fiber of poly (butylene succinate) and its copolymer. The mesh component is the interwoven structure of fiber (preferably the monofilament fiber of poly (butylene succinate) and its copolymer). Preferably, the mesh structure is formed by knitting, weaving and weaving of the fiber (most preferably monofilament fiber) comprising poly (butylene succinate) and its copolymer. The cross section of the mesh component can be ellipsoidal, semi-ellipsoidal, circular, semicircular, convex circular, rectangular, square, crescent, pentagonal, hexagonal, concave belt, convex belt, H-beam, I-beam or dumbbell. Alternatively, the mesh component can present these shapes when it passes through tissue. Preferably, the mesh component flattens when it passes through tissue. The mesh component can also have a cross-sectional profile that changes on the length of the mesh. For example, a part of the cross section of the mesh can be tubular, while the other part is non-tubular. In some embodiments, the cross section of the mesh component is larger than the cross section of the needle. However, in a preferred embodiment, the mesh component has the same cross section as the suture needle, more preferably has a cross section of ± 25% of the cross section of the suture needle. The mesh preferably has a hole with an average diameter of 5 μm to 5mm, more preferably 50 μm to 1mm. The width of the mesh is preferably 1mm to 20mm, more preferably 1mm to 10mm, even more preferably 1mm to 7.8mm. The width can vary along the length of the mesh. In one embodiment, the mesh can have an elasticity similar to that of the tissue at the implantation site. For example, in the case of repairing abdominal tissue, the mesh suture preferably has the same elasticity or similar elasticity as the abdominal tissue. In another embodiment, the elasticity of the mesh is designed to allow even greater tension to be applied to the reattached tissue to keep the reattached tissue close to each other. Preferably, the mesh suture will stretch less than 30%, more preferably less than 20%. It is also desirable that the mesh has enough flexibility to allow it to pass through tissue with tight bends. In a preferred embodiment, the stiffness of the mesh suture is less than 50 Taber units (TU), more preferably less than 10TU, even more preferably less than 2TU or 0.8TU. In another embodiment, the in vivo tensile strength retention of the mesh suture under physiological conditions is at least 75% at 4 weeks, more preferably at least 80% at 4 weeks, even more preferably at least 65% at 12 weeks.

[0516] Sutures, braids, suture tapes, meshes made of high tenacity yarns and monofilament fibers of poly(butylene succinate) and copolymers thereof (for example, but not limited to, hernia patches and / or repair patches for the following: repair of abdominal wall and chest wall defects, inguinal hernias, paracolic hernias, abdominal wall hernias, paraumbilical hernias, scrotal hernias or femoral hernias, hiatal hernias, for muscle flap reinforcement, for staple lines (staple line) and long incision augmentation, for pelvic floor reconstruction including treatment of pelvic organ prolapse (including treatment of cystocele, urethrocele, uterine prolapse, enterocele), and repair of rectal or vaginal prolapse, for sutures and staple pads, for urinary or bladder repair, or for cotton wool) and circular knits can be used for ligament and tendon repair, hernia repair, pelvic floor reconstruction, pelvic organ prolapse repair, Bankart lesion repair, SLAP lesion repair, acromion-clavicular repair, capsule displacement / capsulolabral reconstruction, deltoid repair, shoulder labrum repair, hip capsule / labrum repair, rotator cuff tear repair, biceps tenodesis, medial / lateral foot and ankle repair and reconstruction, midfoot and forefoot repair, hallux valgus reconstruction, metatarsal ligament / tendon repair and reconstruction, Achilles tendon repair, ulnar or radial collateral ligament reconstruction, lateral epicondylitis repair, biceps tendon reattachment, extracapsular knee repair, iliotibial band tenodesis, patellar tendon repair, VMO advancement, knee capsule closure, hand and wrist collateral ligament repair, scapholunate ligament reconstruction, phalangeal tendon transfer, volar plate reconstruction, acetabular labrum repair, anterior ligament repair, spine repair, fracture fixation, cardiovascular surgery, general surgery, gastric surgery, intestinal surgery, abdominoplasty, plastic, cosmetic and reconstructive surgery (including lift operations, forehead lift, brow lift, eyelid lift, face lift, neck lift, breast lift, lateral canthopexy, nipple lift, breast reconstruction, breast reduction, augmentation mammoplasty, mastopexy), cystocele and rectocele repair, low anterior resection (low The patients are referred to as having been placed in the hospital for the following procedures: anterior resection, urethral slings, gynecological and obstetrical surgery, Nissen fundoplication, myomectomy, hysterectomy, sacrolpopexy, cesarean section, general soft tissue approximation and ligation, wound closure (including closure of deep wounds and reduction of wide scars and wound hernias), hemostasis, anastomosis, abdominal closure, augmentation of suture repairs, laparoscopic procedures, partial nephrectomy, vascular grafting, and implantation of cardiac rhythm management (CRM) devices (including pacemakers, defibrillators, generators, neurostimulators, ventricular access devices, infusion pumps, devices for the delivery of medications and hydration solutions, intrathecal delivery systems, pain pumps, and other devices that deliver medications or electrical stimulation to a part of the body).

[0517] B.Network products

[0518] The discovery that fibers of PBS and its copolymers can be prepared with high initial tensile strength and extended strength retention allows the development of mesh implants, particularly for surgical procedures requiring extended strength retention, including extended burst strength retention. Notably, fibers with suitable properties for forming surgical meshes can be prepared.

[0519] As mentioned above, it has been found that fibers of PBS and its copolymers can be prepared that do not degrade in the first 4 weeks, preferably in the first 12 weeks, due to surface corrosion, which can introduce defects and cause fiber surface indentations. Fiber indentations are detrimental to the bursting strength of a mesh formed by the fibers, particularly when the fiber diameter is small. The absence of indentations makes it possible to produce meshes of PBS and its copolymers that have a more predictable degradation rate than other meshes (e.g., biological meshes made from animal or human tissue, collagen, or other absorbable polymer meshes that are subject to surface indentations).

[0520] It is also found that mesh can be formed by PBS and copolymer thereof, and its dimensional stability after implantation improves.As shown in Example 15 and Table 8, the mesh comprising PBS and copolymer thereof keeps dimensional stability for at least 4 weeks, more preferably at least 12 weeks after implantation.From the comparative data obtained by the mesh made of different materials shown in Table 9, this is an unexpected result.When mesh is used for the operation of not expecting mesh contraction and applying other tension force to mesh or surrounding tissue, this discovery is particularly important.Therefore, preferably comprising the mesh derived from PBS and copolymer thereof of monofilament or multifilament oriented fiber, and preferably knitting mesh or weaving mesh, be particularly suitable for such as following operation: hernia repair, breast reconstruction, mastopexy, tissue lifting, the treatment of stress urinary incontinence, pelvic organ prolapse repair (comprising the treatment of cystocele, urethrocele, uterine prolapse, vaginal error prolapse (vaginal fault prolapse), enterocele and rectocele), and other pelvic floor reconstructions. Porous meshes comprising PBS and its copolymers are particularly useful in applications where tissue ingrowth is desired, such as for hernia repair, breast reconstruction, treatment of stress urinary incontinence with a sling, and pelvic floor reconstruction or repair, including treatment of pelvic organ prolapse, including treatment of cystocele, urethrocele, uterine prolapse, vaginal malprolapse, enterocele, and rectocele.

[0521] It was also found that meshes made from PBS and its copolymers did not curl after implantation in vivo. This is another improvement because it prevents curled edges from potentially damaging nearby tissues.

[0522] In one embodiment, the mesh product can be produced, for example, by a warp or weft knitting process from high tenacity yarns and high tensile strength monofilaments of poly(butylene succinate) and its copolymers. In a particularly preferred embodiment, the high strength monofilament fibers of poly(butylene succinate) and its copolymers can be knitted or woven to make the mesh product. In one embodiment, the monofilament knitted mesh can be prepared using the following operation. Forty-nine (49) spools of high strength poly(butylene succinate) or its copolymer monofilaments are mounted on a creel, aligned side by side and pulled to the upper surface of a "kiss" roller under uniform tension. The "kiss" roller is rotated while half immersed in a bath filled with a 10% solution of polyethylene glycol sorbitan monolaurate, polyethylene glycol or other suitable lubricant. The lubricant is deposited on the surface of the fiber sheet. After the lubricant is applied, the fiber sheet is fed into a comb guide and then wound on a warp beam. The warp is a large wide cylinder on which individual fibers are wound in parallel to provide a fiber sheet. Next, the warp beam is converted into a finished mesh fabric by interlocking knitting loops. Eight warp beams are mounted in parallel on the tricot machine let-off and fed into the knitting element at a constant rate determined by the "runner length". Each individual monofilament fiber from each shaft is fed downward into the knitting "guide" through a series of dynamic tension elements. Each fiber passes through a separate guide fixed to a guide rod. The guide rod guides the fibers around the needle to form a mesh fabric structure. The mesh fabric is then pulled off the needle by a take-down roller at a constant rate of speed determined by the fabric "quality". The mesh fabric is then picked up and wound around a roller, ready to be scrubbed. The poly(butylene succinate) or copolymer monofilament web is then ultrasonically scrubbed with water and may be (i) heat set (eg, in a hot conductive liquid bath or oven) and subsequently (ii) washed with a 70% aqueous ethanol solution.

[0523] In one embodiment, the mesh made of monofilaments, multifilaments, or combinations thereof of poly(butylene succinate) or its copolymers has one or more of the following properties: (i) a suture pull-out strength of at least 5N, 10N, or at least 20N, or 0.5kgf to 20kgf, (ii) a burst strength of 0.1kgf to 100kgf, more preferably 1kgf to 50kgf, even more preferably 5kgf to 25kgf, or greater than 0.1kPa, (iii) a thickness of 0.05mm to 5mm, (iv) a strength of 5g / m 2 Up to 800g / m 2The invention further comprises a method for preparing the mesh of claim 1 , wherein the mesh has an area density of at least 100 μm and an area density of at least 100 μm, (v) pores having a pore size of 5 μm to 5 mm, or more preferably 100 μm to 1 mm, (vi) a Taber stiffness of at least 0.01 Taber stiffness unit (TSU), preferably 0.1 Taber stiffness unit to 19 Taber stiffness units, more preferably 0.01 Taber stiffness unit to 1 Taber stiffness unit, (vii) a degradation rate in phosphate buffered saline at 37° C., wherein the weight average molecular weight of the mesh decreases by 10% to 30% over a period of 12 weeks, (viii) an in vivo degradation rate under physiological conditions, wherein the burst strength of the mesh decreases by less than 20% at 4 weeks, or wherein the burst strength of the mesh decreases by less than 35% at 12 weeks, (ix) a tear resistance of 0.1 kgf to 40 kgf, more preferably 1 kgf to 10 kgf, (x) a tear resistance of 0.001 mm 2 Up to 10mm 2 , or more preferably 0.01 mm 2 Up to 1mm 2 pore size, (xi) an elongation at 16 N / cm of 5% to 50%, or more preferably 5% to 20%, and (xii) a residual textile processing lubricant content of less than 0.5wt%, more preferably less than 0.1wt%, or a polyethylene glycol sorbitan monolaurate or polyethylene glycol content of less than 0.5wt%, or less than 0.1wt%.

[0524] The preparation of monofilament mesh implants made with PBS-malic acid copolymer monofilament fibers of varying diameters is described in Example 22. The meshes had the following range of properties: monofilament diameter of 0.106 mm to 0.175 mm, burst strength of 8.9 kgf to 21.9 kgf, elongation at 16 N / cm of 11.1% to 15.4%, suture pull-out strength in the machine direction of 1.4 kgf to 3.9 kgf, suture pull-out strength in the cross-machine direction of 1.1 kgf to 4.5 kgf, machine direction tear resistance of 2.0 kgf to 2.9 kgf, cross-machine direction tear resistance of 1.4 kgf to 4.0 kgf, machine direction stiffness of 0.05 TSU to 0.2 TSU, cross-machine...

Claims

1. A multifilament yarn or monofilament fiber derived from a polymer composition, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units; in: (a) the multifilament yarn has one or more properties selected from the group consisting of: a tenacity greater than 4 g / denier but less than 14 g / denier, an elongation at break of 15% to 50%, and a denier per filament of 1 to 10; (b) the monofilament fibers are oriented and have one or more properties selected from the group consisting of: a tensile strength of 400 MPa to 1200 MPa, a Young's modulus of less than 3.0 GPa, and an elongation at break of 10% to 50%; and wherein the multifilament yarn or monofilament fibers comprise an oriented form of the polymer composition; (c) wherein the polymer composition does not contain urethane bonds and is not prepared using a diisocyanate; and (d) wherein the endotoxin content of the polymer composition is <2.5 EU / g.

2. The multifilament yarn or monofilament fiber derived from the polymer composition of claim 1, wherein the polymer composition comprises isotopically enriched succinic acid units and 1,4-butanediol units.

3. The multifilament yarn or monofilament fiber derived from the polymer composition of claim 1 or 2, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, wherein (i) under physiological conditions in vivo, the weight average molecular weight of the polymer composition decreases by 5% to 15% over a period of 4 to 8 weeks, or by 20% to 35% over a period of 12 weeks, (ii) under physiological conditions in vivo, the percent mass loss is 0% to 5% over a period of 4 weeks, or (iii) after implantation, the strength retention of the fiber is at least 80% at 4 weeks, or at least 65% at 12 weeks.

4. A knitted or woven mesh implant, wherein the mesh is knitted or woven from the multifilament yarn or monofilament fiber of claim 1, wherein when the mesh is incubated in phosphate buffered saline at 37°C: (i) the weight average molecular weight of the polymer composition decreases by 3% to 15% over a 4 week period, (ii) the weight average molecular weight of the polymer composition decreases by 5% to 15% over an 8 week period, (iii) the weight average molecular weight of the polymer composition decreases by 10% to 30% over a 12 week period, (iv) the percent mass loss of the mesh is 0% to 5% over a 4 week period, or (v) the percent mass loss of the mesh is 0% to 5% over an 8 week period.

5. The yarn or fiber of any one of claims 1 to 3, or the web of claim 4, wherein the polymer composition: (i) comprises from 1 ppm to 500 ppm of one or more, or all, of the following: silicon, titanium, and zinc, (ii) does not comprise tin, or (iii) is not a blend of two or more polymers.

6. The yarn or fiber of any one of claims 1 to 3 and 5, or the web of claim 4 or 5, wherein the fiber has a Young's modulus of at least 600 MPa but less than 3 GPa.

7. The yarn or fiber of claim 6, wherein the fiber has a Young's modulus of at least 1 GPa.

8. The yarn or fiber of claim 6 or 7, wherein the fiber has a Young's modulus of at least 2 GPa.

9. The yarn or fiber of any one of claims 1 to 3 and 5 to 8, or the web of any one of claims 4 to 8, wherein the melting temperature of the polymer composition is from 100°C to 150°C.

10. The yarn or fiber of claim 9, wherein the polymer composition has a melting temperature of 105°C to 120°C.

11. The yarn or fiber of any one of claims 1 to 3 and 5 to 10, or the web of any one of claims 4 to 10, wherein (a) the polymer composition further comprises one or more of the following: a second diacid unit, a second glycol unit, 1,3-propylene glycol, ethylene glycol, 1,5-pentanediol, glutaric acid, adipic acid, terephthalic acid, malonic acid and oxalic acid; (b) the polymer composition further comprises one or more of the following: a branching agent, a crosslinking agent, a chain extender and a reactive blending agent; or (c) the polymer composition further comprises hydroxycarboxylic acid units.

12. The yarn, fiber or web of claim 11 wherein the hydroxycarboxylic acid units have: two carboxyl groups and one hydroxyl group; two hydroxyl groups and one carboxyl group; three carboxyl groups and one hydroxyl group; or two hydroxyl groups and two carboxyl groups.

13. The yarn, fiber or web of claim 11 or 12, wherein the branching agent, crosslinking agent or chain extender unit is selected from the group consisting of malic acid, maleic acid, fumaric acid, trimethylolpropane, trimesic acid, citric acid, glycerol propoxylate, tartaric acid and combinations thereof.

14. The yarn or fiber of any one of claims 1 to 3 and 5 to 8 or the web of any one of claims 4 to 8, wherein the polymer composition comprises succinic acid-1,4-butanediol-malic acid copolyester, succinic acid-1,4-butanediol-citric acid copolyester, succinic acid-1,4-butanediol-tartaric acid copolyester, succinic acid-1,4-butanediol-malic acid copolyester further containing citric acid, tartaric acid or a combination thereof, succinic acid-adipic acid-1,4-butanediol-malic acid copolyester, succinic acid-adipic acid-1,4-butanediol-citric acid copolyester, succinic acid-adipic acid-1,4-butanediol-tartaric acid copolyester, or succinic acid-adipic acid-1,4-butanediol-malic acid copolyester further containing citric acid, tartaric acid or a combination thereof.

15. The fiber of any one of claims 1 to 3 and 5 to 8, wherein the fiber has a tensile strength greater than 500 MPa but less than 2000 MPa.

16. The fiber of claim 15, wherein the fiber has a tensile strength greater than 600 MPa.

17. The fiber of claim 15 or 16, wherein the fiber has a tensile strength greater than 700 MPa.

18. The fiber of any one of claims 15 to 17, wherein the fiber has a tensile strength greater than 800 MPa.

19. The yarn or fiber of any one of claims 1 to 3 and 5 to 8 or the web of any one of claims 4 to 8, wherein the weight average molecular weight of the multifilament yarn or monofilament fiber is not less than 80% of the weight average molecular weight of the polymer composition used to prepare the multifilament yarn or monofilament fiber.

20. The yarn or fiber of claim 19, wherein the weight average molecular weight of the multifilament yarn or monofilament fiber is no less than 85% of the weight average molecular weight of the polymer composition used to prepare the multifilament yarn or monofilament fiber.

21. The yarn of any one of claims 1 to 3, 5 to 14 and 19 to 20, the fiber of any one of claims 1 to 3 and 5 to 20, or the web of any one of claims 4 to 14 and 19 to 20, wherein the multifilament yarn or monofilament fiber is produced by a process comprising the steps of: (a) spinning a multifilament yarn or monofilament fiber comprising the polymer composition, (b) drawing the multifilament yarn or monofilament fiber in one or more stages at a temperature of 50°C to 70°C with an orientation ratio of at least 3.0, (c) drawing the multifilament yarn or monofilament fiber in one or more stages at a temperature of 65°C to 75°C with an orientation ratio of at least 2.0, and (d) drawing the multifilament yarn or monofilament fiber at a temperature of 70°C to 75°C with an orientation ratio greater than 1.

0.

22. The multifilament yarn or monofilament fiber according to claim 21, in: The order of the steps is (a) followed by (b) followed by (c) followed by (d).

23. The multifilament yarn or monofilament fiber of claim 21, wherein the multifilament yarn or monofilament fiber is drawn in a conducting liquid chamber.

24. The multifilament yarn or monofilament fiber of claim 21, further comprising the step of quenching the spun multifilament yarn or monofilament fiber in a conductive liquid chamber at a temperature of 50°C to 70°C prior to drawing.

25. The multifilament yarn or monofilament fiber of claim 21, wherein the method further comprises cooling the yarn or fiber after quenching by passing the fiber or yarn between two godet rolls.

26. The multifilament yarn or monofilament fiber of claim 21, wherein the multifilament yarn or monofilament fiber is spun at a temperature ranging from 60°C to 230°C.

27. The multifilament yarn or monofilament fiber of claim 26, wherein the multifilament yarn or monofilament fiber is spun at a temperature ranging from 80°C to 180°C.

28. The multifilament yarn or monofilament fiber of claim 26 or 27, wherein the multifilament yarn or monofilament fiber is spun at a temperature ranging from 80°C to 175°C.

29. The multifilament yarn or monofilament fiber of any one of claims 26 to 28, wherein the multifilament yarn or monofilament fiber is spun at a temperature ranging from 80°C to 170°C.

30. A method for forming the yarn or fiber of any one of claims 1 to 29, wherein the yarn or fiber is produced by a method comprising the steps of: (a) spinning a polymer composition comprising 1,4-butanediol units and succinic acid units to form a multifilament yarn or monofilament fiber comprising the polymer composition, (b) drawing the multifilament yarn or monofilament fiber in one or more stages at a temperature of 50°C to 70°C with an orientation ratio of at least 3.0, (c) drawing the multifilament yarn or monofilament fiber in one or more stages at a temperature of 65°C to 75°C with an orientation ratio of at least 2.0, and (d) drawing the multifilament yarn or monofilament fiber at a temperature of 70°C to 75°C with an orientation ratio greater than 1.

0.

31. The method of claim 30, wherein the multifilament yarn or monofilament fiber is drawn in a conducting liquid chamber.

32. The method of claim 30, further comprising: The following steps are involved: The spun multifilament yarn or monofilament fiber is quenched in a water bath at a temperature of 50°C to 70°C before drawing; and / or the yarn or fiber is cooled after quenching by passing the fiber or the yarn between two godet rollers, and / or the method further comprises drying the polymer composition before spinning so that the water content of the polymer composition is less than 0.1% by weight.

33. The method of claim 32, wherein the polymer composition has a water content of less than 0.05 wt%.

34. The method of claim 32 or 33, wherein the polymer composition has a water content of less than 0.005 wt%.

35. The method of claim 30, wherein the multifilament yarn or monofilament fiber is spun at a temperature ranging from 60°C to 230°C.

36. The method of claim 35, wherein the multifilament yarn or monofilament fiber is spun at a temperature ranging from 80°C to 180°C.

37. The method of claim 35 or 36, wherein the multifilament yarn or monofilament fiber is spun at a temperature in the range of 80°C to 175°C.

38. The method of any one of claims 35 to 37, wherein the multifilament yarn or monofilament fiber is spun at a temperature in the range of 80°C to 170°C.

39. The method of claim 30, in: (a) the spun multifilament yarn or monofilament fiber is not cold quenched or cold stretched, or (b) the sum of orientation ratios exceeds 6.0 and the multifilament fiber or monofilament fiber is drawn at a temperature of 50°C to 90°C.

40. The method of claim 39, wherein the sum of the orientation ratios exceeds 6.

5.

41. The method of claim 39 or 40, wherein the sum of the orientation ratios exceeds 7.

0.

42. The method of any one of claims 39 to 41, wherein the sum of the orientation ratios exceeds 7.

5.

43. The method of any one of claims 39 to 42, wherein the sum of the orientation ratios exceeds 8.

0.

44. A medical implant comprising a polymer composition, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, wherein the implant comprises an oriented form of the polymer composition, and wherein the implant comprises a multifilament yarn derived from the polymer composition having one or more properties selected from the group consisting of: a tenacity greater than 4 g / denier but less than 14 g / denier, an elongation at break of 15% to 50%, a denier per filament of 1 to 10; or wherein the implant comprises a monofilament fiber derived from the polymer composition having one or more properties selected from the group consisting of: a tensile strength of 400 MPa to 1200 MPa, a Young's modulus of less than 3.0 GPa, and an elongation at break of 10% to 50%, and wherein the polymer composition has an endotoxin content of <2.5 EU / g.

45. The medical implant comprising the polymer composition of claim 44, wherein the polymer composition is isotopically enriched.

46. ​​The implant of claim 44 or 45, wherein the oriented form comprises a fiber, a mesh, a woven, a nonwoven, a film, a molded object, a patch, a tube, a laminate, or a pultruded profile.

47. The implant of claim 46, wherein the fibers are monofilament, multifilament, braided or barbed.

48. The implant of claim 46, wherein the mesh, woven and nonwoven form is a knitted mesh, a woven mesh, a monofilament mesh or a multifilament mesh.

49. The implant of claim 44 or 46, wherein the oriented form is already uniaxially or biaxially oriented.

50. A medical implant comprising oriented monofilament fibers derived from a polymer composition, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, wherein the monofilament fibers have one or more properties selected from the group consisting of: a tensile strength of 400 MPa to 1200 MPa, a Young's modulus of less than 3.0 GPa, and an elongation at break of 10% to 50%, in: (a) the implant has a degradation rate under physiological conditions: wherein the weight average molecular weight of the polymer composition decreases by 3% to 15% within a 4 week period in vivo, or wherein the weight average molecular weight of the polymer composition decreases by 10% to 30% within a 12 week period in vivo; (b) when the implant is incubated in phosphate buffered saline at 37°C: (i) the weight average molecular weight of the polymer composition decreases by 3% to 13% within a 4 week period, (ii) the weight average molecular weight of the polymer composition decreases by 5% to 15% within an 8 week period, (iii) the weight average molecular weight of the polymer composition decreases by 10% to 30% within a 12 week period, (iv) the percent mass loss of the implant is 0% to 5% within a 4 week period, or (v) the percent mass loss of the implant is 0% to 5% within an 8 week period; or (c) the polymer composition comprises 1,4-butanediol units and succinic acid units, wherein the strength retention of the implant is greater than 75% at 4 weeks after implantation, or greater than 65% at 12 weeks after implantation.

51. The implant of claim 50, wherein the polymer composition has an endotoxin content of <2.5 EU / g.

52. The implant of any one of claims 44 to 45 and 50, wherein the implant is porous.

53. The implant of claim 47 or 50, wherein the fibers have a tensile strength of 500 MPa to 1,200 MPa.

54. The implant of claim 53, wherein the fibers have a tensile strength of 600 MPa to 1,200 MPa.

55. The implant of claim 53 or 54, wherein the fibers have a tensile strength of 700 MPa to 1,200 MPa.

56. The implant of any one of claims 50 and 53 to 55, wherein the fibers have a Young's modulus of at least 600 MPa but less than 3 GPa.

57. The implant of claim 56, wherein the fibers have a Young's modulus of at least 800 MPa.

58. The implant of claim 56 or 57, wherein the fibers have a Young's modulus of at least 1 GPa.

59. The implant of any one of claims 56 to 58, wherein the fibers have a Young's modulus of at least 2 GPa.

60. The implant of claim 50, wherein the fibers have been knitted or woven into a mesh.

61. The implant of any one of claims 46, 47, and 60, wherein (a) the mesh has a burst strength of 1 kgf to 100 kgf; or (b) the mesh has a Taber stiffness of 0.01 to 10 gf·cm.

62. The implant of claim 61, wherein in (a), the bursting strength is 10 kgf to 30 kgf.

63. The implant of claim 61 or 62, wherein in (b), the mesh has a Taber stiffness of 0.1 gf·cm to 1 gf·cm.

64. The implant of any one of claims 44, 45 and 50, in: (a) the surface of the implant is free of indentations during degradation in vivo under physiological conditions for a period of 4 weeks; or (b) the size of the implant shrinks by no more than 5% of its initial value when implanted in vivo for a period of 4 weeks under physiological conditions.

65. The implant of any one of claims 44, 45, and 50, wherein the implant is derived from a polymer composition further comprising (a) one or more of the following: a second diacid unit, a second diol unit, 1,3-propylene glycol, ethylene glycol, 1,5-pentanediol, glutaric acid, adipic acid, terephthalic acid, malonic acid, and oxalic acid; (b) one or more of the following: a branching agent, a crosslinking agent, a chain extender, and a reactive blending agent; or (c) a hydroxycarboxylic acid unit.

66. The implant of claim 65, wherein the hydroxycarboxylic acid unit has: two carboxyl groups and one hydroxyl group; two hydroxyl groups and one carboxyl group; three carboxyl groups and one hydroxyl group; or two hydroxyl groups and two carboxyl groups.

67. The implant of claim 65 or 66, wherein the branching agent, crosslinking agent or chain extender unit is one or more of the following: malic acid, maleic acid, fumaric acid, trimethylolpropane, trimesic acid, citric acid, glycerol propoxylate, and tartaric acid.

68. The implant of any one of claims 44, 45, and 50, wherein the implant is derived from a polymer composition comprising succinic acid-1,4-butanediol-malic acid copolyester, succinic acid-1,4-butanediol-citric acid copolyester, succinic acid-1,4-butanediol-tartaric acid copolyester, succinic acid-1,4-butanediol-malic acid copolyester further containing citric acid, tartaric acid, or a combination thereof, succinic acid-adipic acid-1,4-butanediol-malic acid copolyester, succinic acid-adipic acid-1,4-butanediol-citric acid copolyester, succinic acid-adipic acid-1,4-butanediol-tartaric acid copolyester, or succinic acid-adipic acid-1,4-butanediol-malic acid copolyester further containing citric acid, tartaric acid, or a combination thereof.

69. The implant of any one of claims 44, 45, and 50, wherein the implant further comprises a plasticizer, a nucleating agent, a coating, a dye, a medical marker, a bioactive agent, a therapeutic agent, a diagnostic agent, a prophylactic agent, a contrast agent, a radiopaque marker, a radioactive material, an anti-adhesion agent, hyaluronic acid, an antibiotic, rifampicin, minocycline, collagen, hydroxyapatite, or a resorbable polymer comprising one or more of the following monomers: glycolic acid, lactic acid, trimethylene carbonate, p-dioxanone, ε-caprolactone, 4-hydroxybutyric acid, and 3-hydroxybutyric acid.

70. An implant as described in any one of claims 44 to 69, wherein the polymer composition: (i) does not contain urethane bonds, (ii) is not prepared with a diisocyanate, (iii) contains 1 ppm to 500 ppm of one or more, or all, of the following: silicon, titanium, and zinc, (iv) does not contain tin; or (v) is not a blend of two or more polymers.

71. The implant of any one of claims 44 to 70, wherein the polymer composition has a melting temperature of 100°C to 150°C.

72. The implant of claim 71, wherein the polymer composition has a melting temperature of 105°C to 120°C.

73. The implant of any one of claims 44, 45, 50, and 61 to 63, wherein the implant is selected from the group consisting of a suture, a barbed suture, a monofilament suture, a braided suture, a mesh suture, a wound closure device, a patch, a wound healing device, a wound dressing, a burn dressing, an ulcer dressing, a skin substitute, a hemostatic agent, a tracheal reconstruction device, an organ salvage device, a dura mater patch or substitute, a nerve regeneration or repair device, a hernia repair device, a hernia repair mesh, a hernia plug, an inguinal hernia plug, a device for temporary wound or tissue support, a tissue engineering scaffold, a guided tissue repair / re Devices for pelvic floor reconstruction, devices for the treatment of pelvic organ prolapse, urethral suspension devices, devices for the treatment of urinary incontinence, devices for the treatment of stress urinary incontinence, bladder repair devices, expansion or filling devices, bone marrow scaffolds, bone plates, fixation devices for implants, ligament repair devices or augmentation devices, anterior cruciate ligament repair devices, tendon repair devices or augmentation devices, rotator cuff repair devices, meniscus repair or regeneration devices, articular cartilage repair devices, osteochondral repair devices, spinal fusion devices, cardiovascular patches, catheter gas capsules, vascular closure devices, intracardiac septal defect repair devices, including but not limited to atrial septal defect repair devices and PFO (patent foramen ovale) closure devices, left atrial appendage (LAA) closure devices, pericardial patches, venous valves, heart valves, vascular grafts, myocardial regeneration devices, periodontal meshes, guided tissue regeneration membranes for periodontal tissue, ocular cell implants, imaging devices, cochlear implants, anastomotic devices, cell seeding devices, cell encapsulation devices, controlled release devices, drug delivery devices, plastic surgery devices, breast lift devices, mastopexy devices, breast reconstruction devices, augmentation mammoplasty devices, breast reduction Small devices, breast implants, devices for removing, reshaping and reorienting breast tissue, devices for breast reconstruction after mastectomy with or without the aid of breast implants, facial reconstruction devices, forehead lift devices, brow lift devices, eyelid lift devices, face lift devices, rhytidectomy devices, thread lift devices, devices for lifting and supporting sagging areas of the face, brow and neck, rhinoplasty devices, devices for cheekbone augmentation, otoplasty devices, neck lift devices, genioplasty devices, buttocks lift devices, cosmetic repair devices, and devices for facial scar repair.

74. The implant of claim 73, wherein the implant is a braided suture comprising oriented multifilament fibers, wherein the braided suture has a breaking strength of 40N to 270N.

75. The implant of claim 74, wherein the suture has an in vivo strength retention of at least 40% at 4 to 6 months under physiological conditions.

76. The implant of any one of claims 44 to 75, wherein the implant comprises less than 20 endotoxin units per implant as determined by a Limulus amebocyte lysate (LAL) assay.

77. A method for making an implant as described in any one of claims 44, 45, 50 and 73, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, the method comprising providing the polymer composition and forming the polymer composition into an implant or incorporating the polymer composition into an implant by one or more methods comprising: casting, solvent casting, solution spinning, solution bonding of fibers, melt processing, extrusion, melt extrusion, melt spinning, fiber spinning, orientation, relaxation, annealing, injection molding, compression molding, lamination, dry spinning, knitting, braiding, crocheting, melt blowing, forming Films, film blowing, film casting, film forming, electrospinning, thermoforming, pultrusion, centrifugal spinning, forming, tube extrusion, spunbond, nonwoven manufacturing, staple fiber entanglement, fiber knitting, braiding and crocheting, mesh manufacturing, coating, dip coating, laser cutting, barbs, stamping, punching, pore forming, freeze drying, stitching, calendaring, freeze drying, phase separation, particle leaching, thermal phase separation, leaching, latex processing, gas plasma processing, emulsion processing, 3D printing, fused filament fabrication, melt pellet deposition, melt extrusion deposition, selective laser melting, printing with slurries and solutions using a coagulation bath, or printing with adhesive solutions and powder particles.

78. Use of an implant comprising the polymer composition of claim 44 or 45 for enhancing the healing of a wound, injury or defect in a part of a patient, or for repairing or regenerating tissue in a part of a patient.

79. A surgical mesh implant comprising a multifilament yarn or a monofilament fiber derived from a polymer composition, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, wherein the multifilament yarn has one or more properties selected from the group consisting of: a tenacity greater than 4 g / denier but less than 14 g / denier, an elongation at break of 15% to 50%, and a single filament denier of 1 to 10; wherein the monofilament fiber has one or more properties selected from the group consisting of: a tensile strength of 400 MPa to 1200 MPa, a Young's modulus of less than 3.0 GPa, and an elongation at break of 10% to 50%; wherein the multifilament yarn or the monofilament fiber comprises an oriented form of the polymer composition.

80. The surgical mesh implant comprising multifilament yarn or monofilament fibers derived from a polymer composition of claim 79, wherein the composition is isotopically enriched.

81. The surgical mesh implant comprising multifilament yarn or monofilament fiber derived from a polymer composition as claimed in any one of claims 79 to 80, wherein the polymer composition has an endotoxin content of <2.5 EU / g.

82. A surgical mesh implant comprising multifilament yarn or monofilament fiber derived from a polymer composition as described in any one of claims 79 to 81, wherein (a) under in vivo physiological conditions: the weight average molecular weight of the polymer composition decreases by 3% to 15% over a period of 4 weeks, or the percentage of mass loss is 0% to 5% over a period of 12 weeks; or (b) the burst strength of the implant decreases by less than 20% at 4 weeks.

83. The surgical mesh implant of claim 82, wherein in (a), the weight average molecular weight of the polymer composition decreases by 20% to 35% over a 12 week period.

84. The surgical mesh implant of claim 82 or 83, wherein in (b), the implant has a burst strength reduction of less than 35% at 12 weeks.

85. The surgical mesh implant comprising multifilament yarn or monofilament fibers derived from a polymer composition as claimed in any one of claims 82 to 84, wherein the implant is sterile.

86. The implant of any one of claims 79 to 85, wherein the implant has one or more of: (i) 5 g / m 2 Up to 800g / m 2 The invention relates to a method of fabricating a web of at least 100 microns in diameter, wherein the web has an area density of at least 100 microns, (ii) a suture pull-out strength of at least 10 Newtons, (iii) pores of at least 10 microns in diameter, (iv) a burst strength of greater than 0.1 kPa, (v) a Taber stiffness of at least 0.01 gf·cm, (vi) fibers that are knitted, woven, crocheted or braided, and (vii) a degradation rate in phosphate buffered saline at 37° C. wherein the weight average molecular weight of the web decreases by 10% to 30% over a period of 12 weeks.

87. The implant of claim 86, wherein in (ii), the suture pull-out strength is at least 20N.

88. The implant of claim 86 or 87, wherein in (iii), the pores have a diameter of at least 50 μm.

89. The implant of any one of claims 86 to 88, wherein in (iii), the pores have a diameter of at least 100 μm.

90. An implant as described in any of claims 86 to 89, comprising fibers having one or more of the following properties: (i) orientation; (ii) a tensile strength of at least 400 MPa but less than 1200 MPa; (iii) a toughness of 4 to 12 g / denier, (iv) a Young's modulus of 600 MPa to 3.0 GPa, (v) an elongation at break of 10% to 50%, (vi) a diameter of 10 μm to 1 mm, (vii) a melting temperature of 100°C to 150°C, and (viii) a degradation rate in phosphate buffered saline at 37°C wherein the weight average molecular weight of the fibers decreases by 10% to 25% over a period of 12 weeks.

91. The implant of claim 90, wherein in (ii), the tensile strength is at least 500 MPa.

92. The implant of claim 90 or 91, wherein in (ii), the tensile strength is at least 600 MPa.

93. The implant of any one of claims 90 to 92, wherein in (ii), the tensile strength is at least 700 MPa.

94. The implant of any one of claims 90 to 93, wherein in (vii), the melting temperature is 105°C to 120°C.

95. The implant of any one of claims 79 to 85, wherein the implant has a burst strength greater than 0.1 kPa, and wherein the implant comprises fibers having a Young's modulus of at least 600 MPa.

96. The implant of claim 95, wherein the implant comprises fibers having a Young's modulus of at least 1 GPa.

97. The implant of claim 95 or 96, wherein the implant comprises fibers having a Young's modulus of at least 2 GPa.

98. An implant as described in any one of claims 95 to 97, comprising fibers having one or more of the following properties: a tensile strength of 400 MPa to 1,200 MPa, a toughness of 4 g / denier to 12 g / denier, a Young's modulus of less than 3.0 GPa, an elongation at break of 10% to 50%, a diameter of 10 μm to 1 mm, and a melting temperature of 100°C to 150°C; or wherein the fibers are prepared by melt extrusion of a polymer composition comprising 1,4-butanediol units and succinic acid units, and the weight average molecular weight of the extruded fibers is not less than 80% of the weight average molecular weight of the polymer composition before extrusion.

99. The implant of claim 98, wherein the melt temperature is between 105°C and 120°C.

100. The implant of claim 98 or 99, wherein the extruded fibers have a weight average molecular weight that is no less than 85% of the weight average molecular weight of the polymer composition prior to extrusion.

101. The implant of any one of claims 95 to 97, wherein the mesh has one or more of the following properties: 5 g / m 2 Up to 800g / m 2 The surface density of the suture is at least 10N, the suture pull-out strength is at least 10μm, and the pores have a diameter of at least 10μm.

102. The implant of claim 101, wherein the suture pull-out strength is at least 20N.

103. The implant of claim 101 or 102, wherein the pores have a diameter of at least 50 μm.

104. The implant of any one of claims 101 to 103, wherein the pores have a diameter of at least 100 μm.

105. The implant of any one of claims 95 to 97, comprising monofilament fibers, wherein the monofilament fibers have been stretched to orient the fibers, and wherein the fibers have a Young's modulus of at least 600 MPa.

106. The implant of claim 105, wherein the fibers have a Young's modulus of at least 800 MPa.

107. The implant of claim 105 or 106, wherein the fibers have a Young's modulus of at least 1 GPa.

108. The implant of any one of claims 105 to 107, wherein the monofilament fibers have a diameter of 10 μm to 1 mm.

109. The implant of any one of claims 105 to 108, wherein the fibers have a Young's modulus of less than 3 GPa, or wherein the fibers have a Young's modulus greater than 1.5 GPa but less than 3 GPa.

110. The implant of claim 109, wherein the fibers have a Young's modulus greater than 2.0 GPa.

111. The implant of any one of claims 95 to 97 and 105 to 108, wherein the fibers are oriented with an orientation ratio of at least 6.

0.

112. The implant of claim 111, wherein the orientation ratio is at least 6.

5.

113. The implant of claim 111 or 112, wherein the orientation ratio is at least 7.

0.

114. A surgical mesh implant comprising a polymer composition, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, wherein the surgical mesh comprises an oriented form of the polymer composition, wherein the mesh comprises fibers, wherein the fibers are produced by a method comprising spinning a multifilament or monofilament fiber comprising the polymer composition and drawing the multifilament or monofilament fiber at an orientation ratio of at least 6 or 8 in one or more stages at a temperature of 50°C to 80°C.

115. The surgical mesh of claim 114, wherein the fibers are first drawn at a temperature of 50°C to 70°C in one or more stages with a minimum orientation ratio of 3 to 4, then hot drawn at a temperature of 60°C to 80°C in one or more stages with a minimum orientation ratio of 2 to 3, then hot drawn at a temperature of 70°C to 80°C with an orientation ratio greater than 1.

0.

116. The surgical mesh of claim 114 or 115, wherein the fibers are prepared by one or more of the following steps: (i) drying the polymer composition prior to melt spinning such that the polymer composition has a water content of less than 0.1 wt %, and (ii) heat drawing the fibers in a heat transfer liquid chamber.

117. The surgical mesh of claim 116, wherein the polymer composition has a water content of less than 0.05 wt%.

118. The surgical mesh of claim 116 or 117, wherein the polymer composition has a water content of less than 0.005% by weight.

119. The implant of any one of claims 79 to 85, 95 to 97, 105 to 107, 108 and 114, wherein the polymer composition used to prepare the implant further comprises: (a) one or more of the following: a second diacid unit, a second diol unit, 1,3-propylene glycol, ethylene glycol, 1,5-pentanediol, glutaric acid, adipic acid, terephthalic acid, malonic acid and oxalic acid; (b) one or more of the following: a branching agent, a cross-linking agent, a chain extender and a reactive blending agent; or (c) a hydroxycarboxylic acid unit.

120. The implant of claim 119, wherein the branching agents, crosslinking agents, chain extenders, and reactive blending agents exclude diisocyanate species and species that incorporate urethane linkages into the polymer composition.

121. The implant of claim 119, wherein the hydroxycarboxylic acid unit has: two carboxyl groups and one hydroxyl group; two hydroxyl groups and one carboxyl group; three carboxyl groups and one hydroxyl group; or two hydroxyl groups and two carboxyl groups.

122. The implant of any one of claims 119 to 121, wherein the branching agent, crosslinking agent or chain extender unit is one or more of the following: malic acid, maleic acid, fumaric acid, trimethylolpropane, trimesic acid, citric acid, glycerol propoxylate, and tartaric acid.

123. The implant of any one of claims 79 to 85, 95 to 97, 105 to 108 and 114, wherein the polymer composition used to prepare the implant comprises succinic acid-1,4-butanediol-malic acid copolyester, succinic acid-1,4-butanediol-citric acid copolyester, succinic acid-1,4-butanediol-tartaric acid copolyester, succinic acid-1,4-butanediol-malic acid copolyester further containing citric acid, tartaric acid or a combination thereof, succinic acid-adipic acid-1,4-butanediol-malic acid copolyester, succinic acid-adipic acid-1,4-butanediol-citric acid copolyester, succinic acid-adipic acid-1,4-butanediol-tartaric acid copolyester, or succinic acid-adipic acid-1,4-butanediol-malic acid copolyester further containing citric acid, tartaric acid or a combination thereof.

124. An implant as described in any one of claims 115 to 123, wherein the polymer composition: (i) does not contain urethane bonds, (ii) is not prepared with a diisocyanate, (iii) contains 1 ppm to 500 ppm of one or more, or all, of the following: silicon, titanium, and zinc, (iv) does not contain tin, or (v) is not a blend of two or more polymers.

125. The implant of any one of claims 79 to 124, wherein the polymer composition has a melting temperature of 100°C to 150°C.

126. The implant of claim 125, wherein the polymer composition has a melting temperature of 105°C to 120°C.

127. The implant of any one of claims 79 to 85, 95 to 97, 105 to 108 and 114, in: (a) The surgical mesh is a knitted mesh, a woven mesh, a crocheted mesh, a monofilament mesh, a multifilament mesh, a weft knitted mesh, a warp knitted mesh, a plug, a hernia plug, a void filler, or an inguinal hernia plug, or has a three-dimensional shape.

128. The implant of claim 127, wherein the three-dimensional shape is capable of temporary deformation, or has an outer portion that curves outward and an inner portion that curves inward; (b) the surgical mesh further comprises an anti-adhesion layer, barbs, hooks, self-anchoring tips, micro-clamps, fleece fabrics, reinforcements, and a reinforced outer edge or border, or (c) the surgical mesh further comprises a plasticizer, a nucleating agent, a coating, a dye, a medical marker, a bioactive agent, a therapeutic agent, a diagnostic agent, a prophylactic agent, a contrast agent, a radiopaque marker, a radioactive substance, an anti-adhesion agent, hyaluronic acid, an antibiotic, rifampicin, minocycline, collagen, hydroxyapatite, or an absorbable polymer comprising one or more of the following monomers: glycolic acid, lactic acid, trimethylene carbonate, dioxanone, ε-caprolactone, 4-hydroxybutyric acid, and 3-hydroxybutyric acid.

129. The surgical mesh implant of any one of claims 79 to 85, 95 to 97, 105 to 108 and 114, wherein the implant is selected from a wound closure device, a patch, a wound healing device, a device for tissue or suture reinforcement, a tracheal reconstruction device, an organ salvage device, a dura mater patch or replacement, a nerve regeneration or repair device, a hernia repair device, a hernia mesh, a hernia plug, an inguinal hernia plug, a device for temporary wound or tissue support, a tissue engineering scaffold, a guided tissue repair / regeneration device, an anti-adhesion membrane or barrier, a tissue separation membrane, Resident membrane, sling, device for pelvic floor reconstruction, device for treating pelvic organ prolapse, urethral suspension device, device for treating urinary incontinence, bladder repair device, void filling device, bone marrow scaffold, ligament repair device or augmentation device, anterior cruciate ligament repair device, tendon repair device or augmentation device, rotator cuff repair device, meniscus repair or regeneration device, articular cartilage repair device, osteochondral repair device, spinal fusion device, cardiovascular patch, vascular closure device, intracardiac septal defect repair device, atrial septal defect repair device, patent foramen ovale closure device, left atrial appendage closure device anastomosis devices, pericardial patches, vascular grafts, myocardial regeneration devices, periodontal meshes, guided tissue regeneration membranes for periodontal tissue, imaging devices, anastomosis devices, cell seeding devices, controlled release devices, drug delivery devices, plastic surgery devices, breast lift devices, mastopexy devices, breast reconstruction devices, augmentation mammoplasty devices, breast implants, breast reduction devices, devices for breast reconstruction after mastectomy with or without breast implants, facial reconstruction devices, forehead lift devices, brow lift devices, eyelid lift devices, face lift devices, Rhytidectomy devices, rhinoplasty devices, devices for zygomatic bone augmentation, otoplasty devices, neck lift devices, genioplasty devices, buttocks lift devices, cosmetic repair devices, devices for facial scar repair, bags, holders, covers, housings or casings that partially or completely encase, surround or contain an implantable medical device, cardiac rhythm management devices, pacemakers, defibrillators, generators, implantable access systems, neurostimulators, ventricular access devices, infusion pumps, devices for delivering medications and hydration solutions, intrathecal delivery systems, pain pumps, and devices for delivering medications or electrical stimulation to the body.

130. A method of making a surgical mesh implant as claimed in any one of claims 79 to 85, 95 to 97, 105 to 108 and 119 to 129, wherein the mesh comprises fibers, the method include: A polymer composition including 1,4-butanediol units and succinic acid units is melt-spun to obtain extruded fibers, the extruded fibers are quenched, the fibers are heated, and the fibers are drawn in multiple stages.

131. The method of claim 130, wherein the method comprises one or more of the following steps: (i) quenching the extruded fiber in a water bath at a temperature of 40°C to 70°C, (ii) cooling the extruded fiber after quenching without stretching, (iii) drawing the cooled extruded fiber in a conducting liquid chamber at a temperature of 50°C to 70°C with an orientation ratio of at least 3.0, (iv) drawing the cooled extruded fiber in a conducting liquid chamber at a temperature of 60°C to 80°C with an orientation ratio of at least 2.0 after the initial drawing, The method comprises the following steps: (i) drawing the fiber in a plurality of stages as the temperature is gradually increased, (ii) drawing the extruded fiber in a plurality of stages as the temperature is gradually increased, (iii) extruding the fiber at a temperature of 80° C. to 180° C., (ix) extruding the fiber at a temperature below 230° C., and (x) drying the polymer composition before melt spinning so that the water content of the polymer composition is less than 0.1 wt %.

132. The method of claim 131, wherein in (ix), the fibers are extruded at a temperature below 200°C.

133. The method of claim 131 or 132, wherein in (x), the polymer composition has a water content of less than 0.05 wt%.

134. The method of any one of claims 131 to 133, wherein in (x), the polymer composition has a water content of less than 0.005 wt%.

135. The method of claim 130, in: (a) the melting temperature of the polymer composition is 100°C to 150°C; (b) the fiber is prepared by solvent spinning or 3D printing; or (c) the method further comprises drying the polymer composition so that the water content of the polymer composition is less than 0.1 wt%.

136. The method of claim 135, wherein in (a), the polymer composition has a melt temperature of 105°C to 120°C.

137. The method of claim 135 or 136, wherein in (c), the polymer composition has a water content of less than 0.05 wt%.

138. The method of any one of claims 135 to 137, wherein in (c), the polymer composition has a water content of less than 0.005 wt%.

139. Use of an implant as claimed in any one of claims 90 to 138 for enhancing the healing of a wound, injury or defect in a part of a patient, or for repairing, enhancing or reconstructing tissue in a part of a patient.

140. The use of claim 139, wherein the implant is for delivery by one or more of the following methods: minimally invasive techniques, laparoscopic techniques, temporarily deforming the implant, and passing the implant through an inserter.

141. The use of claim 139, wherein when used: (a) the implant conforms to the anatomical contours of the patient; (b) the implant does not curl at the edges after implantation, (c) the implant has no surface indentations during a period of 4 weeks after application of the implant to the site, and (d) the size of the implant does not shrink by more than 5% of its initial value in any direction.

142. The use of claim 139 or 140, wherein the implant is used for hernia repair, inguinal hernia repair, femoral hernia repair, incisional hernia repair, ventral hernia repair, umbilical hernia repair, wound management, reinforcement, tracheal reconstruction, organ salvage, dura repair, nerve regeneration or repair, tissue engineering, guided tissue repair or regeneration, anti-adhesion or tissue separation applications, sling manipulation, pelvic floor reconstruction, urethral suspension, urinary incontinence treatment, bladder repair, void filling, bone marrow replacement, ligament repair device or augmentation, anterior cruciate ligament repair, tendon repair or augmentation, rotator cuff repair, meniscus repair or regeneration, articular cartilage repair, osteochondral repair, spinal fusion, cardiovascular patch, vascular closure, intracardiac septal defect repair, atrial septal defect repair, patent foramen ovale closure, left atrial appendage closure, pericardial patch, vascular transplant, myocardial remodeling for the treatment of gingival congestion, guided tissue regeneration for periodontal tissue, imaging, anastomosis, cell seeding, controlled release, drug delivery, plastic surgery, breast lift, mastopexy, breast reconstruction, augmentation mammoplasty, breast reduction, breast reconstruction after mastectomy with or without breast implants, facial reconstruction, forehead lift, brow lift, eyelid lift, face lift, rhytidectomy, rhinoplasty, zygomatic augmentation, otoplasty, neck lift, genioplasty, buttocks lift, cosmetic repair, facial scar repair, and complete or partial encapsulation of an implantable medical device, a cardiac rhythm management device, a pacemaker, a defibrillator, a generator, an implantable access system, a neurostimulator, a ventricular access device, an infusion pump, a device for delivering drugs and hydration solutions, an intrathecal delivery system, a pain pump, or a device for providing drugs or electrical stimulation to the body.

143. A hernia repair mesh comprising an oriented polymer composition, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, wherein the mesh comprises monofilament fibers, multifilament fibers, or a combination thereof formed from the polymer composition, and wherein the mesh has a burst strength of 1 kgf to 100 kgf.

144. The hernia repair mesh of claim 143, wherein the mesh is coated with an anti-adhesion agent.

145. The hernia repair mesh of claim 144, wherein the anti-adhesion agent is hyaluronic acid or a derivative thereof.

146. The hernia repair mesh of any one of Claims 143 to 145, wherein the endotoxin content of the polymer composition is <2.5 EU / g.

147. A breast reconstruction mesh comprising an oriented polymer composition, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, wherein the mesh comprises monofilament fibers, multifilament fibers, or a combination thereof formed from the polymer composition, and wherein the mesh has a burst strength of 0.5 kgf to 50 kgf.

148. The breast reconstruction mesh of claim 147, wherein the polymer composition has an endotoxin content of <2.5 EU / g.

149. The mesh of any one of claims 147 to 148, wherein the mesh is a mastopexy mesh, a mesh for breast reconstruction after mastectomy, a mesh for augmentation mammoplasty, a mesh used as a void filler, a pleated mesh, a mesh used as a scaffold, a mesh used as a scaffold for fat grafting, a mesh used with a tissue expander, or an expandable mesh.

150. The mesh of claim 143 or 147, wherein the mesh is porous.

151. The mesh of claim 147, wherein the mesh has one or more of the following properties: (a) the mesh is a knitted mesh, a warp-knitted monofilament mesh, a woven mesh, or a crocheted mesh; (b) the mesh is formed into a plug, a 3D shape, or is formed to conform to the contours of the patient's anatomy, or the contours conform to the patient's anatomy; (c) the mesh is capable of temporary deformation for minimally invasive delivery to the patient.

152. The mesh of claim 151, wherein the peripheral border of the mesh is reinforced so that the mesh can be deformed from its original shape for implantation and recover its shape after placement in the patient; and (d) 5 g / m 2 Up to 800g / m 2 The surface density of the suture is at least 10N, the suture pull-out strength is at least 10μm, and the pores have a diameter of at least 10μm.

153. The mesh of claim 152, wherein the suture pull-out strength is at least 20N.

154. The mesh of claim 152 or 153, wherein the pores have a diameter of at least 50 μm.

155. The mesh of any one of claims 152 to 154, wherein the pores have a diameter of at least 100 μm.

156. The mesh of claim 150, wherein the mesh further comprises barbs, fleece, hooks, self-fixating tips, anchoring devices, micro-clamps, protrusions, connecting portions or bands, sutures with or without the aid of a needle for securing the mesh to the patient's tissue.

157. A web as described in claim 150, (a) wherein the fibers have one or more of the following properties: (i) orientation, (ii) a tensile strength of at least 400 MPa but less than 1,200 MPa, (iii) a tenacity of 4 g / denier to 12 g / denier, (iv) a Young's modulus of at least 600 MPa but less than 3 GPa, (v) an elongation at break of 10% to 50%, (vi) a diameter of 10 μm to 1 mm, and (vii) a melting temperature of 100°C to 150°C.

158. The web of claim 157, wherein in (ii), the tensile strength is at least 500 MPa.

159. The web of claim 157 or 158, wherein in (ii), the tensile strength is at least 600 MPa.

160. The web of any one of claims 157 to 159, wherein in (ii), the tensile strength is at least 700 MPa.

161. The web of any one of claims 157 to 160, wherein in (iv), the Young's modulus is at least 1 GPa.

162. The web of any one of claims 157 to 161, wherein in (iv), the Young's modulus is at least 2 GPa.

163. The web of any one of claims 157 to 162, wherein in (vi), the diameter is 50 μm to 500 μm.

164. The web of any one of claims 157 to 163, wherein in (vii), the melting temperature is from 105°C to 120°C.

165. The web of claim 150, wherein the weight average molecular weight of the polymer composition decreases by 3% to 15% over a 4 week period, or by 20% to 35% over a 12 week period.

166. The mesh of claim 150, wherein when incubated in phosphate buffered saline at 37°C: (i) the weight average molecular weight of the polymer composition decreases by 3% to 13% over a 4 week period, (ii) the weight average molecular weight of the polymer composition decreases by 5% to 15% over an 8 week period, (iii) the weight average molecular weight of the polymer composition decreases by 10% to 30% over a 12 week period, (iv) the percent mass loss of the mesh is 0% to 5% over a 4 week period, or (v) the percent mass loss of the mesh is 0% to 5% over an 8 week period.

167. The mesh of claim 150, wherein (a) after in vivo implantation, the mesh has a bursting strength greater than 80% at 4 weeks, or greater than 65% at 12 weeks; and (b) after implantation, during a 4-week period of in vivo degradation under physiological conditions, the surface of the mesh fibers has no dents.

168. The mesh of claim 150, wherein the mesh retains 95% to 100% of its original surface area for a period of 4 weeks following in vivo implantation under physiological conditions.

169. The web of claim 168, wherein the web does not shrink more than 5% in any direction during the time period.

170. The web of any one of claims 150 to 169, wherein the web is derived from a polymer composition, in: (a) the polymer composition further comprises one or more of the following: a second diacid unit, a second diol unit, 1,3-propylene glycol, ethylene glycol, 1,5-pentanediol, glutaric acid, adipic acid, terephthalic acid, malonic acid and oxalic acid; (b) a branching agent, a crosslinking agent, a chain extender and a reactive blending agent; or (c) the polymer composition further comprises a hydroxycarboxylic acid unit.

171. The web of claim 170, wherein the hydroxycarboxylic acid units have: two carboxyl groups and one hydroxyl group; two hydroxyl groups and one carboxyl group; three carboxyl groups and one hydroxyl group; or two hydroxyl groups and two carboxyl groups.

172. The web of claim 170 or 171, wherein the branching agent, cross-linking agent, chain extender, and reactive blending agent are one or more of the following: malic acid, maleic acid, fumaric acid, trimethylolpropane, trimesic acid, citric acid, glycerol propoxylate, and tartaric acid.

173. A web as described in any one of claims 156 to 172, wherein the web is derived from a polymer composition comprising succinic acid-1,4-butanediol-malic acid copolyesters, succinic acid-1,4-butanediol-citric acid copolyesters, succinic acid-1,4-butanediol-tartaric acid copolyesters, succinic acid-1,4-butanediol-malic acid copolyesters also containing citric acid, tartaric acid or a combination thereof, succinic acid-adipic acid-1,4-butanediol-malic acid copolyesters, succinic acid-adipic acid-1,4-butanediol-citric acid copolyesters, succinic acid-adipic acid-1,4-butanediol-tartaric acid copolyesters, or succinic acid-adipic acid-1,4-butanediol-malic acid copolyesters also containing citric acid, tartaric acid or a combination thereof.

174. A web as described in any one of claims 143 to 173, wherein the polymer composition: (i) does not contain urethane bonds, (ii) is not prepared with a diisocyanate, (iii) contains 1 ppm to 500 ppm of one or more of elemental silicon, titanium and zinc, (iv) does not contain tin; or (v) the polymer composition is not a blend of two or more polymers.

175. The web of any one of claims 143 to 174, wherein the web has a melting temperature of 100°C to 150°C.

176. The web of claim 175, wherein the web has a melting temperature of 105°C to 120°C.

177. A web as described in any one of claims 143 to 175, wherein the fibers are produced by a method comprising spinning a multifilament or monofilament fiber comprising the polymer composition, drawing the multifilament or monofilament fiber at an orientation ratio of at least 3 or 4 at a temperature of 50°C to 70°C, then drawing the multifilament or monofilament fiber in one or more stages at an orientation ratio of at least 2 at a temperature of 65°C to 75°C, and then drawing the multifilament or monofilament fiber at an orientation ratio greater than 1.0 at a temperature of 70°C to 75°C.

178. A sling comprising a polymer composition, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, wherein the sling comprises an oriented form of the polymer composition, wherein the sling comprises oriented monofilament fibers, oriented multifilament fibers, or a combination thereof formed from the polymer composition, and wherein the sling has been sterilized.

179. The sling of claim 178, wherein the sling further comprises one or more of a second diacid unit, a second glycol unit, 1,3-propylene glycol, ethylene glycol, 1,5-pentanediol, glutaric acid, adipic acid, terephthalic acid, malonic acid and oxalic acid, a branching agent, a crosslinking agent, a chain extender and a reactive blending agent, a hydroxycarboxylic acid unit.

180. The sling of claim 179 wherein the hydroxycarboxylic acid unit has: two carboxyl groups and one hydroxyl group; two hydroxyl groups and one carboxyl group; or two hydroxyl groups and two carboxyl groups.

181. The sling device of claim 179 or 180, wherein the branching agent, crosslinking agent or chain extender unit is one or more of the following: malic acid, maleic acid, fumaric acid, trimethylolpropane, trimesic acid, citric acid, glycerol propoxylate and tartaric acid.

182. The sling device of claim 178, wherein the polymer composition comprises succinic acid-1,4-butanediol-malic acid copolyester, succinic acid-1,4-butanediol-citric acid copolyester, succinic acid-1,4-butanediol-tartaric acid copolyester, succinic acid-1,4-butanediol-malic acid copolyester also containing citric acid, tartaric acid or a combination thereof, succinic acid-adipic acid-1,4-butanediol-malic acid copolyester, succinic acid-adipic acid-1,4-butanediol-citric acid copolyester, succinic acid-adipic acid-1,4-butanediol-tartaric acid copolyester, or succinic acid-adipic acid-1,4-butanediol-malic acid copolyester also containing citric acid, tartaric acid or a combination thereof.

183. The sling of claim 178, wherein the polymer composition: (i) does not contain urethane linkages, (ii) is not prepared with a diisocyanate, or (iii) is not a blend of two or more polymers.

184. The sling device of claim 178, wherein the polymer composition has a melt temperature of 100°C to 150°C.

185. The sling device of claim 184 wherein the polymer composition has a melt temperature of 105°C to 120°C.

186. The sling device of any one of Claims 178 to 185, wherein the device is a urethral suspension device.

187. The sling device of any one of Claims 178 to 186, wherein the device has one or more of the following properties: a thickness of 0.1 mm to 1 mm, a strength of 100 g / m 2 Up to 300g / m 2 The invention relates to a fiber having an area density of 1000 μm, a pore size of 5 μm to 5 mm, fibers having a tensile strength of at least 400 MPa but less than 1,200 MPa, and oriented fibers having an average diameter of 70 μm to 199 μm.

188. The sling device of Claim 187, wherein the fibers have a tensile strength of at least 500 MPa.

189. The sling device of Claim 187 or 188, wherein the fibers have a tensile strength of at least 600 MPa.

190. The sling device of any one of Claims 187 to 189, wherein the fibers have a tensile strength of at least 700 MPa.

191. The sling device of any one of Claims 178 to 190, wherein the polymer composition has an endotoxin content of <2.5 EU / g.

192. An implant selected from the group consisting of: a hernia mesh, a breast reconstruction mesh, a mastopexy device, and a sling device, wherein the implant comprises a polymer composition, wherein the polymer composition comprises 1,4-butanediol units and succinic acid units, wherein the implant comprises an oriented form of the polymer composition, and wherein the implant is formed by 3D printing.

193. The implant of claim 192, wherein the polymer composition has an endotoxin content of <2.5 EU / g.

Citation Information

Cited By

  • Wire passing pliers for nasal cavity operation

    CN122208214A

  • A type of suture forceps for nasal surgery

    CN122208214B